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ABSTRACT 
 
Introduction: 
Rooibos is an indigenous South African plant ingested as herbal tea and well-known for its 
strong anti-oxidant effects. Rooibos has shown to have cardioprotective properties in vitro 
and in vivo, but the role of individual Rooibos flavonoids in cardioprotection still remains 
unclear. This in vitro study investigated Aspalathin, a dihydrochalcone unique to rooibos, for 
(i) cardioprotective effects in the context of age- and obesity-induced insulin resistance, 
known to attenuate myocardial glucose uptake and utilization and (ii) the applicable signaling 
pathways involved.  
Methods: 
Male Wistar rats were allocated into three groups: 16-30 weeks feeding with either standard 
rat chow (C) or a high-fat, high-caloric diet (HFD), or 6-7 weeks feeding with C. 
Cardiomyocytes were isolated by collagenase perfusion digestion, using a Langendorff 
apparatus and glucose uptake determined by 2-[3H]-deoxyglucose (2DG) accumulation 
using liquid scinitillation analysis. In addition, H9C2 cells were differentiated into 
cardiomyocyte analogs and also used. Viability was tested by either Trypan-blue exclusion, 
JC-1-staining or PI-staining and FACS analysis, and metabolic activity determined with an 
ATP assay. Intracellular signaling was evaluated using Western blot analysis and 
commercially available antibodies to PKB and AMPK. 
Results: 
HFD caused significant increases in body weight gain, visceral adiposity, fasting and non-
fasting blood glucose, serum insulin levels and an elevated HOMA-IR index. HFD 
cardiomyocytes were glucose uptake resistant to increasing concentration of insulin (1-
100nM). Aspalathin (10uM) and insulin (10nM) co-incubation for 45mins induced 2DG 
uptake in younger control cardiomyocytes, while incubation for longer than 90 mins with 
aspalathin (10uM) induced 2DG uptake independent of insulin in younger control 
cardiomyocytes and differentiated H9C2 cells. Aspalathin improved metabolic activity and 
membrane integrity in cultured, differentiated H9C2 cells. Aspalathin also enhanced insulin-
mediated 2DG uptake in older control cells, but failed to induce 2DG uptake in HFD cells. 
Acute treatment with aspalathin (15min) in conjunction with insulin in vitro significantly 
increased PKB activation and AMPK expression. Extended treatment with aspalathin 
(90mins) in young cells resulted in significantly increased AMPK activation/expression ratio, 
whereas aspalathin co-treatment with insulin resulted in increased PKB activation. Aged rats 
had significantly higher AMPK expression and activation compared to young rats.  
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Conclusions: 
A high-fat, high-sucrose diet of at least 16 weeks is an effective model to induce insulin-
resistant, obese rats. Aspalathin and insulin co-treatment for 45 mins in cardiomyocytes 
isolated from young rats, and co-treatment for 90 mins in aged, control rats, induced glucose 
uptake. Aspalathin of at least 90 mins induced glucose uptake in cardiomyocytes from young 
Wistar rats, and differentiated H9C2 cells. In addition, it resensitized the insulin-signaling 
pathway in cardiomyocytes, possibly through activation of PKB and AMPK, resulting in an 
additive response. These beneficial effects of aspalathin may ultimately be due to its 
antioxidant capacity, receptor-mediated actions or role in GLUT4 translocation, but this 
remains to be established. 
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ABSTRAK 
 
Inleiding: 
Rooibos is ‘n inheemse plant, eie aan Suid-Afrika, wat as tee gedrink word en bekend is vir 
sy sterk anti-oksidant eienskappe. Rooibos speel ‘n belowende rol in die beskerming van die 
hart, maar die rol van sy individuele flavanoïdes moet steeds ondersoek word in die konteks 
van die hart. In hierdie in vitro studie is die rol van aspalatien, ‘n ‘dihidrochalcone’ uniek aan 
rooibos, ondersoek vir sy: (i) vermoë om die hart te beskerm in die konteks van ouderdom- 
en vetsug-geïnduseerde insulienweerstandigheid (albei risiko faktore wat glukose opname 
deur die hartspiere verswak), en (ii) die moontlike seintransduksiepaaie betrokke tydens 
hierdie proses.  
Metodiek: 
Manlike Wistar rotte is ingedeel in drie groepe: ‘n 16-30 weke dieet met standaard rotkos 
(C), ‘n hoë vet, hoë koolhidraat dieet vir 16-30 weke (HFD), of ‘n 6-7 weke standaard rotkos 
groep. Kardiomiosiete is deur kollagenase perfusievertering geïsoleer deur gebruik te maak 
van ‘n Langendorff sisteem, en daarna is die glukose opname bepaal deur 2-[3H]-
deoksiglukose (2DG) akkumulasie te meet. Verder is H9C2 selle gedifferensieer om hartsel 
analoë te vorm en ook bestudeer. Sellewensvatbaarheid is bepaal deur Trypan-blou 
eksklusie, JC-1-kleuring of propidium jodied-kleuring en vloeisitometrie en die metaboliese 
aktiwiteit is bepaal deur ATP vlakke te meet. Intrasellulêre seinstransduksie is ondersoek 
deur Western klad analise en die kommersiëel-beskikbare teenliggaampies teen PKB and 
AMPK.  
Resultate: 
HFD het beduidende verhogings in liggaamsgewig, intraperitoneale vet, vastende- en nie-
fastende bloed glukose, serum insulienvlakke en die HOMA-IR indeks tot volg gehad. Verder 
was die glukose opname van HFD hartselle onderdruk in reaksie op stapsgewyse 
verhogings in insulin konsentrasies (1-100nM). In jong rothartselle kon ‘n kombinasie van 
aspalatien (10uM) en insulin (10nM) vir 45min 2DG opname verhoog, terwyl ten minste 
90min van aspalatien behandeling nodig was om 2DG opname in jong rot hartselle en 
gedifferensieerde H9C2 selle te verhoog. Verder het 1uM aspalatien ook die metaboliese 
aktiwiteit en membraanintegriteit van gedifferensieerde H9C2 selle in kultuur verhoog. 
Aspalatien kon insulien-afhanklike 2DG opname in hartselle van C diere verhoog, slegs na 
90 minute in kombinasie met insulien. Aspalatien het geen effek gehad as behandeling op 
HFD selle nie. Akute behandeling met 10nM insulien in kombinasie met 10uM aspalatien 
(15mins) in vitro het ‘n verhoogde PKB aktivering en AMPK uitdrukking tot volg gehad. 
Verlengde behandeling met aspalatien (90mins) het gelei tot ‘n beduidende verhoging in die 
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AMPK aktiverings-/uitdrukking verhouding, terwyl kombinasie met insulien PKB beduidend 
geaktiveer het. Ouer rotte het beduidend hoër vlakke en aktivering van AMPK as jonger rotte 
gehad.  
Gevolgtrekking: 
‘n Hoë-vet, hoë-sukrose dieet van ten minste 16 weke is voldoende om 
insulienweerstandigheid en vetsug te induseer in ‘n Wistar rot model. Aspalatien kan 
insulien-afhanklike glukose opname verhoog na 45 minute behandeling in jong rothart selle, 
terwyl ten minste 90 minute benodig word om dieselfde effek in ouer kontrole rotte te verkry. 
Aspalatien het glukose opname in die hartselle van jong Wistar rotte, asook 
gedifferensieerde H9C2 selle ontlok na ten minste 90 minute van behandeling. Verder het 
aspalatien die insulien-seinstransduksie pad in hartselle gesensitiseer, heel moontlik deur 
aktivering van PKB and AMPK wat lei tot ‘n verhoogde glukose opname in kombinasie met 
insulien. Hierdie voordelige effekte van aspalatien kan heel moontlik aan sy antioksidant 
kapasiteit toegeskryf word, asook die spesifieke reseptor-gemedieerde effekte, en/of sy rol in 
GLUT4 translokering, maar dit moet nog bevestig word.  
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MOTIVATION FOR RESEARCH 
 
 Obesity and Insulin Resistance Concerning Risk Factors for Cardiovascular 
Disease 
Obesity is currently classified as a pandemic and recognized as one of the leading causes in 
the development of the metabolic syndrome, a cluster of pathophysiological conditions giving 
rise to cardiovascular disease (Grundy, 2004). Conditions related to the metabolic syndrome 
also include insulin resistance or glucose intolerance (pre-diabetes), hypertension, 
atherogenic dyslipidaemia and proinflammatory states. These indicators lead to non-
communicable diseases (NCDs) and chronic diseases such as heart disease, stroke, 
cancer, respiratory disease and diabetes. As the leading cause of death globally, NCDs 
were responsible for 38 million (68%) of the world’s 56 million deaths in 2012. More than 
40% of them (16 million) were premature deaths under the age of 70 years. Almost three 
quarters of all NCD deaths (28 million), and the majority of premature deaths (82%), occur in 
low- and middle-income countries (Global Status Report on Noncommunicable Diseases, 
World Health Organization, 2014). In South Africa, cardiovascular disease is currently the 
4th leading cause of death (4.7%) (Statistics South Africa, 2011). Recently, there has been a 
shift towards research into natural products, including plant extracts (concentration of active 
compounds in plants), phytochemicals (isolation of active compounds in plants) and 
microbial metabolites (isolation of microbes present in plants) (Lahlou, 2013). These 
products are increasingly getting recognized for their potential in treating and preventing the 
metabolic syndrome, and subsequent type 2 diabetes (T2D) and cardiovascular diseases.  
 
 Rooibos Beneficial for Cardiovascular Health 
Rooibos (Aspalathus Linearis) is an indigenous herbal tea of South Africa. Traditionally, 
rooibos has been used as a treatment or ointment for alleviating stress-related ailments such 
as insomnia and anxiety. Rooibos has been shown to exhibit antioxidant potential, 
antimutagenicity and improve cardiovascular health in humans (Van der Merwe et al., 2006; 
Marnewick et al., 2011). Furthermore, it has been demonstrated that rooibos resensitized 
insulin signalling in C2C12 skeletal muscle cells, via specific biochemical pathways, 
including Protein Kinase B (PKB) and through activation of the insulin-independent 
Adenosine Monophosphate Protein Kinase (AMPK) pathway, which culminated in increased 
levels of glucose uptake via the Glucose Transporter 4 (GLUT4) (Mazibuko et al., 2013).  
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 Rooibos’ Aspalathin Promising 
Aspalathin is a unique, primary polyphenol present only in rooibos. It has been implicated as 
one of the main contributors of rooibos’ antioxidant potential (Joubert et al., 2009; Dludla et 
al., 2014) and could also prove essential in eliciting rooibos’ other therapeutic effects. 
Kawano et al. (2009) recently reported that aspalathin improved glucose uptake in muscle 
cells and insulin secretion from pancreatic β-cells. These findings were confirmed by Son et 
al. (2013) who also reported that aspalathin increased glucose uptake in L6 myotubes by 
increasing AMPK phosphorylation and GLUT4 translocation to the membrane. Further, in 
ob/ob mice, aspalathin reduced fasting blood glucose levels, and reduced 
hypertriglyceridaemia by reducing enzymes related to gluconeogenesis, glycogenolysis and 
lipogenesis. No research has been performed to date to determine the cardiovascular 
consequences of aspalathin treatment.  
 
 We have plenty of Aspalathin :) 
A recent patent, claiming aspalathin for the prevention and treatment of T2D has been 
awarded to our members of Diabetes Discovery Platform (DDP) of the South African Medical 
Research Council (SA MRC) and the Agricultural Research Council at Stellenbosch (ARC) in 
collaboration with the University of Free State (UFS). This method is currently the only 
protocol whereby aspalathin can be synthesised in the required 5 steps or less, providing a 
unique opportunity for research using synthetically produced pharmaceutical grade 
aspalathin. This product has the potential to be developed into an effective therapy in 
preventing and managing the metabolic consequences associated with obesity and T2D, 
and thereby contribute to the health of South Africans.  
 
GENERAL AIM 
 
We propose to use aspalathin to induce glucose uptake in heart cells isolated from various 
rat models, including young rats, a 16 – 30 week diet induced obesity and insulin resistant 
group, and their age-matched controls. The secondary aim is to understand the mechanism 
of actions of aspalathin and to ensure its effectiveness and safety using cell culture and rat 
models. 
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CHAPTER 1 
LAYMAN’S OVERVIEW OF THE THESIS 
 
We are all aware that too much of anything, is a bad thing. In the case of type 2 diabetes, too much 
glucose in the blood, can give rise to various problems, including insulin insensitivity, damaged 
nerves and arteries, and all of these increase your risk for heart attacks and strokes. It is estimated 
that people with type 2 diabetes are 4 times more likely to die of heart disease or stroke, and at 
least 65 percent of people with type 2 diabetes die from these complications. In 2012 alone, 1.5 
million deaths globally were attributed to diabetes. All of this being said, type 2 diabetes remain 
one of the major controllable risk factors for cardiovascular disease. So, how do we control 
diabetes? Quite simply, as always: Through diet; and exercise. However, if healthy living fails, it 
becomes the hope of medicine together with ongoing research to prevent further deterioration of 
health in diabetic patients. Various medications are already prescribed to treat type 2 diabetes, 
each with it’s own set of pros and cons. Each of these medications have a different mode of action, 
including: enhancing insulin action in peripheral tissues, enhancing the amount of insulin secreted 
by the body, suppressing glucose production, and also by delaying the absorption of carbohydrates 
after meals. The biggest problem with these medications are that they are only treatments, but not 
in themself a cure. There is also high costs involved with being dependent on these medications, 
and prolonged use can carry the risk of weakening the heart and causing liver toxicity.  
 
The diabetic journey brings us to our humble country, where rooibos might bring new hope. 
Rooibos or aspalathin linearis is indigenous to the Western Cape region of South Africa. The plant 
is most commonly consumed as a herbal infusion, by which hot water is added to the “fermented” 
rooibos tea to extract the inherent polyphenols. It has been shown, however, that through the 
process of fermentation the polyphenolic content of the plant is severely diminished, consequently 
reducing the plants’ antioxidant capacity. Lately, there has been a shift towards consuming the 
green or unfermented rooibos and it’s also the grade of choice when isolating aspalathin. Of the 
various compounds within rooibos, aspalathin is the most prominent polyphenol and the biggest 
contributor to rooibos’ beneficial effects. Aspalathin was first isolated and characterised in 1965 by 
Koepen and colleagues and since then has amounted about 60 mentions in research, alot of which 
were studies done with fermented and unfermented rooibos. Of these articles, about 33 are of 
direct relevance to this research. The major effects attributed to aspalathin is its strong antioxidant 
capacity, and also its ability to stimulate glucose uptake in skeletal muscle cells.  
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In the present study, we investigated whether asplathin can induce glucose uptake in 
cardiomyocytes from both healthy and compromised heart cells. And if so, through which cellular 
mechanism does this occur? I made use of three groups of animals:  
(i) Young controls of at least 220g and 6-7 weeks of age 
(ii) One group with 16 – 30 week diet-induced obesity and insulin resistance; and 
(iii) Age-matched control group. Groups (ii) and (iii) were 22-36 weeks of age. 
 
The first part of all the experiments is to isolate the cardiomyocytes. We do this by using a 
Langendorff perfusion system, by which we use solutions with enzymes, such as collagenase to 
perfuse and digest the dissected heart. The cardiomyocytes can then be stabilized and used in 
subsequent experiments. To determine glucose uptake, cells were treated with radioactive 2-
deoxyglucose and analyzed using liquid scintillation counting.  
 
First, we tried to establish an aspalathin dose response in cardiomyocytes of young control rats. 
We could not find a direct stimulation of glucose uptake by aspalathin, and to the contrary it 
appeared to inhibit the glucose uptake. To test for the cytotoxic effects of DMSO, used as solvent 
for synthetic aspalathin, we performed a cell viability assay using propidium iodide. There was no 
significant difference in cell viability between the treatment groups and the observed suppression in 
glucose uptake was not due to DMSO, but possibly through some other responsive mechanism. 
Next, we tried to see whether asplathin might have an indirect effect on glucose uptake through 
stimulation of insulin. 10M aspalathin was able to increase glucose uptake in conjunction with 
10nM Insulin. 
 
Then we moved on to the animal models, and first had to determine that the high-fat, high -sucrose 
diet did in fact cause hyperglycemia, obesity and insulin resistance. An oral glucose tolerance test, 
fasting blood glucose and non-fasting blood glucose all showed elevated blood glucose levels in 
diet rats compared to controls. The diet rats also had significantly higher total body weight and 
intraperitoneal fat compared to controls. The young rats had the most sensitive response to insulin, 
followed by our age-matched control groups that also had a healthy response. The high-fat, high-
carbohydrate diet had a weak response to increasing concentrations of insulin, and was deemed 
insulin resistant. A preliminary study done on cardiomyocytes from the diet rats, showed no 
significant differences when treated with aspalathin.  
 
We made use of embryonic rat-heart derived H9C2 cells to verify whether aspalathin can induce 
glucose uptake independent of insulin as this was previously published. Initially, these cells are 
immortal cells, but once differentiated by reducing the amount of serum in the culture medium and 
adding Retinoic Acid, the cell’s nuclei start to “clump together” and they have a closer resemblance 
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to the isolated cardiomyocytes. Glucose uptake in differentiated H9C2 cells was assayed for 3 and 
6 hours, and for both instances, aspalathin induced a significant increase in glucose uptake, with 6 
hours being more pronounced. 
 
Returning to the rat models, we extended our experiments to 3 hours in the isolated 
cardiomyoctes. Surprisingly, incubating the aspalathin for a mere 30 mins longer than the previous 
experiments, had a significant increase in glucose uptake in young controls, while the effect in 
conjunction with insulin was even more pronounced. This was also evident in older controls with 
aspalathin inducing a significant increase in insulin-mediated glucose uptake. The high fat diet 
group showed no significant increases when treated with aspalathin. Also, no effect was visible 
after 1 and a half hours of treatment. 
 
The mechanism by which aspalathin induced this slight increase in myocardial glucose uptake by 
western blot analysis was investigated. In particular, the markers of interest were: Protein Kinase B 
(PKB), an insulin-dependent, pro-‘life’, growth marker; and Adenosine Monophosphate Protein 
Kinase (AMPK) – the body’s key metabolic regulator, which is an insulin-independent marker of 
glucose uptake quite central to all cell signaling. PKB activation was significantly increased in 
young rats treated for 15 minutes with both insulin and aspalathin. This effect was also observed 
when comparing the ratio of activated PKB to the total amount of PKB expressed. After 1 and a 
half hour of treatment, PKB activation was also significantly increased with aspalathin together with 
insulin in young rats. No significant differences were found for the older diet rats. Aspalathin 
significantly increased AMPK activation WITH insulin, as well as increased the expression of 
AMPK in young rats after 15 minutes of stimulation. Aspalathin increased the phospho-to-total ratio 
of AMPK in young rats, possibly explaining the mechanism by which aspalathin induced glucose 
uptake at the hour and a half time point. Also, both expression and activation of AMPK was 
elevated in aged-diet controls compared to young controls. This might point towards AMPK 
becoming a more prominent metabolic regulator as ageing progresses.  
 
In summary, the high-fat, high-sugar diet was an effective model to induce insulin resistance in 
rats. Aspalathin induces myocardial glucose uptake directly in young rats and indirectly through 
mediating insulin’s action in aged control rats. The possible mechanism for this is through 
activation of PKB and increasing the expression and activation to expression ratio of AMPK. 
Aspalathin had no significant effect when used as treatment in heart cells from high-fat, high-
caloric diet rats.  
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CHAPTER 2 
LITERATURE REVIEW 
 
1. OBESITY AND INSULIN RESISTANCE FROM THE HEART’S PERSPECTIVE 
1.1 INTRODUCTION 
Cardiovascular diseases (CVD) are the leading cause of death worldwide, constituting 31% of all 
annual global deaths (17.5 million people) (Cardiovascular Diseases, WHO, 2015). This shocking 
figure is in part aggravated by the presence of individual risk factors such as obesity (excessive 
energy storage) and insulin resistance (declining ability to utilize blood glucose in the presence of a 
given level of insulin). Under normal physiological conditions, the heart’s contractile function 
enables circulation of nutrient rich blood through the arteries and veins of the entire body. The 
heart also relies on these nutrients, including glucose and free fatty acids, as energy substrates for 
its contracting cardiomyocytes. The rate at which nutrients are transported into all cells and used 
as substrates is heavily dependent on the action of the hormone, insulin. Insulin induces anabolic 
processes through activating energy consumption, while simultaneously counterbalancing blood 
glucose levels. However, in diseased conditions, such as type 2 diabetes (T2D), various 
complications start to arise hindering the heart’s performance. Ineffective clearing of blood glucose, 
primes the pancreas to increase insulin production in order to compensate for elevated blood 
glucose levels, and when this state progresses, insulin receptors become so desensitized that the 
pancreas cannot maintain sufficient insulin levels (Shanik et al., 2008). The effect of a decreased 
insulin potential detrimentally affects peripheral insulin sensitive organs, namely the muscle, fat 
and liver . According to Kannel & McGee (1979), a prolonged insulin desensitized state leads to a 
4-fold increase for the risk of developing coronary heart disease and strokes. Furthermore, as a 
direct consequence of obesity, meaning having excess fat mass, higher levels of circulating free 
fatty acids and cholesterol are also present in the blood. These can cause a plaque build-up inside 
arteries, narrowing or completely blocking blood flow (Kwan et al., 2014). Arguably, the slightest 
reduction in blood flow to the heart is severely detrimental to the heart’s function.  
 
1.2 OBESITY 
1.2.1 OVERVIEW OF OBESITY 
Obesity and overweight are defined as abnormal or excessive fat accumulation that presents a risk 
to health (Obesity, WHO, 2015). These two related conditions can severely alter metabolism and 
contribute to a cluster of pathophysiological conditions, collectively called the metabolic syndrome 
(Grundy, 2004). Furthermore, the risk of cancer, coronary heart disease, ischemic stroke and T2D 
also increase as the severity of obesity increases (Chamie et al., 2013; Eckel, 1997; Saboor Aftab 
et al., 2014). Essentially, a body fat percentage of at least 3-5% in men and 12-15% in women is 
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required for healthy functioning. The fats are stored in all major tissue types and are especially 
essential in maintaining hormonal balance and pregnancy in women (Kotecki, 2011). Additional fat 
is retained in adipose tissue (fat cells) which protects internal organs against impact trauma, 
insulate the body to prevent temperature fluctuations and serve as reserve energy stores. 
Specifically, brown adipose tissue (BAT) dissipates chemical energy in response to cold and 
overfeeding and can modulate energy balance (Stanford et al., 2012). Under normal physiological 
conditions, it is estimated that adipose tissue account for <5% of glucose clearance (Thiebaud et 
al., 1982). Furthermore, adipose tissue is also a metabolically active endocrine organ and 
produces biologically active substances, including pro-inflammatory cytokines, angiotensin II, 
leptin, resistin and adiponectin (Kershaw & Flier, 2004). Continually having an excess intake of 
calories (energy) compared to what the body is able to utilize by regular daily metabolic demands, 
results in the storage of these excess calories in the adipocytes, contributing to body weight gain 
and eventual obesity. The secondary contributing factors are physical inactivity, an unhealthy diet, 
pregnancy, lack of sleep, as well as certain medical conditions and medications (Appendix A – 
Secondary Causes of Obesity). 
 
1.2.2 ASSESSMENT 
A crude method of determining obesity is given by the body mass index (BMI), in which a person’s 
weight (in kg) is divided by the square of their height (in meters) (Center for Disease Control and 
Diabetes, 2009). A BMI between 25 and 30 kg/m2 is considered overweight, whereas a BMI of 
above 30 kg/m2 is classified as obese (Figure 2.1). 
  
 
 
 
 
 
 
 
 
 
Figure 2.1 Body mass index classification according to metric height and weight (Obtained 
from Global Diabetes Community, 2015). 
 
However, total body mass constitutes fat mass and lean body mass (muscle, bone, organ tissue, 
blood). Therefore, BMI alone can not indicate total amount of body fat since it does not distinguish 
between fat and lean body mass. This makes the test unreliable in classifying young people, 
BMI (kg/m
2
) Weight Status 
Below 18.5 Underweight 
18.5-24.9 Normal 
25.0-29.9 Overweight 
30.0-34.9 Obese (Class I) 
35.0-39.9 Obese (Class II) 
40.0 and higher Morbidly Obese (Class III) 
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pregnant women and muscular patients, such as professional athletes. Health experts use BMI in 
conjunction with a measure of percentage body fat and body proportions to assess health risk.  
These assessments include:  
 waist circumference (circumference of natural waist) 
 waist-to-hip ratio (waist circumference divided by hip circumference) (Noble, 2001) 
 skinfold thickness (measure subcutaneous fat using calipers) (Gray, 1990) 
 underwater weighing (body density measurement) (Kotecki, 2011) 
 bio-electrical impedance (electrical current passed through body to determine electrical 
impedance, which serves as a measure of total body fat) (Gray, 1990). 
 
Additional tests, used only in research settings and to confirm the accuracy of above mentioned 
techniques, include Dual Energy X-ray Absorptiometry (DEXA) (X-ray beams used to distinguish 
between fat-free mass, fat mass and bone mineral density), Computerized Tomography (CT) (X-
ray images used to generate cross-sectional and three-dimensional images of internal organs and 
structures) and Magnetic Resonance Imaging (MRI) (protons/hydrogen atoms in water molecules 
of different tissues detected and used to construct three-dimensional image of entire body 
composition) (Hu, 2008). To date, the most accurate assessment of body composition is given by 
CT and MRI scans. 
 
1.2.3 EPIDEMIOLOGY 
Annually, 2.8 million people die as a consequence of being overweight or obese (Obesity, WHO, 
2015). In 2008, 35% of adults worldwide over the age of 20 were overweight, and an estimated 
205 million (3%) men and 297 million (4%) women over the age of 20 were obese. 
 
1.2.3.1 CHILDREN AND ADOLESCENCE 
Obesity is a growing concern amongst children and adolescence. Globally, the prevalence of 
overweight and obese infants and young children (0 to 5 years of age) increased from 32 million in 
1990 to 42 million in 2013 (Obesity, WHO, 2015). In Africa, the number of overweight or obese 
young children more than doubled, from 4 million to 9 million children. In developed countries, such 
as the United States, childhood obesity (6 – 11 years of age) increased from 7% in 1980 to 18% in 
2012, while adolescent obesity (12 – 19 years of age) also increased from 5% to 21% in this 
period. These figures estimate that over one third of all children and adolescents in the United 
States are overweight or obese (Ogden et al., 2014). No current data exists for the developing 
world, but regardless, without therapeutic intervention, obesity will likely proceed into childhood, 
adolescence and adulthood.  
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1.2.3.2 SOCIO-ECONOMIC STATUS 
Additionally, a country’s socio-economic status also influences the prevalence of obesity as was 
determined by Pampel et al. (2012). They sampled 67 different countries around the world and 
classified them as either low-income and low middle-income countries (LIC and LMIC) or high 
middle- and high-income countries (HMIC and HIC) – South Africa is classified as a HMIC. They 
found that the higher the country’s income level, the higher the prevalence of raised BMI’s. HMIC 
and HIC had an overweight prevalence of more than double that of LIC and LMIC. For obesity, the 
prevalence more than triples from 7% obesity in LMIC to 24% in HMIC. In LIC and LMIC, obesity 
was twice as prevalent in women as in men, whereas it was similar in high-income countries.  
 
The increasing trend of overweight individuals also hinders the overall health of a population. 
Overweight individuals present with an array of chronic conditions and can suffer premature 
mortality. This trend is prevalent in developed countries, and is becoming an increasing concern in 
developing countries as well (Popkin, 2009). Even though socio-economic development advances 
our management of health, it also creates new problems. For instance, in higher income countries, 
the dilemma of malnutrition is systematically replaced by overconsumption (Pampel et al. 2012). 
Arguably, the group to be most severely impacted by this growing trend of obesity, will be those 
least financially advantaged.  
 
1.2.4 OBESITY-RELATED CONDITIONS 
1.2.4.1 CORONARY HEART DISEASE AND STROKES 
Obesity is not just a superficial term for excess weight, but has long-standing health implications. 
As your severity of obesity increase, so too does your risk for coronary heart disease (CHD) – the 
leading cause of CVD (Cardiovascular Disease, WHO, 2015). CHD is the consequence of a 
sustained plaque build-up in the coronary arteries which supplies the heart with oxygen-rich blood 
(National Institutes of Health, 2015). As the arteries narrow, blood supply to the heart is reduced 
causing chest discomfort and could possibly trigger a heart attack when coronary arteries are 
completely blocked. Similarly, an overworked heart can fail completely, preventing adequate blood 
supply to meet the body’s needs. Another implication of obesity-induced plaque buildup is the 
potential rupture of a plaque region, forming blood clots. These clots can cause a stroke by 
blocking off oxygenated blood flow to the brain, causing irreversible neuronal damage or premature 
deaths. 
 
1.2.4.2 METABOLIC SYNDROME 
Metabolic syndrome (or insulin resistance syndrome) refers to a collection of conditions prevalent 
in overweight and obese individuals that have been known to increase the risk for CVD and T2D. 
The characteristics include:  
 large waist size (≥102cm for men, ≥89cm for women)  
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 elevated blood triglycerides (≥150mg/dL) 
 abnormal blood cholesterol (HDL cholesterol of ≥40mg/dL for men or ≥50mg/dL for women)  
 high blood pressure (≥130/85)  
 high blood glucose levels (fasting blood glucose level ≥100mg/dL or ≥5.6mmol/L)  
 
Metabolic syndrome is the prevalence of at least 3 of these characteristics and besides CVD and 
T2D, have also been linked to non-alcoholic fatty acid liver disease, chronic kidney disease and 
polycystic ovary syndrome (a condition which detrimentally affect women’s hormone levels and 
ovulation cycle) (Alberti et al. 2009). 
 
1.2.4.3 DIABETES 
 DIABETES OVERVIEW 
Diabetes mellitus has become one of the most common metabolic diseases worldwide (Wild et al., 
2004). The disease can be sub-divided into Type 1, Type 2 or gestational diabetes. Type 1 
diabetes (T1D) is an autoimmune disease that selectively targets the destruction of pancreatic β-
cells, leading to an inability to produce sufficient insulin to meet the body’s energy demands. Type 
2 diabetes (T2D) on the other hand, is the result of a decline in insulin sensitivity of peripheral 
insulin sensitive tissues, such as the liver, adipose tissue and muscle (DeFronzo, 1999). This 
results in an overexpression of insulin, exacerbated β-cell function and an eventual inability to 
effectively clear blood glucose. Initially it was proposed that diabetic patients present solely with 
insulin resistance, rather than insulin deficiency (Himsworth, 1936). However, it is now understood 
that both insulin resistance together with impaired β-cell function is essential in the disease 
progression of T2D. The third most common type of diabetes, gestational diabetes, is defined as 
having a degree of glucose intolerance during pregnancy (Metzger & Coustan, 1998). Gestational 
diabetes is prevalent in approximately 7% of all pregnancies, especially during the third trimester 
(24 – 28 weeks of gestation) and increases the risk of developing T2D post-pregnancy (American 
Diabetes Association, 2003). T2D has a much higher incidence (about 95% of all cases of 
diabetes) and is usually connected to obesity. Typically, T1D is predominantly diagnosed in 
younger people, while older individuals are diagnosed with T2D, but recent years have indicated a 
growing trend in younger people developing T2D as well (Huang et al., 2009). Futhermore, the 
genetic make-up of a person also contributes to the development of diabetes – T1D and T2D is 
dependent on the control of multiple genes together with the epigenetic changes caused by a 
person’s environment. Some forms of diabetes, for example maturity-onset diabetes (Fajans et al., 
2001) and neonatal diabetes (Støy et al, 2010), are the direct effect of a single gene mutation that 
alters pancreatic β-cells. These single-gene disorders account for less than 2% of cases. In 
general, the multiplicity of genes responsible for T2D makes risk assessment and therapeutic 
interventions based on genetic make-up problematic.  
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 TREATMENT 
Maintaining blood glucose levels is the primary concern when treating diabetes and preventing 
further complications (Polonsky, 2012). T1D can also be managed with dietary changes and 
exercise (Eiselein et al., 2004), but the most prominent treatment for T1D still remains injectable 
insulin, which remains the only treatment proven safe and effective after clinically significant 
pancreatic β-cell destruction. Additionally, T2D treatments also include non-insulin oral antidiabetic 
medications, comprising of sulfonylureas, biguanides, α-glucosidase inhibitors, and 
thiazolidinediones. Each class of medication has a unique mechanism of action (Figure 2.2):  
o sulfonylureas increase insulin production by the pancreatic β-cells (Raptis & Dimitriadis, 2001);  
o metformin (biguanide) increases the liver’s insulin sensitivity and restores its glucose 
metabolism (Viollet et al., 2012); 
o α-glucosidase inhibitors delay the absorption of carbohydrates from the gastro-intestinal tract 
(Willms et al., 1991); 
o thiazolidinediones increase insulin sensitivity in peripheral tissues, such as the muscles and fat 
cells (Kahn et al., 2000). 
 
 
Figure 2.2 Anti-diabetic therapies and their method of action (Obtained from Beaser et al., 
2015). 
 
The different oral agent classes have different effects on basal insulin and postprandial glucose – 
effects which only become apparent as T2D progresses. The latest drugs available for treating 
T2D are incretins, such as glucagon-like peptide-1 (GLP-1) – a gastrointestinal hormone that 
increase insulin production in β-cells (Kjems et al., 2003). Similarly, dipeptidyl peptidase-4 (DDP-4) 
inhibitors can be used to delay the breakdown of GLP-1 (Dicker, 2011). All of the above have, 
however, been linked to a variety of serious adverse health effects, prompting a search for safer 
natural hypoglycemic agents to be used (Patel et al., 2012).   
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1.2.4.4 OTHER CONDITIONS 
Obesity is related to an increased risk for cancer, specifically colon, breast, endometrial and 
gallbladder cancers (Vucenik & Stains, 2012). As mentioned as part of the metabolic syndrome, 
obesity is also associated with increased risk for high levels of triglycerides and cholesterol in the 
blood. Accumulation of cholesterol, specifically, can lead to hard, stone-like pieces within the 
gallbladder, called gallstones, inducing stomach or back pain (Erlinger, 2000). Obesity, together 
with injury and aging, can also cause osteoarthritis – a condition whereby the protective cartilage at 
bone junctions start to degrade leading to joint pain and decreased joint function. This effect is due 
to the added mechanical stress put on joints by extra body weight (Cooper et al., 1998). 
Furthermore, obesity can lead to sleep apnea, a common disorder in which individuals have 
episodes of ceased breathing while sleeping. Excessive fat accumulation over the chest, abdomen 
and around the neck in obese individuals can potentially narrow the airway and thus make 
breathing more troublesome (Vgontzas, 2000). Another respiratory condition associated with 
obesity is obesity hypoventilation syndrome (OHS), whereby shallow breathing leads to oxygen 
scarcity and excessive carbon dioxide in the blood (BaHamman & Al Dabal, 2009). Fertility is also 
negatively correlated with obesity (Pasquali et al., 2007). In women, early development of obesity 
can cause menses irregularities, chronic oligo-anovulation and could lead to eventual infertility in 
adults. Obesity also increases the risk for miscarriages. In men, as the severity of obesity 
increases, the production of testosterone and sperm decrease, and frequency of erectile 
dysfunction increases, contributing towards infertility (Pasquali et al., 2007). 
 
1.3 THE HEART 
1.3.1 OVERVIEW OF THE HEART 
“The heart is the conductor of all human beings.” It sets the rhythm and tempo of a person’s entire 
metabolic state. The heart beats an average 100 000 times per day, pumping 7 500 liters of blood 
through the body (Watson, 2009). On average a male human heart weighs only 280g, whereas a 
female heart weighs in at 230g – constituting on average a mere 0.5% of our entire body weight 
(The Normal Size of the Heart Muscle Weight, 1951). At the size of a human fist, the heart 
circulates blood through 95 000 km of veins and arteries, feeding organs and tissues along the 
way. Furthermore, by increasing the heart rate through exercise the cardiac output (the amount of 
blood the heart circulates per minute through the body) can be increased as much as 6-fold 
(Baggish & Wood, 2011). Heart rate can also vary from as little as 40 beats per minute (bpm) at 
rest to more than 200 bpm (Uusitalo et al., 1998). It has been determined that a person’s maximum 
heart rate is an innate genetic feature that decreases with age (Jose & Collision, 1970). 
Furthermore, it is estimated that a mere 1% of all heart cells are renewed per year from age 20, 
and declines to 0.3% by 75 – equating to less than 50% turnover of heart cells during an entire 
lifespan (Bergmann et al., 2009). Even though regular exercise is strongly associated with good 
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health it does not exclude cardiovascular complications, as is evident from pro-athletic patients 
with cardiovascular diseases, stemming from various structural and functional heart abnormalities 
(Baggish & Wood, 2011). Understandably, any damage inflicted to this organ, albeit via damage to 
the heart’s chambers, veins or valves, or in the circulatory system via occlusions, constrictions, or 
loss of blood, forces the system to overcompensate in order to maintain the body’s functional 
demand for nutrient rich blood.  
 
1.3.2 ENERGY METABOLISM 
The heart consists of specialized muscle cells and has the unique feature of uninterrupted 
contraction and relaxation (An & Rodrigues, 2006). This also makes the heart the most 
metabolically active organ in the body (Neubauer, 2007), needing a high supply of energy 
equating, to 6kg of adenosine triphosphate (ATP) per day to circulate nearly 10 tons of blood daily 
(Raff, 2003) to meet the demands of cellular maintenance and sustaining contractile function (Shah 
& Shannon, 2003). The heart has very little stored ATP content (5 mol/g of wet heart) and a high 
turnover of ATP (~30 mol/g of wet heart per minute at rest), meaning the entire pool of ATP can 
be turned over every 10 seconds (Bing et al., 1954; Opie et al., 1968; Opie et al., 1969). The heart 
can utilize various substrates for energy generation (An & Rodrigues, 2006), but the most 
prominent are fatty acids, which account for 50-70% of ATP production (Lopaschuk et al., 1994). 
The remaining energy is derived from glucose, amino acids, lactate and ketones. The heart 
switches between these substrates to facilitate optimal energy production during different 
physiological (post-prandial and fasted) or pathological conditions. These conditions can influence 
the demand for energy, the amount of oxygen supplied to the heart, the amount of fatty acid 
supplied to the heart and the prevalence of the competing substrates, as well as change the 
mechanisms of substrate uptake and utilization within the cell (Lopaschuk et al., 2010). 
 
1.3.2.1 ATP 
ATP is the primary form of energy used on molecular level to support contractile proteins, facilitate 
ion transport and enable enzymes to be functional. It is generated when phosphate ions are linked 
to adenosine diphosphate (ADP) through complex cellular processes (Lodish et al., 2000). Under 
normal physiological conditions, energy production and utilization are in balance. However, when 
ATP usage exceeds the supply, intracellular ADP increases. This leads to ADP molecules 
combining and reconverting into ATP and adenosine monophosphate (AMP) by action of the 
adenylate kinase enzyme. Though this process renews ATP, the excess AMP serves as an 
internal cell signaling molecule that indicates the presence of metabolic stress, amongst other 
things (Figure 2.3). AMP is extremely sensitive to a compromised energy status (Hardy et al., 
2006) and directly regulates AMP-activated protein kinase (AMPK) - its main effector. Furthermore, 
it regulates enzymes involved in metabolism, such as glycogen phosphorylase and 
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phosphofructokinase-1 (PFK-1), which respectively releases glucose from glycogen stores and 
regulates glucose entry into glycolysis (Dzeja & Terzic, 2009).  
 
 
Figure 2.3 AMP signals up- or downregulated by adenylate kinase in response to various 
processes. 
 
1.3.2.2 GLUCOSE METABOLISM 
Glucose, a monosaccharide carbohydrate, is one of the major fuels utilized by the heart under 
normal physiological conditions. Glucose can either be derived from carbohydrates, such as 
sugars and starches after being processed by the digestive tract, or endogenously made by the 
body through breakdown of muscle and liver glycogen, or by de novo synthesis from lactate, 
glycerol, alanine and glutamine (Newsholme, 2003). Its entry into cells is facilitated by glucose 
transporters, denoted GLUT’s, of which there are 14 isoforms with varying tissue distribution and 
subcellular localization described to date (Augustin, 2010). Upon contractile stimulation during 
movement or insulin secretion after a meal, GLUT4 translocates to the plasma membrane to 
facilitate glucose uptake (Figure 2.4). Glucose utilization is always limited by the rate of uptake, 
rather than the rate of phosphorylation of glucose-dependent processes - as a result, the 
concentration of free glucose inside the cardiomyocytes are always lower than within the blood, 
creating a glucose gradient favouring glucose entry (Manchester et al., 1994). After entering 
cardiomyocytes or skeletal muscle cells, glucose can either be converted to energy through the 
processes of glycolysis (in the cytosol) and glucose oxidation (in the mitochondria), or stored as 
glycogen. 
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Figure 2.4 Simplified Glucose Metabolism Overview. 1) Insulin binds the insulin receptor, 2) 
activating kinase cascades and 3) recruiting GLUT4 to the plasma membrane, facilitating glucose 
uptake. Glucose is then either stored as 4) glycogen, used in 5) glycolysis or 6) glucose oxidation. 
(Adapted from en.wikipedia.org/wiki/Insulin) 
 
 GLYCOLYSIS 
The initial stage of glucose metabolism, known as glycolysis, occurs in the absence of oxygen in 
the cytosol of cells. The whole process only amounts to 2 ATP and 2 three-carbon pyruvate 
compounds per glucose molecule (Figure 2.5). The first step in glycolysis is the phosphorylation of 
glucose to glucose-6-phosphate (G-6-P) by hexokinase. In the heart, hexokinase is prevalent in 2 
different isozymes: hexokinase I, predominantly in fetal and newborn hearts; and hexokinase II, 
predominantly in the adult heart (Printz et al., 1995). Hexokinase is situated in both the cytosolic 
fraction of the cells, as well as being bound to the outer mitochondrial membrane (Arora & 
Pedersen, 1988). Under physiological conditions, an estimated two-thirds of G-6-P is converted to 
glycogen (DeFronzo & Tripathy, 2009), whereas the rest enters glycolytic pathways to generate 
ATP. The first regulator that commits glucose to glycolysis is 6-phosphofructo-1-kinase (PFK-1), 
catalyzing the phosphorylation of fructose-6-phosphate (F-6-P) to fructose-1,6-bisphosphate (F-
1,6-BP). It is considered to be the rate-limiting step of glycolysis given the complexity of allosteric 
control - ATP, citrate and protons are all negative allosteric effectors, while AMP and fructose-2,6-
diphosphate are positive allosteric effectors (Uyeda, 1979). Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) catalyzes the oxidation and phosphorylation of glyceraldehyde 3-
phosphate (G-3-P) into 1,3-diphosphoglycerate (1,3-DG). The activity of GAPDH, similar to other 
dehydrogenases, is decreased in the presence of high concentration of NADH and protons 
(Mochizuki & Neely, 1979). Pyruvate kinase (PK) irreversibly catalyzes phosphoenol pyruvate into 
pyruvate, and can increase glycolytic flux in response to stimulation by F-1,6-BP, the product of 
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PFK-1. PFK-1 is thus capable of accelerating glycolytic flux, without causing a buildup of various 
glycolytic intermediates (Kiffmeyer & Farrar, 1991).  
 
Figure 2.5 Glycolysis Pathway. Two molecules of ATP generated by conversion of one glucose 
molecule to 2 pyruvate molecules. 
 
 GLUCOSE OXIDATION 
In aerobic cells, pyruvate, produced from either glycolysis or exogenous lactate, enters the 
mitochondria where it is further oxidized in the presence of O2 to CO2. After full oxidation of a 
glucose molecule a further 34 molecules ATP are generated (Figure 2.6). Pyruvate enters the 
mitochondria via a monocarboxylate carrier (Poole & Halestrap, 1993). It is then further oxidized to 
acetyl coenzyme A (acetyl-CoA) by the pyruvate dehydrogenase complex (PDC) and convened 
into the tricarboxylic acid (TCA) or citric acid cycle. Pyruvate can also be transformed into TCA 
cycle intermediates such as oxaloacetate by action of pyruvate carboxylase or malic enzyme 
(Peukhurinen et al., 1982). PDC can either be inhibited by pyruvate dehydrogenase kinase (PDK) 
following stimulation by acetyl-CoA and NADH (produced from fatty acid oxidation), or activated 
when PDK is inhibited by pyruvate (Roche & Hiromasa, 2007). PDC in working hearts are activated 
in response to increased workloads or during perfusion with epinephrine, resulting in increased 
mitochondrial Ca2+ entry (McCormack & Denton, 1990). In the end, the majority (80 – 90%) of 
glucose undergoing glycolysis is converted to ATP, carbon dioxide and water, while the remainder 
is converted to lactate (DeFronzo & Tripathy, 2009). 
 
During prolonged contraction of skeletal muscles, oxygen supply grows limited, inhibiting complete 
oxidation of glucose. In this scenario, glucose is fermented to two molecules of ATP and lactic 
acid, rather than pyruvate (Lodish et al, 2000). Lactic acid accumulates in skeletal muscle 
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(arguebly, leading to muscle and joint aches) till it is cleared by secretion into the blood. Once in 
circulation, it is either taken up by the heart or liver, where it can be reprocessed to pyruvate and 
further metabolized to ATP and CO2 or converted back to glucose (Lodish et al., 2000).  
 
 
Figure 2.6 Glucose Oxidation Pathway. 34 molecules of ATP generated by conversion of 2 
pyruvate molecules (1 glucose molecule). (Obtained from Lodish et al., 2000) 
 
 GLYCOGEN SYNTHESIS  
Cardiac glycogen concentration can vary based on training status, exercise and diet (Depré et al., 
1998). Glycogen comprises about 2% of the adult heart cell volume, and 30% of fetal and newborn 
cardiomyocytes (Shelley, 1961). In contrast to liver and skeletal muscle cells, cardiomyocytes 
produce glycogen during fasting (Schneider et al., 1991). In times of fasting, fatty acids become the 
predominant fuel for the heart, whilst glycolysis (to a greater extent) and glucose uptake is 
decreased. This leads to a repurposing of glucose for glycogen synthesis. Glycogen stores can be 
further expanded as a result of insulin, which simultaneously stimulates glucose transport and 
glycogen synthase activity (Moule & Denton, 1997). Glycogen synthesis is also upregulated when 
lactate is used as the primary fuel for the heart (Laughlin et al., 1994). The rate of glycogen 
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synthesis is limited by the enzyme, glycogen synthase (GS) (Figure 2.7), which transfers glucose 
from UDP-glucose to an amylose chain. The enzyme has 2 distinct conformations, namely a G-6-
P-dependent or inactive D-form, and a G-6-P-independent or active I-form. Control of these 
conformations are dependent on phosphorylation-dephosphorylation reactions.  
 
Figure 2.7 Glycogen Synthesis Pathway.  
 
Furthermore, heart glycogen can also be broken down in response to adrenaline or oxygen 
deprivation to produce glucose (Morgan & Parmeggiani, 1964). Glycogenolysis is controlled by 
glycogen phosphorylase, which is activated in direct response to increased Ca2+ concentrations 
and indirectly through cyclic AMP-dependent protein kinase (PKA). Both these activators can be 
upregulated in response to catecholamines (Depré et al., 1998).  
 
In a failing heart, metabolism switches to glucose as the preferred substrate due to the efficiency of 
glucose oxidation in the generation of high-energy phosphates (Shah & Shannon, 2003). 
Increasing the amount of energy derived from glucose requires the upregulation of glucose 
transport and glucose oxidation. However, in the case of insulin resistance, glucose uptake and 
oxidation are both impaired, leading to less ATP generated from glucose.  
 
1.3.2.3 FATTY ACID METABOLISM 
Mammalian adipose tissue responds to two distinct classes of peptide hormones, namely 
‘adipokinetic’ hypophyseal peptides (stimulate lipolysis resulting in free fatty acids), and insulin 
(stimulate the conversion of glucose into CO2, triglycerides and glycogen) (Girolamo et al., 1965). 
In the heart, utilizing fatty acids (FAs) for energy metabolism is very dynamic and can account for 
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nearly 100% of total energy requirements or feature only in a minor capacity (Bing et al., 1954; 
Opie et al., 1968; Opie et al., 1969).  
 
The degree of FA utilization is subject to:  
o the energy demand 
o the presence of competing energy substrates 
o FA concentration, type available and supply to the heart  
o the amount of oxygen available 
o allosteric control of FA uptake into cells and transport to mitochondria  
o esterification of FA to Coenzyme A (FA must be esterified to CoA before they can undergo 
lipid oxidation) 
o functioning of the mitochondria which includes β-oxidation, TCA cycle and electron 
transport chain (ETC) activity 
o the presence of lipoprotein lipase (LPL) which derives FFA from chylomicrons, effectively 
lowering VLDL concentration  
o transcription of new enzymes involved in FA metabolism (Lopaschuk et al., 2010).  
 
 SOURCE OF FATTY ACIDS 
FAs reach the heart in one of two forms: free FAs (FFAs) bound to albumin or FAs released from 
triacylglycerol (TAG) found in chylomicrons or very-low-density lipoproteins (VLDL) (Van der Vusse 
et al., 2000). Both are equally important in metabolism by heart cells. Under normal physiological 
conditions, FFAs circulate at concentrations between 0.2 and 0.6 mM, but under diseased 
conditions such as myocardial ischemia and diabetes, concentrations can rise to above 2 mM 
(Kurien & Oliver, 1971). Excess body fat can be broken down and released as FFAs to meet 
energy requirements. It is estimated that one kilogram of bodily fat contains 7740 calories of 
potential energy (Jennings & Lesser, 2012), which is double the amount of energy stored in equal 
amounts of glycogen (Kotecki, 2011). However, persisting levels of high circulating FFAs in obesity 
and diabetes is a strong determinant of high rates of FA uptake and β-oxidation in these diseased 
states.  
 
1.3.2.4 INTERSPECIE DIFFERENCES 
Curiously, in mouse hearts perfused with high fatty acid levels, sensitivity to insulin persists and 
still leads to dramatic increases in glucose oxidation rates, whereas in rats, insulin sensitivity was 
inhibited by the presence of fatty acids (Abdel-aleem & Lowe, 2012; Chandrasekera & Pippin, 
2014). Also, insulin did not reduce myocardial fatty acid β-oxidation rates in rats in the presence of 
high levels of FA (Saddik & Lopaschuk, 1991), but did reduce the rates in mice (Folmes et al., 
2006). Interspecie differences in regulating fatty acid and insulin sensitivity are an important 
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concept researchers need to be aware of when aiming to duplicate high-fat diet, obesity and 
diabetic studies.   
 
In humans, the primary insulin-sensitive tissue is the skeletal muscle which account for 50-90% of 
glucose clearance, and stores up to 10 times more glycogen than the liver (DeFronzo & Tripathy, 
2009). In contrast, in rodents the primary site for glucose clearance is the liver, which stores 5-10 
times more glycogen than the skeletal muscle (Kuo et al., 1999). Furthermore, in human skeletal 
muscle, glucose uptake is primarily regulated by a high affinity GLUT4, which also serves as the 
rate-limiting step, whereas in rodent livers, glucose uptake is facilitated by a low affinity of GLUT2 
and the rate-limiting step is given by glucose phosphorylation rather than glucose uptake (Petersen 
& Shulman, 2002). Thus, comparatively, physical exercise capable of mimicking the actions of 
insulin, target skeletal muscles in humans more significantly than in rodents by increasing glucose 
uptake and glycogen synthesis, whereas the exercise-mediated glucose transport in the liver is 
less significant (Jensen & Richter, 2012). Furthermore in humans, insulin resistance present with a 
significantly reduced GLUT4 content, and subsequently impaired glucose transport into skeletal 
muscles, impaired glycogen synthesis and high blood glucose (DeFronzo & Tripathy, 2009). 
However, GLUT4-knockout mice and rodents lacking GLUT4 do not present with high blood 
glucose (Fam et al., 2012). Furthermore, in humans, impaired glucose uptake result from 
decreased GLUT4 expression levels, whereas in rodents, it is a result of impaired GLUT4 
translocation to the cell membrane (Hansen et al., 1998).  
 
1.3.2.5 ALTERATIONS IN OBESITY AND DIABETES 
Under normal physiological conditions, excess supply of energy not utilized for immediate energy 
needs, are stored in the form of triacylglycerols (TAG) in adipocytes. The release of FFA is also 
acutely regulated to meet the energy requirements. When this balance is disturbed through 
mechanisms such as persistent overconsumption of food, adipose tissue greatly expands, leading 
to greater release of FFA into circulation and in turn elevated levels of circulatory FFA and TAG 
(Boden, 2008). Elevated FFA in circulation leads to increased VLDL-TAG synthesis in the liver, 
further exacerbating hyperlipidemia. In both experimental animals and humans, elevated 
circulating fatty acids and TAG levels are important contributors to cardiac substrate selection in 
obesity (Koutsari & Jensen, 2006; Lopaschuk et al., 2010). Thus, there is an increase in fatty acid 
oxidation with increased obesity and insulin resistance (Lopaschuk et al., 1991; Turcotte et al., 
2001). In the heart, myocardial triglyceride content has been found to proportionally increase with 
BMI (Szczepaniak et al., 2003) and is a strong indicator of cardiac dysfunction and heart failure 
(Sharma et al., 2004). In diabetic patients without heart disease, an increase in fatty acid 
circulation has also been correlated with a decrease in heart metabolism and diastolic functioning 
(stiff heart muscles leading to slower filling of the ventricles after a contractile cycle) (Lopaschuk et 
al. 2010; Leichman et al., 2006). Increasing FA supply to the heart can lead to increased FA 
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uptake and in turn increased β-oxidation in obesity and diabetes. This can lead to accelerated FA 
oxidation and has been shown to contribute to the development of diabetic cardiomyopathies by 
decreasing glucose oxidation and lowering cardiac mechanical efficiency (How et al., 2006). 
Fortunately, contractile function can be improved in diabetic patients by pharmacologically 
inhibiting fatty acid metabolism and activating glucose metabolism (Stanley, 1997). 
 
1.4 INSULIN RESISTANCE 
1.4.1 OVERVIEW OF INSULIN RESISTANCE 
Insulin resistance is the condition whereby the insulin sensitive tissues in the body become 
gradually less sensitive to insulin, giving way to ineffective glucose utilization (Beale, 2013). This 
leads to glucose accumulation in the blood instead of being cleared through entering muscle, fat 
and liver cells. In order to compensate for the decrease in insulin sensitivity, higher levels of insulin 
are needed to facilitate glucose uptake by the cells. Initially, the β-cells within the pancreas 
increases insulin production to meet the demand (Leibiger et al., 2008). This response is 
responsible for maintaining normal blood glucose levels in healthy individuals. However, insulin 
resistance left untreated, overburden the β-cells, leading to a lack of insulin to effectively clear 
blood glucose (Figure 2.8). Insulin insensitivity together with a decline in insulin secretion, over 
time, lead to T2D mellitus, and contributes to the metabolic syndrome, increasing the risk for 
cardiovascular disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8 Simplified Schematic of Insulin Resistance. (Obtained from Steiner-Victorin et al., 
2014) 
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1.4.2 ASSESSMENT 
Insulin resistance can be assessed by measuring the insulin levels in the blood or by measuring 
the glucose levels in response to insulin (Bray & Hamman, 2014). The first test, known as a 
hyperglycemic clamp, requires keeping blood glucose levels constantly elevated through 
hyperinfusion of glucose and measuring the response of pancreatic β-cells to produce insulin. The 
second test, known as an euglycemic clamp, intravenously infuses high levels of insulin into a 
patient’s blood, while simultaneously measuring the fluctuating blood glucose levels. The 
euglycemic clamp is considered to be the gold standard in human trials and pharmacodynamic 
studies of drug interactions in diabetes patients (Bray & Hamman, 2014). However, the test is too 
costly and impractical to be used for clinical assessment of diabetes pathology. Rather, blood tests 
are performed to determine the likely presence of insulin resistance, a strong indicator for 
prediabetes. All blood tests involve drawing blood by a health care provider, followed by further 
laboratory analysis. In humans, instant glucose measuring devices serve purely as indicator of 
blood glucose levels, but further analysis is needed to make a diagnosis of prediabetes/diabetes.  
 
1.4.2.1 HEMOGLOBIN A1C 
Hemoglobin A1c (HbA1c), or glycohemoglobin, is used as an indicator of average blood glucose 
over the past 3 months (Insulin Resistance and Prediabetes, National Institutes of Health (NIH), 
2015). The test is based on binding of glucose to hemoglobin, the oxygen-carrier protein present in 
red blood cells, which typically have a lifespan of 3 months. The percentage of bound HbA1c can 
be used to determine a person’s diabetic status. A percentage between 5.7 and 6.4 is considered 
prediabetic (Figure 2.9). It is considered to be the most reliable test, but not always the most 
sensitive to recent developments in prediabetes. However, the HbA1c test can be unreliable for 
diagnosing prediabetes in people of African, Mediterranean or Southeast Asian descent, as well as 
people having a known familial history of sickle cell anemia, due to possesing a hemoglobin variant 
that interferes with the results of the HbA1c test.  
 
1.4.2.2 FASTING PLASMA GLUCOSE TEST 
Measuring fasting blood glucose in people who have not eaten for at least 8 hours, can serve as a 
strong indicator of prediabetes (Insulin Resistance and Prediabetes, NIH, 2015). A fasting glucose 
level between 100 to 125mg/dL (5.6–6.9 mmol/L) (Figure 2.9) is indicative of prediabetes and 
known as impaired fasting glucose (IFG). The test is most reliable when performed in the morning 
hours following sleeping and fasting.  
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1.4.2.3 ORAL GLUCOSE TOLERANCE TEST 
Similar to the fasting plasma glucose test, the oral glucose tolerance test (OGTT) also entails 8 
hours of fasting, but additionally, at the start of the test, a person receives a sweet (glucose-
prevalent) liquid to consume, succeeded by follow-up blood glucose tests to determine how quickly 
the blood glucose is cleared (Insulin Resistance and Prediabetes, NIH, 2015). A blood glucose 
level between 7.8–11.0 mmol/L (140 and 199mg/dL) (Figure 2.9) is indicative of prediabetes and 
known as impaired glucose tolerance (IGT).  
 
 
Figure 2.9 Blood glucose tests used as indicator of insulin resistance in humans (Obtained 
from Standards of Medical Care in Diabetes, 2012)  
 
1.4.3 INSULIN 
Insulin is a peptide hormone that plays a crucial role in energy metobolism. In response to an 
increase in blood glucose or amino acids, insulin is produced by the β-cells present in pancreatic 
islets. The produced insulin is then secreted into the blood circulation where it facilitates the 
absorption and utilization of glucose as energy substrate by organs in the body. Insulin’s action is 
essential for tissue development, growth and maintaining energy homeostasis (Sesti, 2006). Insulin 
also influences lipid metabolism by regulating lipid synthesis in liver cells and adipocytes, 
restricting fatty acid breakdown of fat tissue (Sesti, 2006), regulating food intake, stimulating 
sympathetic activity, inducing energy uptake in peripheral tissues, as well as being involved in 
learning and memory (Zhao & Alkon, 2001). Insulin was first discovered in 1921 (Banting et al., 
1956), in search of an effective therapy for diabetes. Today, it is still used as one of the major 
treatments for T1D. 
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1.4.4 INSULIN SECRETION 
Insulin is synthesized from a polypeptide, called preproinsulin, in pancreatic β-cells (Figure 2.10). 
As the preproinsulin is translocated into the lumen of the rough endoplasmic reticulum (RER), the 
polypeptide is cleaved forming proinsulin (Chhabra, 2015). Further maturation of proinsulin into 
insulin occurs at the trans-Golgi apparatus via action of cellular endopeptidases, such as 
prohormone convertases (PC1 and PC2) and exoprotease carboxypeptidase E. PC1 and PC2 
cleave proinsulin at the B-chain-C-peptide junction and C-peptide-A-chain junction respectively 
(Smeekens et al., 1992), releasing a C-peptide fragment and 2 peptide chains, referred to as the 
B- and A-chains which are linked by 2 disulfide bonds. These bonded chains are collectively called 
insulin and stored in mature secretory granules within the pancreatic β-cells, where it is exocytosed 
from the cell into the systemic circulation after stimulation by most notably glucose. Insulin 
secretion is also induced by amino acids (such as leucine and arginine) and lipids (non-esterified 
fatty acids) (Fu et al., 2013), incretins (gastrointestinal tract stimulated hormones, including 
glucose-dependent insulinotropic polypeptide (GIP) and GLP-1) (Baggio & Drucker, 2007), vagal 
nerve stimulation (Ahrén & Taborsky, 1986) and various other hormones (growth hormone, 
glucagon, secretin, cholecystokinin, gastrin, VIP, gastrin-releasing peptide) (Wilcox, 2005). 
 
 
Figure 2.10 Insulin Synthesis. a) The pancreas contain clusters of cells (islets) which contain β-
cells. b) Within the β-cells, insulin is synthesized between the endoplasmic reticulum and the trans 
Golgi apparatus. c) Pre-prosinsulin, a pro-hormone, is cleaved several times to produce mature 
insulin. d) The structure of the final insulin product which is released into the blood in response to 
high blood glucose. (Adapted from Chhabra, 2015) 
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After consuming a meal, blood glucose rises and insulin is subsequently released into the blood 
via the pancreas. Insulin plays a multifunctional role within the body. Firstly, it aids in the 
absorbtion of blood glucose by muscle, fat and liver cells, which in turn lowers blood glucose. It 
also facilitates in converting excess blood glucose levels into glycogen in the liver, muscle and 
heart tissues. Lastly, insulin inhibits the production of glucose by the liver, effectively lowering 
blood glucose levels. Interplay between glucose and insulin in healthy individuals help maintain 
normal blood glucose levels. 
 
1.4.5 INSULIN FUNCTION 
Insulin has been shown to play an intermediate role in a variety of body tissues, eliciting a specific 
response for each organ or tissue target (Benito, 2011). In the heart, skeletal muscle and fat cells, 
insulin stimulates the uptake of glucose by promoting translocation of GLUT4 from an intracellular 
reservoir compartment to the cell border or plasma membrane. Insulin is mainly responsible for 
substrate utilization in the heart, but also augments cardiomyocyte contraction, affects myocardial 
relaxation, promotes angiogenesis and cell survival, downregulates apoptosis, enhances 
myocardial microcirculation and reduces coronary artery resistance, which improves blood 
perfusion of the myocardium (Iliadis et al., 2011). Under normal physiological conditions, skeletal 
muscle is the primary organ responsible for glucose uptake and clears an estimated 80% of total 
blood glucose (Thiebaud et al., 1982). Of this glucose, up to 80% of insulin-stimulated muscle 
glucose is converted to glycogen, while the rest is oxidized to CO2 and H2O (Abdul-Ghani & 
DeFronzo, 2010). Insulin plays a dual role in pancreatic β-cells - historically, insulin is suggested to 
negatively impact β-cells through autocrine feedback, but it has also been found to play a positive 
role in transcription, translation, ion flux, insulin secretion, proliferation, and β-cell survival (Liebiger 
et al., 2008). Insulin is also crucial for proper kidney function (Hale & Coward, 2013). Poor insulin 
signalling, as in the case of insulin resistance, can lead to renal complications such as 
hypertension and albuminuric glomerular disease (Re, 2015). A strong link between endothelial 
dysfunction and insulin resistance has also been observed, further aggravating metabolic and 
cardiovascular diseases (Muniyappa & Quon, 2007). In the brain, insulin was shown to serve as a 
key neuromodulator in behavioural, cellular, biochemical and molecular studies (Derakhshan & 
Toth, 2013).  
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1.4.6 INSULIN SIGNALING 
The insulin hormone is circulated throughout the body via the blood, until it reaches its target tissue 
where it binds to the insulin receptor (IR). From this point, three distinct pathways can follow: the 
phosphatidyl-inositol 3-kinase (PI3K)/Akt pathway; Ras-mitogen-activated protein kinase (Ras-
MAPK) or the CAP/CbI/TC10 pathway. Once activated these pathways elicit the effects of insulin 
which pertain to (Wilcox, 2005): 
 
Carbohydrate Metabolism 
 translocation of GLUT4 to the membrane – increases glucose uptake into cells 
 inhibits glycogen synthase kinase-3 (GSK-3) – increases glycogen synthesis 
 inhibits glycogen phosphorylase kinase – decreases glycogen breakdown 
 activates pyruvate kinase - increases glycolysis (Figure 2.5) 
 inhibits 2,6-bisphosphate kinase – decreases gluconeogenesis 
 enhances irreversible pyruvate to acetyl Co-A conversion (Figure 2.6) 
 
Lipid Metabolism 
 activates acetyl CoA carboxylase – increases fatty acid synthesis and storage 
 inhibits carnitine acyltransferase – decreases fat oxidation 
 stimulates esterification of glycerol phosphate – increases triglyceride synthesis 
 inhibits hormone sensitive lipase – decreases triglyceride breakdown  
 activates HMG-CoA reductase – increases cholesterol synthesis 
 inhibits cholesterol esterase – decreases cholesterol breakdown 
 
Protein Synthesis 
 enhances mRNA transcription of glucokinase, pyruvate kinase, fatty acid synthase, albumin 
in liver 
 enhances mRNA transcription of pyruvate carboxylase in adipose tissue 
 enhances mRNA transcription of casein in mammary gland 
 enhances mRNA transcription of amylase in pancreas.  
 Protein translation heavily influenced by the presence of insulin-like growth factor-1 
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1.4.6.1 PI3K/PKB PATHWAY 
The PI3K/PKB pathway is the primary signaling cascade mediating metabolic effects induced by 
insulin. Briefly (Figure 2.11), activation of the IR initiates tyrosine phosphorylation of insulin 
receptor substrates (IRS) 1-4, leading to association with the p85 regulatory subunit of PI3K. PI3K 
phosphorylates phosphatidylinositol phosphates (PIPs) in the membrane e.g. phosphatidylinositol 
4,5-bisphosphate (PIP2) to create phosphatidylinositol 3,4,5-triphosphate (PIP3). Following this 
activation, phosphoinositide-dependent kinase-1 (PDK1) and related down stream effector 
molecules are recruited and activate PKB/Akt, which elicits the metabolic effects of insulin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11 Insulin Dependent and –Independent Pathways of Glucose Uptake 
 
 IR 
IR (Figure 2.12) is a tetrameric enzyme consisting of two extracellular α-subunits and two 
transmembrane β-subunits linked together by disulfide bonds (Ottensmeyer et al., 2000). Upon 
insulin binding to the α-subunits of the receptor (Figure 2.11), the intrinsic tyrosine kinase activity 
of the β-subunits are activated. This causes an autophosphorylation of various tyrosine residues 
present in the β-subunits. This creates phosphotyrosine binding domains that can be recognized 
by proteins containing Src Homology 2 (SH-2) domains in their structure. Once activated, IR binds 
its downstream effectors, insulin receptor substrate (IRS) family and Shc. This induces the 
activation of two primary pathways, namely the PI3K and the MAPK pathways, respectively 
(Bertrand et al., 2008).  
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Figure 2.12 Insulin Receptor (Obtained from Nelson et al., 2008) 
 
 IRS 1 
IRS proteins are primary insulin signaling regulators central to cell growth, survival and metabolism 
(Liberman & Eldar-Finkelman, 2005). They serve as a link between the IR and downstream 
signaling molecules with SH2 domains (Figure 2.11). The IRS family consists of four different 
isoforms, IRS-1, IRS-2, IRS-3 and IRS-4, each expressed to different degrees in specific tissue 
types and subcellular localization. IRS-1’s function pertains primarily to glucose uptake in cardiac, 
skeletal muscle and adipose tissue, whereas IRS-2 regulates glucose production in the liver and 
insulin production in pancreatic β-cells (Sesti et al., 2001). In insulin-resistant states, such as 
obesity and type 2 diabetes, only defective IRS-1 and IRS-2 expression has been implicated, 
whereas the rest of the IRS family plays an insignificant role. 
 
 PI3K 
Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) is a heterodimeric protein consisting of a 
p110 catalytic and a p85 regulatory subunit (Mora et al., 2005). Once activated in response to 
insulin, PI3K recruits to the plasma membrane. The regulatory subunit, consisting of SH2 domains, 
binds to phosphorylated tyrosine residues on IR and IRS adaptor proteins. PI3K primarily 
phosphorylates phosphatidylinositol-3,4-bisphosphate (PIP2) lipids into phosphatidylinositol-3,4,5-
triphosphate (PIP3) on the plasma membrane creating rafts where proteins containing a pleckstrin 
homology (PH) domain can associate. This induces further recruitment of phosphoinositide-
dependent kinase 1 (PDK1) and PKB. In the heart (Figure 2.12), it has been shown in PDK1 
knockout mice that PDK1 is necessary for the activation of cardiac PKB (Mora, 2003). Thus, in 
response to insulin stimulation, co-localization of both PDK1 and PKB is important for metabolism. 
Synergy between PDK1 and PKB is also essential in regulating glucose uptake in the heart 
(Dummler & Hemmings, 2007).   
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 PTEN 
PTEN (Phosphatase and tensin homolog) is a phosphatase involved in cell cycle regulation, 
controlling cell growth and division (Besson et al., 1999). It plays a role in the hydrolyses of 
phospho-inositide substrates, such as converting the product of PI3K, PIP3 into 
phosphatidylinositol-4,5-bisphosphate, thereby inhibiting the PKB signaling pathway (Sasaoka et 
al., 2006). Inhibition of PKB signaling also regulates cell cycling by preventing cells from growing 
and dividing too rapidly (Chu & Tarnawski, 2004). Inhibiting further cell division is an important 
mechanism in apoptosis of cancer cells and suppressing tumor growth, and therefore, PTEN plays 
a central role as a tumor suppressor as well (Gupta & Dey, 2012). Mutation of the PTEN gene has 
been linked to various forms of cancer. Inhibition of PTEN in skeletal muscle and adipose tissue 
can serve as a protective mechanism in insulin resistance and diabetes (Wijesekara, 2005). 
 
 PKB 
Protein Kinase B (PKB) or Akt is a serine/threonine kinase which plays a diverse cellular signaling 
role in especially insulin metabolism. The PKB family has 3 major isoforms, PKB1, PKB2 and 
PKB3, which are all activated in response to PI3K recruitment. Furthermore, the PKB pathway is 
also activated in response to receptor tyrosine kinases, integrins, B and T cell receptors, cytokine 
receptors, G-protein coupled receptors (GPCRs) and especially, stimulation of PKB’s upstream 
activators PIP3 and PDK1 (Hemmings & Restuccia, 2012). PKB consists of a N-terminal PH 
domain, followed by a catalytic domain and a short C-terminal tail (Alessi, 1996) (Figure 2.13). 
PKB activation results from phosphorylation of PKB’s two main regulatory subunits: Thr309, located 
within the T loop of the catalytic domain; and Ser474, located in the C-terminal, non-catalytic region 
of the enzyme referred to as the hydrophobic motif. 
 
 
Figure 2.13 Schematic of Protein Kinase B (Obtained from Yang, 2002) 
 
Our current understanding of PKB activation, inactivation and inhibition is indicated in Figure 2.14. 
Once PKB is recruited to the plasma membrane by binding of its PH domain to PIP3, the Thr
309 
subunit is activated by PDK-1 (Alessi, 1996), whereas the Ser474 subunit is proposed to be 
activated in response to PDK-2, however this mechanism remains elusive since various other 
mediators have also been implicated including MAPKAP kinase-2, protein kinase C (PKC) 
isoforms, integrin-linked kinases, DNA-dependent protein kinase, ataxia telangiectasia mutated 
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(ATM) and PDK-1 itself (Farese, 2002; Bayascas & Alessi, 2005). It has also been proposed that 
the Ser474 subunit of PKB might be activated through autophosphosphorylation after Thr309 
phosphorylation (Bayascas & Alessi, 2005). Post activation, PIP3 decreases and PKB activity is 
surpressed through inactivation by serine/theonine phosphatases (Nicholson & Anderson, 2002). 
Inhibition of PKB occurs when inhibitors induce a conformational change near the PH domain. This 
results in a ‘closed-off’ conformation of PKB, obstructing the binding site for PDK-1 (Barnett et al., 
2005). PKB activation by insulin and other growth factors is blocked when cells are pre-incubated 
with PI3K inhibitors, such as wortmannin (Burgering & Coffer, 1995). 
 
 
Figure 2.14 Model of PKB activation and inhibition through PH-domain dependent 
mechanisms (Obtained from Barnett et al., 2005) 
 
PKB plays an important role in insulin signaling and glucose metabolism, and mutation in the PKB 
gene has been identified in promoting cancerous conditions and impair glucose metabolism 
(Carnero et al., 2008). PKB regulates cell cycling and proliferation by direct action on the cyclin-
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dependent kinase inhibitors, p21 and p27, preventing it’s localization to the nucleus where it 
inhibits cell-cycle effects (Viglietto et al., 2002) (Figure 2.15). PKB can also regulate cell cycling 
indirectly by acting on the transcription factor, p53 (Hlobilkova et al., 2007). PKB can promote cell 
survival by inhibition of pro-apoptotic signals, such as Bcl-2-associated death promoter (BAD) and 
forkhead box O3 (FOXO3) (Manning & Cantley, 2007).  
 
Figure 2.15 Cellular Functions of PKB’s Substrates (Obtained from Manning & Cantley, 2007) 
 
In the heart, PKB activation is regulated by insulin and nutritional status (Shiojima, 2002), exercise 
training (Konhilas et al., 2005), pressure overload (Naga et al., 2000) and advanced heart disease 
(Taniyama, 2005). PKB signaling can regulate myocyte size through the activation of the TSC1/2 
complex and mTOR-dependent pathways (Shioi, 2002), suppression of GSK3β (Haq, 2000) and 
FOXO3a (Skurk, 2005) (Figure 2.15). Activation of the PKB pathway in response to insulin and 
diet-induced changes in body size has been found to induce cardiac growth (Shiojima, 2002). 
Shiojima et al. also found that overexpression of PKB1 in cultured rat heart cells can lead to non-
pathological hypertrophy. PKB1 also plays a protective role in the myocardium of both acute and 
chronic cardiac ischemic injuries (Fujio et al., 2000). PKB1 is the most characterised isoform, while 
very little is still known about the roles of PKB2 and PKB3 in the heart (Walsh, 2006). PKB2 is 
highly expressed in the heart and other tissues involved in metabolism, including skeletal muscle 
and the liver (Altomare et al., 1995). PKB3 is expressed at low levels in the non-stressed heart and 
upregulated in the diseased heart, whereas PKB1 and PKB2 expression remains constant 
(Taniyama, 2005). The diversity of PKB’s influence has made it a prominent therapeutic target for 
treating cancer, diabetes, strokes and neurodegenerative diseases. 
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 GSK-3  
GSK-3 (glycogen synthase kinase-3) is a protein kinase responsible for glycogen synthase 
regulation and plays a prominent role in glucose homeostasis (Ali et al., 2001). Within the heart it 
contains two isoforms, GSK-3α and GSK-3β, with molecular weights of 51 kDa and 37 kDa 
respectively (Woodgett, 1990). GSK-3 plays a multifunctional role in cell signaling involved in 
proliferation, migration, inflammatory responses, glucose transport, glycogen synthesis, apoptosis 
and muscle contractility (Huisamen & Flepisi, 2014; Huisamen & Lochner, 2010). As discussed 
previously, upon entry into the cell, glucose is either metabolised to pyruvate through the glycolytic 
pathways or converted into glycogen by the enzyme glycogen synthase (GS) (Section 1.3.2.2 – 
Glucose metabolism). In response to insulin stimulation, PI3K and PKB is activated, which 
inactivates GSK-3 by phosphorylation of the Ser21 site in GSK-3α and Ser9 site in GSK-3β, 
leading to GS activation (Cohen et al., 1997). In contrast, GSK-3 can be activated by CK2 (casein 
kinase 2) which in turn inhibits glycogen synthesis (Rayasam et al., 2009). Also, once active, GSK-
3 phosphorylates IRS-1 and IRS-2 at their Ser307 and Ser332 sites accordingly, inhibiting IRS-1 
signaling and decreasing subsequent PI3K activation (Eldar-Finkelman & Krebs, 1997). This has 
implicated GSK-3 as a potential negative effector of glucose uptake contributing to insulin 
resistance (Flepisi et al., 2013; Aguirre et al., 2000).  
 
 GLUT4  
Glucose transport type 4 (GLUT4) is an insulin-regulated transporter of glucose into cells, present 
in fat, muscle and heart tissues (Olson & Pessin, 1996). Within the heart cells, five isoforms; 
GLUT1 and GLUT4 (which are most highly expressed), and also GLUT8, GLUT11 and GLUT12 
are responsible for glucose uptake (Abel, 2007). GLUT1 is constitutively present in the 
sarcolemma and facilitates basal myocardial glucose uptake, especially in dormant heart cells, 
whereas GLUT4 is found in intracellular vesicular compartments at basal conditions (Joost & 
Thorens, 2001). GLUT4 is primarily dependent on insulin, and its functioning is impaired when 
insulin signaling is defective (Garvey et al., 1998). Insulin signaling leads to the activation of PKB, 
which in turn phosphorylates PKB substrate of 160kDa (AS160) on 5 suggested sites, of which the 
Ser588 and Thr642 are the most prominent (Manning & Cantley, 2007), resulting in stimulation of 
GLUT4 translocation to the cell membrane. Mutations at these two sites significantly inhibits 
insulin-induced GLUT4 translocation (Sano et al., 2003). Currently, the mechanism proposed for 
PKB-AS160 mediation of GLUT4 translocation, states that PKB activation on the various binding 
sites on AS160 inhibits GTPase-activating protein (GAP) activity, recruiting a Rab-family GTPase 
to become GTP loaded. Upon stimulation, GLUT4 vesicles translocates to the plasma membrane 
and facilitate the uptake of glucose from the blood stream (Mîinea, 2005) (Figure 2.11). 
Alternatively, AMPK has also been found to phosphorylate AS160 independent of insulin (Treebak 
et al., 2006). 
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Skeletal muscle is responsible for 75-80% of glucose disposal from the blood circulation (Abdul-
Ghani & DeFronzo, 2010) and also the most affected tissue type at the onset of insulin resistance 
(Shimokawa et al., 2000). However, GLUT4 levels still remain normal in insulin resistant states 
within the muscle, which implicates defective translocation of GLUT4 as a major contributor to 
insulin resistance (Garvey et al., 1998). Likewise in T2D patients, GLUT4 translocation in skeletal 
muscle is downregulated, while the GLUT4 contents remain the same (Volchuk, 1998). The 
defective translocation is thus either due to impaired insulin signaling or a problem specific to the 
GLUT4 transport system. Various studies have shown that physical exercise can effectively 
resensitize the insulin signaling pathway and increase glucose uptake in skeletal muscles via 
upregulated GLUT4 translocation (Kennedy, 1999).  
 
1.4.6.2 RAS/MAPK PATHWAYS 
The Ras-MAPK-dependent pathway cooperates with the PI3-K/PKB pathway to control cell 
proliferation. MAP kinases (MAPK’s) consists of 3 groups of serine threonine kinases: extracellular 
signal-regulated kinases (ERK1/2/3), c-Jun amino-terminal kinase/stress-activated protein kinases 
(JNK), and p38 MAPK’s (discussed in more depth in Appendix A – Alternative Pathways of 
Insulin-dependent Glucose Uptake). Depending on the extracellular stimuli, these kinases can 
initiate a network of cell signaling cascades with various responses. The different isoforms of ERK, 
JNK, and the p38 MAPK’s are expressed in nearly all types of tissues and cells (Deng et al., 2012).  
 
1.4.6.3 CAP/CBL PATHWAY 
The CAP/CbI pathway is the third proposed mechanism of glucose uptake (Saltiel & Kahn, 2001). 
According to this pathway, after activation of IRS, the Cbl associated protein (CAP) recruits the 
proto-oncogen Cbl resulting in a cascade that also recruit GLUT4 translocation (Figure 2.11). The 
insulin signaling pathways, PI3K-Akt pathway and Cap/Cbl pathway, work together to coordinate 
the regulation of GLUT4 vesicle trafficking, protein synthesis, enzyme activation and inactivation, 
and gene expression which facilitates the actions of insulin such as regulation of glucose, lipid and 
protein metabolism (Sesti, 2006) 
 
 
1.4.6.4 INSULIN-INDEPENDENT MECHANISMS 
 AMPK 
AMPK (AMP-activated protein kinase) is one of the main metabolic energy sensors within cells and 
plays an imperative role in maintaining energy homeostasis (Hardie et al., 2006). AMPK is a 
heterotrimeric protein that contains a catalytic subunit (α) and two regulatory subunits (β and γ) 
(Figure 2.16). AMPKα2 is most commonly expressed in liver, skeletal muscle and heart tissues 
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(Hardie & Carling, 1997). AMPK remains in an unphosphorylated inactive state through interplay 
between the kinase domain (KD), autoinhibitory domain (AID) and N-terminus of the regulatory β 
subunit. AMPK is activated in response to an increase in intracellular AMP/ATP ratio,which effects 
the α hook domain (H) bringing about a conformational change in the heterotrimeric complex by 
relieving AID. Conditions of stress, such as exercise and hypoxia (Mungai, 2011), initiate the 
binding of AMP to AMPK, exposing the regulatory Thr172 site in the catalytic α-subunit, which 
promotes phosphorylation and enhance AMPK activity (Frederich & Balschi, 2002). This also 
protects AMPK from protein phosphatases (PPase) that remove the phosphate groups from the 
Thr172 site, which would lead to the deactivation of AMPK. The β-subunit also contains a glycogen 
binding domain (GBD) which further modulates kinase activation (Zaha & Young, 2012). Once 
activated, AMPK promotes energy generating pathways and inhibits energy consuming processes. 
Additionally, AMPK can be phosphorylated by upstream AMPK kinases, such as liver kinase B1 
(LKB1) and calcium-calmodulin-activated protein kinase β (CAMKKβ) (Woods, 2003) under the 
influence of hormones such as adiponectin (Shibata et al., 2005) and insulin (Beauloye, 2001), 
which also modulates AMPK activity. Adiponectin is a hormone derived from fat cells, and plays a 
protective role when blood supply to the heart is restricted, by activating AMPK to generate energy 
using countermeasures. In contrast, insulin inhibits AMPK activation in response to an excess of 
nutrients. Insulin promotes glycogen, triglyceride and protein synthesis, while AMPK inhibits these 
energy consuming processes (Towler & Hardie, 2007). AMP-activated protein kinase has been 
shown to directly stimulate glucose uptake in skeletal muscle, thereby improving insulin 
insensitivity (Fisher et al., 2002) (Figure 2.11). 
 
 
 
Figure 2.16 Molecular Structure of the AMPK complex. (Obtained from Zaha & Young, 2012)  
 
Stellenbosch University  https://scholar.sun.ac.za
  
 
33 
    
1.4.7 CAUSE OF INSULIN RESISTANCE 
The mechanism underlying insulin resistance is still not completely understood. Maintaining a 
positive or surplus energy balance leads to expanded adipose tissue (obesity) and obesity-related 
disorders, which are commonly associated with insulin resistance. Furthermore, the relationship 
between lipid displacement, insulin resistance and the subsequent development of serious 
disorders including type 2 diabetes, hypertension, dyslipidemia and disorders of coagulation and 
fibrinolysis are well established and can lead to cardiovascular diseases (Boden, 2011). Also, 
adipose tissue not only stores additional calories, but as an endocrine organ also secrete pro-
inflammatory cytokines (Wieser et al., 2013), angiotensin II (Ogihara et al., 2002), leptin, resistin, 
adiponectin, PAI-1. These compounds, when expressed in great quantities, can produce insulin 
resistance. Insulin resistant obese individuals often present with low levels of systemic 
inflammation, as well as adipose tissue inflammation (Wieser et al., 2013). The pro-inflammatory 
cytokines tumour necrosis factor (TNF-α), interleukin (IL)-1 and IL-6 expressed in adipose tissue 
are all upregulated in an insulin state. Angiotensin II has been implicated in the development of 
both hypertension and insulin resistance (Ogihara et al., 2002). It is speculated that elevated 
angiotensin II levels give rise to increased oxidative stress, which impairs downstream activation of 
PI3K – thus, inhibiting the insulin signaling pathway. However, to confirm a significant link between 
obestiy and insulin resistance, these factors need to be elevated to such extent that it induces 
insulin resistance, and conversely, lowering the factors need to reduce insulin resistance (Boden, 
2011).  
Impaired glycogen synthesis, especially in muscle, is one of the earliest detectable defects in 
insulin resistance (Bonadonna, 1993). In skeletal muscle and adipose tissue, glucose uptake is 
initiated through insulin action. Given that nearly 80% of glucose entering the skeletal muscles is 
converted to glycogen, impairment in the synthesis of glycogen, and thus the subsequent lack of 
clearance of glucose from the blood, is one of the major indicators of insulin resistance (DeFronzo 
& Tripathy, 2009). Pancreatic β-cells respond to insulin resistance, regardless of the cause of the 
condition, by increasing the secretion of insulin. However, this leads to abnormally high circulating 
insulin levels in blood plasma that further deteriorates insulin sensitivity in especially skeletal 
muscles (DeFronzo & Tripathy, 2009). Thus, hyperinsulinemia is not only a response to insulin 
resistance, but also exarcerbates the condition (Cavaghan et al., 2000). 
 
1.4.8 SUMMARY OF INSULIN RESISTANCE 
The increased prevalence of obesity in insulin resistant patients is evident. However, insulin 
resistance is only viewed as an adaptive mechanism (to protect cells against acute lipid overload 
and inflammation) which becomes ineffective and leads to multiple metabolic abnormalities in the 
chronic state (Tsatsoulis et al., 2013). Althought many of these abnormalities can also occur in 
non-insulin resistant subjects (McLaughlin et al., 2004), they are closely related to obesity (Cornier 
et al., 2008) and are strongly associated with increased risk for cardiac diseases (Reaven,1988).  
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2. ASPALATHIN: A POLYPHENOL WITH PURPOSE  
2.1 INTRODUCTION 
In South Africa, 80% of the population appeal to indigenous or traditional medicines for primary 
health care (Street & Prinsloo, 2013). Moreover, the Chinese have been using tea medicinally 
since 2700 BC (Heiss & Heiss, 2011). The Western culture was the last to discover the value of tea 
and made it popular in the 17th century, albeit mostly as a social beverage. In recent years, teas 
and herbal teas have yet again been receiving more and more attention as a dietary supplement 
due to their health-promoting effects. Besides water, teas are the most popular drink of choice in 
the world (MacFarlane & MacFarlane, 2004). Generally speaking, teas are aromatic beverages 
prepared by adding hot water to cured leaves of Camellia sinensis or green tea. In comparison, 
herbal teas are infusions made from fruits or herbs, without using the green tea plant (Zhang, 
2002). Consuming tea has also been reported to lower the risk of cardiovascular disease (Bøhn et 
al., 2012) and certain teas have especially potent antioxidant and hypoglycemic properties, which 
aid in preventing oxidative damage to cell structure and function. One of these prominent teas, 
which has gained international acclaim for it’s beneficial properties, is Rooibos - a caffeine-free 
herbal tea with a low-tannin status.  
 
2.2 ROOIBOS 
2.2.1 OVERVIEW OF ROOIBOS 
Rooibos is produced by an infusion of the foliage, stems and leaves of Aspalathus Linearis (from 
the Latin aspalathus or Greek aspalathos – a scented and spiny bush) (Quattrocchi, 2012). In the 
industry, hot water extracts of rooibos are used as a food ingredient in food products, such as 
yogurt and jam, and in beverages, such as instant tea drinks (Joubert & De Beer, 2011). The 
popularity of rooibos has grown significantly since it became a commodity in 1904. In 2010, nearly 
a quarter of teas sold in South Africa was Rooibos, constituting approximately 5 000 tons of 
produce, while 5 000 tons were exported for consumption in Germany, the Netherlands, the United 
Kingdom, Japan and the United States of America (Street & Prinsloo, 2013). 
 
Traditionally, rooibos has been used as a treatment or ointment for alleviating stress-related 
ailments such as insomnia and anxiety. Rooibos polyphenols (Figure 2.17) also exhibit similar 
properties to the polyphenols of honeybush (Cyclopia intermedia), black and green (Camellia 
sinensis) teas when comparing antioxidant potential and antimutagenicity (Van der Merwe et al., 
2006). Furthermore, increased antioxidant levels in unfermented rooibos compared to fermented 
rooibos (FRE), led to the development of green rooibos (GRE). This has become a prominent 
product for nutraceutical industries isolating rooibos compounds for its anti-oxidant properties. 
Rooibos is gaining more popularity as a dietary antioxidant supplement and drinking merely 2 cups 
of either fermented or unfermented rooibos has the potential to raise plasma anti-oxidant levels in 
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healthy adults (Villaño et al., 2011). Furthermore, in adults susceptible to cardiovascular disease, 
consuming 6 cups of fermented rooibos infusions per day for 6 weeks has been shown to improve 
lipid profiles and redox status (Marnewich et al., 2011). 
 
Figure 2.17 Major compounds present in rooibos tea 
 
2.2.2 PROCESSING 
Commercially, rooibos shoots are shredded and bruised, and left to enzymatically and chemically 
oxidize. This is followed by fermentation and sun drying (Joubert & Schultz, 2006). Finally, the tea 
is steam pasteurized to ensure that the final product is microbiologically safe. However, steam 
pasteurization significantly reduces the soluble solids, total polyphenols, total colour and most 
importantly, aspalathin contents of rooibos infusions (Koch et al., 2013). The polyphenol content 
(specific chemical structures with strong anti-oxidant capacity occuring naturally in plants) in 
rooibos extracts, especially the aspalathin and nothofagin (another prominent polyphenol in 
rooibos) content, are dependent on the concentration present in the plant (Schulz et al., 2003) and 
the extent to which the plant material is fermented (Joubert, 1996) (Table 2.1).  
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Table 2.1 Aspalathin and nothofagin content of unfermented (green) and fermented 
(traditional) rooibos tea (Joubert & Schulz, 2006) 
Tea Parameter Aspalathin 
(g/100g) 
Nothofagin 
(g/100g) 
Unfermented 
Range 
Average (n = 97) 
3.84 – 9.66 
6.62 
0.2 – 1.24 
0.67 
Fermented 
Range 
Average (n = 89) 
0.02 – 1.16 
0.26 
0 – 0.40 
0.12 
*n = number of different strains tested 
 
Rooibos processed using hot-water extracts for commercial purposes has similar total polyphenol 
and dihydrochalcone content, but lower flavone content compared to a fresh cup of tea (Joubert & 
De Beer, 2012). Citric acid, a natural preservative found in citrus fruits, and ascorbic acid (vitamin 
C) is usually added to aspalathin-related products to stabilize aspalathin content during heat 
treatment and long term storage (De Beer et al., 2011, Joubert et al., 2010). However, commercial 
beverages such as iced teas contain low to no detectable aspalathin or the related oxidation 
products, orientin and isoorientin (Joubert et al., 2009). 
 
2.3 ASPALATHIN 
2.3.1 OVERVIEW OF ASPALATHIN 
Aspalathin is the primary polyphenol and flavonoid present in the leaves of Rooibos or Aspalathus 
Linearis (Koeppen & Roux, 1966). Flavonoids are plant-derived polyphenols which are naturally 
present in fruits, vegetables, teas and herbs, however aspalathin occurs exclusively in rooibos. 
Aspalathin can either be isolated from rooibos extracts or synthetically produced. It is gaining 
increasing popularity in research as a potent anti-oxidant (Dludla et al., 2014; Joubert et al., 2009), 
stimulant of glucose clearance in muscle cells (Muller et al., 2012) and regulator of energy 
metabolism (Son et al., 2013). Very few studies have been done in humans, and aspalathin have 
been found to have a very low detectable bioavailability, ranging between 0.1 and 0.9% of total 
aspalathin consumed (Kreuz et al., 2008). Aspalathin, is absorbed, metabolized and its 
glucuronidated and sulfonated conjugated metabolites excreted in the urine (Courts & Williamson, 
2009). It is however possible that aspalathin can aggregate over time and elicit its various 
physiological responses. 
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2.3.2 STRUCTURE 
Aspalathin (2’,3,4,4’,6’-pentahydroxy-3-C-β-D-glucopyranosyldihydrochalcone) is considered to be 
a C-glycosyl dihydrochalcone (Figure 2.18). Aspalathin is soluble in water and other polar 
solvents, but insoluble in non-polar media. It is also not stable during heat treatment, and oxidizes 
rapidly in the presence of light. Aspalathin is biogenetically related to other flavonoids isolated from 
rooibos tea (Koeppen & Roux, 1966). It is one of the few naturally occuring dihydrochalcones, 
together with nothofagin and pterosupin, also discovered in plants (Yoshida et al., 1993) and a rare 
class of flavonoid compound (Williams, 1964). To date, aspalathin is found to be exclusively 
present in Aspalathus Linearis.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.18 Structure of aspalathin (A) and the root chemical structure, dihydrochalcone (B) 
 
2.3.2.1 ROOIBOS TEA COLOURATION 
Koeppen & Roux (1966) found that, in the presence of oxygen and sunlight, aspalathin produced 
the flavanones 2,3-dihydro-iso-orientin and 2,3-dihydro-orientin, which converted to unknown 
brown products. This was thought to be the mechanism by which the red-brown colour 
development of rooibos tea occurred till Joubert (1994) was able to show the colouration in the 
absence of sunlight under controlled conditions, implicating aspalathin as the sole colouration 
agent (Joubert, 1994). 
 
2.3.3 ASPALATHIN SYNTHESIS 
Fermentation of rooibos is very detrimental to aspalathin content with losses as high as 98% 
reported (Schulz et al., 2003). Aspalathin is degraded through various nonenzymatic mechanisms 
during fermentation. The first mechanism to be elucidated is through oxidation in the presence of 
heat and light - aspalathin is converted into the flavanones (S)- and (R)-eriodictyol-6-C-β-D-
glucopyranoside, which further converts to the flavones, iso-orientin and orientin (Marais et al., 
2000). The second mechanism, also by means of oxidation, results in aspalathin dimers formation, 
when O-quinones are nucleophilically linked to aspalathin compounds (Krafczyk & Glomb, 2008). A 
 
(B) 
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third mechanism, and key to the colour formation of rooibos during fermentation, was discovered 
by Heinrich et al. (2012), by which aspalathin is oxidized to coloured structures with dibenzofuran 
skeletons, called (S)- and (R)-3-(7,9-dihydroxy-2,3-dioxo-6-β-D-glucopyranosyl-3,4-
dihydrodibenzo[b,d]furan-4a(2H)-yl) propionic acid. Yepremyan et al. (2010) was also able to 
synthetically isolate aspalathin in 8 steps, using tribenzyl glucal, tribenzylphloroglucinol, and either 
4-(benzyloxy) phenylacetylene or 3,4-bis(benzyloxy)phenylacetylene with 20% overall yield. 
 
2.3.4 BIOAVAILABILITY 
Bioavailability is assessed by quantifying the metabolites of a compound in order to determine the 
extent of flavonoid metabolism, and in this case metabolites of rooibos compounds in vivo (Walle, 
2004). It has been repeatedly shown that in vitro activity does not necessarily mimic in vivo activity. 
This is especially true for polyphenols which are known to be first metabolized by phase I and II 
liver enzymes, as well as the kidneys, resulting in conjugates forming in the blood plasma and 
urine (McGurk et al., 1998). Unfortunately, the biological properties of the majority of these 
products still remain unknown (Scalbert et al., 2002). Through conjugation, the biological effects of 
the parent compound can be either reduced or completely inhibited (Day et al., 2000). Flavonoids 
bind to proteins, such as albumin, effectively lowering the detectable free flavonoid levels in the 
plasma (Manach et al., 1997), while the majority of flavonoids can be directly transported to the 
large intestine.  
 
Huang et al. (2008) tested the transport of aspalathin across human skin and Caco-2 intestinal 
epithelial cells. They found that only 0.01% of the initial dose administered was able to cross the 
skin-barrier, while nearly 80% of the aspalathin was transported across the Caco-2 cell monolayer. 
Breiter et al. (2011) found low bioavailability of flavonoids in plasma (only 0.26% of the total 
flavonoids ingested), which correlated with no significant increase in antioxidant capacity of the 
blood. After ingestion of aspalathin, the glycoronyl and sulphate conjugates are present in rat liver 
extracts (Van der Merwe et al., 2010) and O-linked methyl-, sulphate-, glucoronide-, and O-methyl-
O-glucoronide derivates in human urine and plasma (Stalmach et al., 2009). Unmetabolized 
aspalathin is also detectable in human plasma (Laue et al., 2009). Aspalathin has a very low 
estimated absorption rate between 0.1% and 0.9% in pigs and humans (Kreuz et al., 2008, Courts 
& Williamson, 2009, Stalmach et al., 2009). The unconjugated polyphenols as well as the 
remaining conjugates, could possibly aggregate in the body and elicit pharmacological activities 
(Zhang et al., 2007), which is to say, even though aspalathin has a low bioavailability in humans, it 
could still accumulate and produce effects in tissue and body fluids.  
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2.3.4.1 MECHANISM OF METABOLISM 
The metabolism of aspalathin is dependent on how aspalathin is distributed between the aqueous 
(cytosolic) and lipid (membrane) compartments in the cell. At a physiological pH of 7.4, the majority 
of polyphenols associate with the polar head groups of the membrane phospholipids, exposing its 
OH-group for glucoronidation (Verstraeten et al., 2003). Polar metabolites accumulate in the 
cytosol of cells and undergo methylation and sulfation. For instance, the major urinary metabolite 
of aspalathin, O-methyl glucoronide (Stalmach et al., 2009), seems to be the result of methylation 
in the cytosol, followed by glucoronidation in the endoplasmic reticulum. Also, conjugation 
increases hydrophilicity compared to the parent compounds, altering their site of action, and should 
they retain their anti-oxidant properties, cause altered interaction with cellular antioxidants. 
Glucoronidation of aspalathin dissipates its antioxidant potential, but it can still elicit other biological 
properties, as compared with the conjugation of another rooibos compound, quercetin (O’Leary et 
al., 2003; Day et al., 2000). The rate of conjugation reactions can also be impeded due to high 
demand for the same substrates. The factors influencing the rate include the concentration or dose 
of polyphenol administered and the hydrophobic/hydrophilic nature of the subcellular environment 
(Koster et al., 1981). The higher the dose, the more likely sulfation conjugation will occur, rather 
than glucoronidation. Even though polyphenolic conjugation is well recognized, most biological 
studies still incorporate unmetabolized, natural, plant polyphenols. 
 
2.3.4.2 METABOLITES 
Breiter et al. (2011) identified 5 different metabolites derived from aspalathin in urine. Of these, 4 
are conjugated forms, namely sulphated, glucoronidated, methylated and both glucoronidated and 
methylated aspalathin and the 5th is referred to as the aglycone (glucoronidated-2,3,4,4’,6-
pentahydroxy-dihydrochalcone) of aspalathin. Also, unchanged aspalathin was identified in the 
urine of volunteers consuming rooibos tea and isolated aspalathin-enriched rooibos fractions 
(ARF). Methylated aspalathin was detected in a higher concentration, compared to free aspalathin, 
indicating methylation as a significant conjugation pathway (Breiter et al., 2011). Metabolites are 
still excreted 5 hours after consumption of aspalathin-containing drinks, indicating the small 
intestine as the primary point of absorption (Stalmach et al., 2009). 
 
2.3.4.3 CLINICAL STUDIES 
Fermented rooibos consumed as part of a dietary regime was shown to elevate total blood plasma 
polyphenol levels and improve the lipid profile and redox status (Marnewick et al., 2011). Villano et 
al. (2010) was also able to verify an increase in blood plasma antioxidant potential 1 hour after 
healthy adults consumed 2 cups of fermented rooibos, similar to other strong antioxidants, such as 
black tea (Widlansky et al., 2005), green tea (Coimbra et al., 2006) and cranberry juice (Duthie, 
2005). 
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2.3.4.4 ANIMAL TOXICITY 
Marnewick et al. (2003) treated ten Fisher 344 rats with 2 g/100 ml GRE and FRE for 10 weeks 
and found no adverse effects on body weight, liver, kidney or serum parameters (including 
aspartate transaminase, alanine transaminase (ALT), alkaline phosphatase (ALP), creatinine, 
bilirubin, total protein, cholesterol and iron status).  
 
2.3.4.5 HUMAN TOXICITY 
Poorly processed rooibos contains high amounts of Salmonella, a gram-negative bacteria which 
can cause severe diarrhea, fever and abdominal cramps in infected patients (Gouws et al., 2014). 
However, proper processing of rooibos usually insures that the rooibos is microbially safe (Joubert 
& Schultz, 2006). In 2010, Sinisalo et al. reported a case study describing a 42-year-old woman 
who had been experiencing possible hepatotoxicity from consuming 1L of rooibos tea (Forsman 
Rooibos tea; Vantaa, Finland) per day for 2 weeks. She exhibited elevated plasma levels of ALT, 
ALP and gamma-glutamyl transferase. Given that this was an isolated incident regarding rooibos’ 
toxicity, it is speculated that the hepatotoxicity could be due to a genetic predisposition to one of 
the bioactive compounds in rooibos causing an adverse reaction, or that the specific brand of 
rooibos she consumed might have been laced with hepatotoxic compounds (Sinisalo et al., 2010). 
In contrast, Marnewick and colleagues (2011) gave 40 volunteers six cups of fermented rooibos 
per day for six weeks (equating to ~1.5L per day) and found some individuals to present with minor 
elevations in hepatic enzymes, but not enough to be of clinical significance. Overall, rooibos has 
been confirmed as safe for human consumption by at least 3 studies (Hesseling et al., 1979; Breet 
et al., 2005; Marnewick et al., 2011).  
 
2.3.5 ASPALATHIN FUNCTION 
2.3.5.1 ANTIOXIDANT POTENTIAL 
Under baseline conditions, cells have a natural scavenging capacity to balance reactive oxygen 
species (ROS) production through anti-oxidants such as glutathione (GSH). During diseased 
condition such as diabetes, however, there is an increased vulnerability for cellular damage and 
apoptosis due to an imbalance in the antioxidant to oxidative stress ratio. It has repeatedly been 
shown that diets consisting of primarily plant-based foods and beverages can lower the risk of 
developing chronic diseases (Hu, 2003). Consuming flavonoids reduces the incidence of 
cardiovascular diseases and cancer (Arts & Hollman, 2005; Knekt et al., 2002). Also, dietary 
interventions consisting of polyphenol-rich foods, have shown to improve plasma antioxidant 
capacity and total phenolic content (Lotito & Frei, 2006). Conversely, as shown by Prior et al. 
(2007), consuming nutrients without anti-oxidants, results in a loss of anti-oxidant potential in the 
blood. Moreover, strong anti-oxidant polyphenols have been researched in treating diabetic-
associated complications (Zang et al., 2006). Aspalathin is implicated as one of the main 
contributors of rooibos’ antioxidant potential (Joubert et al., 2009) (Figure 2.19), which is partly due 
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to the relatively high content of aspalathin in rooibos, compared to the other compounds, and also 
its radical scavenging activities.  
 
Figure 2.19 Comparison of the aspalathin’s free radical scavenging ability compared to 
other rooibos flavonoids. DPPH: 2,2-diphenyl-1-picrylhydrazyl free radical, O2
: superoxide 
radical (Joubert et al., 2006) 
 
 IN VITRO 
Dlulda et al. (2014) showed that pretreating cardiomyocytes with FRE improved the anti-oxidant 
status of the cells by reducing intracellular ROS and cell death in response to pro-oxidants 
(exogenous H2O2). This was tested within a solution mimicking an ischemic environment (Dludla et 
al., 2014). Furthermore, FRE preserved GSH and ATP content in cardiomyocytes. They also 
showed that fermented rooibos extract is more effective at protecting cardiomyocytes against cell 
damage than the antioxidant vitamin E (a strong anti-oxidant used in radiotherapy treatment) 
(Prasad et al., 2002). Aspalathin was found to have even greater antioxidant potential than the 
commercial standard EGCG (epigallocatechin gallate), which is the most abundant catechin in 
green tea (Snijman et al., 2007). However, high dosages of polyphenols are known to exhibit pro-
oxidant, rather than anti-oxidant effects (Mennen et al., 2005). This was verified by Dludla et al. 
(2014) as high doses of FRE reduced its protective effect against exogenous H2O2. Aspalathin also 
proved a potent scavenger of ROS induced advanced glycation end products (AGE) in RIN-5F 
cells (Son et al., 2013). In addition, GRE and aspalathin was able to protect against juglone toxicity 
(used in high dosages to generate intracellular superoxides, O2
 and H2O2) by scavenging the 
superoxide anion radicals. Rooibos protects against acute oxidative damage by upregulating hsp-
16, a protein involved in the insulin/IGF-1 signaling pathway. Also, rooibos upregulated sod-3, an 
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enzyme that eliminates ROS, leading to an increase in stress resistance. Similarly, rats treated 
with rooibos tea, had upregulated serum SOD (superoxide dismutatase) levels (Baba et al., 2009). 
 
Chen et al. (2013) investigated the protective properties of aspalathin, GRE and FRE in C.elegans 
- an invertebrate organism used for investigating hyperglycemic conditions, ageing and longevity 
through simulation of a high glucose environment (Schlotterer et al., 2009). They found that both 
rooibos and aspalathin ameliorate the amount of hydrodren peroxide anions and related ROS 
generating compounds, such as juglone. Furthermore, ARF and purified aspalathin inhibited the 
activity of xanthine oxidase (XOD), an enzyme responsible for generating reactive oxidant species. 
Aspalathin was found to be a competitive inhibitor of XOD with an inhibition constant (Ki) of 3.1 
M, comparative to other flavonoids like phloretin, which has a Ki of 0.66 M (Nagao et al., 1999). 
  
 IN VIVO 
Rats treated with both GRE and FRE displayed increased myocardial total GSH content and 
reduced oxidative stress, which was also associated with improved aortic output recovery after 
ischemia/reperfusion (Pantsi et al., 2011). In a study done by Marnewick et al. (2011), 40 human 
adults at risk for cardiovascular disease consumed 6 cups of fermented rooibos for 6 weeks, and 
were shown to have an improved redox status and elevated plasma GSH levels. Likewise, Villaño 
et al. (2010) found elevated plasma antioxidant capacity for 1 hour in healthy adults following the 
consumption of 2 cups of both fermented and unfermented rooibos tea.  
 
 SYNERGY BETWEEN RELATED COMPOUNDS IN ROOIBOS 
Simpson et al. (2013) showed that the antioxidant activity of green and fermented rooibos infusions 
are controlled by the presence of the two active dihydrochalcones, aspalathin and nothofagin. They 
also found that, by preparing artificial infusions, using the most abundant polyphenols in similar 
concentrations present in natural rooibos infusions, created a synergistic effect between the 
polyphenols allowing a greater antioxidant activity than that of natural infusions.  
 
 ANTI-AGEING EFFECTS 
Glucose shortens the life span of C.elegans through inhibition of the FOXO transcription factor daf-
16, present in the insulin-signaling pathway (Lee et al., 2009), however Chen et al. showed that 
aspalathin is able to reverse these aging effects by upregulating daf-16. The balance between 
internal and external ROS production in response to stress, is at the core of the ageing process 
and many age-related diseases. Aspalathin, as a strong anti-oxidant, is able to intervene in the 
ageing mechanism (Finkel & Holbrook, 2000).  
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2.3.5.2 CARDIOPROTECTION 
Pretreatment of cardiomyocytes with fermented rooibos prevented damage induced by ischemia, 
as indicated by a reduced amount of high fatty acid binding protein leakage (Dludla et al., 2014). 
The effect of pure aspalathin on the heart, heart cells or heart cell analogs have not been 
investigated to date. 
 
2.3.5.3 GLUCOSE UPTAKE 
Aspalathin has been found to dose-dependently increase glucose uptake in rat L6 skeletal 
myotubes at concentrations between 1 and 100 M (Kawano et al., 2009; Son et al., 2013). 
 
 PKB-DEPENDENT MECHANISM 
In rats supplemented for 7 weeks with GRE and FRE, Pantsi et al. (2011) found low to no effect by 
rooibos flavonoids on total PKB levels in the hearts. Mazibuko et al. (2013) also found no influence 
on total PKB, but found that rooibos did in fact increase phospho-PKB (P-PKB) levels in the heart. 
Arguably, the specific composition of polyphenols present in the rooibos extracts used in their 
respective studies could have contributed to this effect. In another study done by Son et al. (2013), 
rooibos also did not activate PKB in normal L6 myocytes, whereas Mazibuko et al. was able to 
show activation of PKB in insulin resistant C2C12 myocytes when treated with rooibos. Mazibuko 
et al. observed that chronic exposure to saturated free fatty acids, such as palmitate, reduces 
downstream activation of IRS-1 resulting in decreased PKB activation and GLUT4 translocation, 
effectively producing more insulin resistant cells (Bhattacharya et al., 2007). However, when 
treated with rooibos, the P-PKB levels of the palmitate treated cells resembled that of normal PKB 
levels when stimulated by insulin, suggesting that rooibos can resensitise downstream insulin 
signaling. 
 
 AMPK-DEPENDENT MECHANISM 
Mazibuko et al. (2013) found that insulin resistant mouse C2C12 skeletal muscle cells treated with 
rooibos, resulted in the activation of the insulin-independent AMPK pathway which culminated in 
increased levels of GLUT4. Similarly, Son et al. (2013) found that aspalathin activated AMPK 
signaling and promoted endogenous GLUT4 translocation to the plasma membrane in L6 
myocytes and in skeletal muscle of ob/ob mice fed a diet substituted with 0.1% aspalathin for 5 
weeks (effective aspalathin dose 100mg/kg/day/mouse), but did not affect PKB activation. In 
C2C12 mouse skeletal muscle cells, Muller et al. (2012) also showed aspalathin is able to improve 
glucose uptake, while this same effect could not be mimicked in Chang liver cells, which does not 
contain GLUT4. This strongly implicates GLUT4 and AMPK as essential role players in eliciting 
aspalathin’s response.  
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2.3.5.4 RESTORE GLUCOSE HOMEOSTASIS 
Mazibuko et al. (2013) found that treating palmitate-induced insulin-resistant C2C12 skeletal 
muscle cells with either FRE or GRE enhanced glucose uptake, mitochondrial activity and ATP 
production. GRE also completely reversed the effects of palmitate by restoring basal glucose 
uptake. Aspalathin suppressed elevated fasting blood glucose and improved impaired glucose 
tolerance in ob/ob mice (Son et al., 2013) and db/db mice (Kawano et al., 2009). Aspalathin also 
suppress gene expression of enzymes related to gluconeogenesis and glycogenolysis, while 
upregulating glycogenesis in the liver of ob/ob mice, resulting in a reduced blood glucose levels 
(Son et al., 2013). In RIN-5F pancreatic β-cells aspalathin upregulates insulin secretion at 
concentrations of 100 M, a further mechanism leading to improved glucose homeostasis (Kawano 
et al., 2009). 
 
 SYNERGY BETWEEN RELATED COMPOUNDS IN ROOIBOS 
Muller et al. (2012) showed that Streptozotocin (STZ)-induced T1D Wistar rats (STZ used to ablate 
insulin producing pancreatic β-cells) pretreated for 1 hour with ARF, suppressed blood glucose 
level increases. Purified aspalathin was unable to elicit the same response, but when aspalathin 
was combined with rutin (another prominent flavanoid present in rooibos), blood glucose was 
effectively suppressed for upto 6 hours (Muller et al., 2012). 
 
2.3.5.5 LIPID PROFILE 
A person’s lipid profile is determined by screening the blood for abnormalities in lipids, including 
cholesterol and triglycerides. In adults at risk for cardiovascular disease, it was found that 6 cups of 
fermented rooibos per day for 6 weeks improved the lipid profile by lowering the LDL-cholesterol 
and TAG levels, and increasing the HDL-cholesterol (Marnewick et al., 2011). In addition, 
fermented rooibos reduced lipid peroxidation, by decreasing conjugated dienes (CDs) and 
thiobarbituric acid reactive substances (TBARS). Furthermore, 0.1% aspalathin administered for 5 
weeks (effective aspalathin dose 100mg/kg/day/mouse) reduced hypertriglyceridemia, serum 
TBARS and adiponectin levels in ob/ob mice (Son et al., 2013). Aspalathin also suppressed gene 
expression of enzymes related to lipogenesis leading to reduced serum triglyceride levels (Son et 
al., 2013) 
 
2.3.5.6 HYPERURICEMIA 
Hyperuricemia is considered to be one of the risk factors in developing metabolic syndrome and 
cardiovascular disease (Dawson et al., 2007; Soltani et al., 2013). Increases in uric acid levels can 
be attributed to a high intake of purine-rich foods, fructose, alcohol and obesity (Emmerson, 1997; 
Nakagawa, 2005). During the metabolism of purines, xanthine and hypoxanthine are converted to 
uric acid by the enzyme xanthine oxidase in the liver and intestine (Borges et al., 2002). Kondo et 
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al. found that ARF and purified aspalathin both significantly suppressed plasma uric acid levels in 
hyperuricemic mice (Kondo et al, 2013). 
 
2.3.5.7 ANTI-APOPTOTIC 
Pantsi et al., (2011) showed that both GRE and FRE fed to rats for 7 weeks, were able to 
significantly decrease poly ADP ribose polymerase (PARP) cleavage (a pro-apoptotic protein), 
while only FRE was able to decrease caspase-3 (also a pro-apoptotic protein) activity, inhibiting 
apoptosis and thereby having a cardioprotective effect. 
 
2.3.5.8 ANTIMUTAGENICITY 
GRE has been shown to reduce oesophageal papilloma (cancer) development in rats (Sissing et 
al., 2011). This strongly implicates rooibos polyphenols as having key anti-cancer potential. In an 
earlier study done by Van der Merwe et al. (2006), FRE was found to be more effective than GRE, 
but highly mutagen specific. Snijman et al. (2007) tested the antimutagenic activity of the major 
flavonoids in rooibos. They found that aspalathin and nothofagin only exhibited moderate 
antimutagenic properties, compared to luteolin and chrysoeriol, and concluded that the 
antimutagenic properties of rooibos is probably not due to aspalathin, but more likely a synergistic 
mechanism between the rooibos compounds.  
 
2.3.5.9 STEROID METABOLISM 
In a study done in non-steroidogenic COS-1 cells by Schloms & Swart (2014), five of the major 
flavonoid compounds present in rooibos (the dihydrochalcones, aspalathin and nothofagin; the 
flavones, orientin and vitexin; and a flavonol, rutin) caused inhibition of adrenal steroidogenic 
enzymes, P450 17α-hydroxylase/17,20-lyase (CYP17A1) and 3BHSD2 (3β-hydroxysteroid 
dehydrogenase). These enzymes guide steroid metabolites in the glucocorticoid, mineralocorticoid 
and andrenal androgen pathways (Schloms & Swart, 2014), and thus serve as upstream regulators 
of the adrenal steroidal pathways. Physiologically, inhibition of steroidogenesis can be beneficial in 
individuals presenting with chronic elevated levels of hormones, such as cortisol which have been 
implicated in metabolic disorders, including obesity, insulin resistance, hypertension, CVDs and 
T2Ds (Chrousos, 2009).  
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CHAPTER 3 
MATERIALS AND METHODS 
 
1. MATERIALS 
AMERSHAM BIOSCIENCES CORP. (GE HEALTHCARE LTD.), UNITED STATES 
Enhanced chemiluminescence (ECL) western blotting detection reagents 
BAYER HEALTHCARE ANIMAL HEALTH, SOUTH AFRICA  
Eutha-naze (sodium pentobarbital) 
BDH CHEMICAL LTD., UNITED KINGDOM 
Glycerol 
BIOMEDICAL RESEARCH AND INNOVATION PLATFORM, MEDCIAL RESEARCH COUNCIL, SOUTH 
AFRICA 
Aspalathin 
BIO-RAD LABORATORIES, INC., UNITED STATES  
Bovine Serum Albumin, Clarity Western ECL Substrate, Millipore Immobilon-p Polyvinyledene 
Fluoride (PVDF) microporous membrane, Quick Start Bradford, Mini-PROTEAN Precast Gels, 
TGX Stain-Free FastCast Acrylamide Kit, 10%, Trans-Blot Turbo Transfer Buffer, Trans-
Blot Turbo RTA Transfer Kit, Mini-PROTEAN TGX Stain-Free Precast Gels 
CELL SIGNALING TECHNOLOGY, UNITED STATES 
Anti-rabbit and anti-mouse IgG HRP-linked secondary antibody, Total-(AMPKα, GLUT4 (1F8) 
mouse mAb, PKB) primary antibodies, Phospho-(AMPKα (Thr172), PKB (Ser473)) primary antibodies 
CLOVER S.A. (PTY) LTD., SOUTH AFRICA 
Elite fat-free milk powder 
GLUCOPLUS INC., CANADA 
Blood glucose meter strips 
HANNA INSTRUMENTS (PTY) LTD., SOUTH AFRICA 
HI 70300L pH Electrode Storage Solution, HI 7004 and HI 7007 pH Buffer Solution 
LASEC SA (PTY) LTD, SOUTH AFRICA  
Parafilm 
LONZA GROUP LTD., SWITZERLAND 
DMEM (with high glucose and L-Glutamine), ViaLight Plus kit, phosphate buffer saline (PBS), 
MycoAlert PLUS Mycoplasma Detection Kit 
MERCK (PTY) LTD., SOUTH AFRICA  
HCl, KCl, KH2PO4, MgSO4, Na2HPO4, Na2SO4, NaCl, NaH2PO4, NaHCO3, Na
+K+-Tartrate, NaOH, 
tetra-Na+-pyrophosphate, tris (hydroxymethyl) aminomethane, dimethyl sulfoxide (DMSO), butanol, 
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Folin-Ciocalteu’s phenol reagent, Millipore Rat/Mouse Insulin ELISA, Luminata Forte Western HRP 
substrate, Calbiochem SignalBoost Immunoreaction Enhancer Kit 
NEXT ADVANCE, INC., UNITED STATES 
0.15 mm diameter zirconium oxide beads 
PERKIN-ELMER INC., UNITED STATES 
2-Deoxy-[H3]-glucose, Emulsifier Scintillator Plus 
ROCHE PRODUCTS (PTY) LTD. - DIAGNOSTICS, SOUTH AFRICA 
BSA fraction V - fatty acid free, BSA fraction V 
SEMPERMED TECHNICAL PRODUCTS, AUSTRIA 
SemperCare Examination Gloves 
SIGMA-ALDRICH LIFE SCIENCE, UNITED STATES  
2,3-BDM, 2-deoxy-D-glucose, 2-mercaptoethanol (solution), acrylamide, aprotonin, CaCl2, D-(+)-
glucose, DMEM (without glucose, L-glutamine, phenol red, sodium pyruvate and sodium 
bicarbonate), EDTA, EGTA, HEPES hemisodium salt, insulin, leupeptin, MgCl2, Na
+-pyruvate, 
SDS, TEMED, trypan blue stain (0.4%), trypsin-EDTA solution, Tween-20, wortmannin, β-
glycerophosphate, β-mercaptoethanol, ammonium persulfate (APS), Triton X-100, 2-
mercaptoethanol, phenylmethylsulfonyl fluoride (PMSF), Coomassie Brilliant Blue G, sodium 
orthovanadate, propidium iodide, JC-1 solid, retinoic acid, phloretin 
THERMO FISHER SCIENTIFIC INC., SOUTH AFRICA 
Countess Cell Counting Chamber Slides, Fetal Bovine Serum, PageRuler Prestained Protein 
Ladder (Fermentas Life Sciences), Penicillin-Streptomycin, 15/50ml Falcon Conical Centrifuge 
Tubes, Horse Serum 
WORTHINGTON BIOCHEMICAL CORP., UNITED STATES 
Collagenase type 2 
2. EQUIPMENT 
AMERSHAM BIOSCIENCES CORP. (GE HEALTHCARE LTD.), UNITED STATES  
Electrophoresis Power Supply (EPS) 301 
BANTE INSTRUMENTS LTD., CHINA 
PHS-3BW Digital pH Meter 
BECTON DICKINSON BIOSCIENCES INC., UNITED STATES 
BD FACSCalibur 
BECKMAN-COULTER INC., UNITED STATES 
L7 Ultracentrifuge, LS6500 Liquid Scintillation Counter 
BENCHMARK SCIENTIFIC INC., UNITED STATES 
Incu-Shaker Mini 
BIO-RAD LABORATORIES, INC., UNITED STATES  
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ChemiDoc MP System, Image Lab Version 5.0, Mini 2-D Cell, Mini-PROTEAN Tetra System, 
PowerPac Basic, Trans-Blot Turbo Transfer System 
BIOTEK INSTRUMENTS INC., UNITED STATES  
ELx800 Absorbance Reader 
GLUCOPLUS INC., CANADA 
Blood glucose meter 
GRANT INSTRUMENTS LTD., UNITED KINGDOM 
Water Bath 
GRAPHPAD SOFTWARE INC., UNITED STATES 
GraphPad Prism 5 
HAUSSER SCIENTIFIC COMPANY, UNITED STATES 
Haemocytometer 
INTERNATIONAL EQUIPMENT COMPANY, UNITED STATES 
Model CM Centrifuge 
LASEC SA (PTY) LTD., SOUTH AFRICA 
Sigma 1-14K Refrigerated Microfuge 
NEXT ADVANCE, INC., UNITED STATES 
Bullet Blender 
NEW BRUNSWICK SCIENTIFIC INC., UNITED STATES 
Galaxy R CO2 Incubator 
OLYMPUS LIFE SCIENCE INC., JAPAN 
Olympus CKX41 Inverted Microscope 
ORTO ALRESA, SPAIN  
Digicen 20 Centrifuge 
OXFORD UNIVERSITY, UNITED KINGDOM 
HOMA2 Calculator 2.2.3 
PERKIN-ELMER INC., UNITED STATES 
Tri-Carb 2810 TR Liquid Scintillation Analyzer 
SENSOR SCIENTIFIC INC., UNITED STATES 
Temperature probe 
SIGMA-ALDRICH LIFE SCIENCE, UNITED STATES  
Eppendorff Minispinplus 
THE LAB WORLD GROUP, UNITED STATES 
Nikon TMS-F Microscope, Nikon Eclipse Ti 
THERMO FISHER SCIENTIFIC INC., SOUTH AFRICA  
Invitrogen Countess Automated Cell Counter, Spectronic 20 Genesys Spectrophotometer, 
HiMark Pre-Stained Protein Standard  
Stellenbosch University  https://scholar.sun.ac.za
  
 
49 
    
3. METHODS 
AIM 1 : ESTABLISH A WISTAR RAT MODEL OF INSULIN RESISTANCE AND OBESITY 
a. Determine the biometric parameters of rats fed a high-fat, high-sucrose diet for 16-30 weeks 
compared to age-matched control groups.  
b. Determine the metabolic parameters of rats fed a high-fat, high-sucrose diet for 16-30 weeks 
compared to age-matched control groups 
 
1.1. STUDY DESIGN: GROUPING, FEEDING AND TREATMENT 
Male Wistar rats at 6 weeks of age and weighing 190±10 g were randomly selected and grouped 
into control and high-fat, high-sucrose diet (HFD) groups. Control rats received a standard 
commercial rat chow containing 1,272 kJ/100 g and unlimited drinking water, whereas the HFD 
groups received a diet consisting of normal chow, supplemented with sucrose, condensed milk and 
holsum fat containing a fairly similar 1,354 kJ/100 g (Table 3.1). Additionally, young control rats on 
a standard commercial rat chow diet weighing between 180-300 g was used throughout the study 
as positive controls to verify the validity of experimental protocols. The present investigation was 
divided into 3 sub-studies according to their specific aim (Figure 3.1). H9C2 cell line was also used 
to test for the efficacy of using the compound. 
 
Table 3.1 Diet composition of Control and High-Fat, High-Sucrose Diet 
*HFD: High-Fat, High-Sucrose Diet 
 
  
Diet Control HFD 
Protein (%) 17.1 8.3 
Carbohydrates (%) 34.6 42 
Sugar(g/100 g) 6.6 24.4 
Fat (g/100 g) 4.8 11.6 
Saturated Fat (g/100 g) 0.9 7.6 
Mono-unsatured Fat (g/100 g) 1.5 2.9 
Poly-unsaturated Fat (g/100 g) 2.4 1.1 
-3 Polyunsaturated Fat (g/100 g) 0.2 0.1 
-6 Polyunsaturated Fat (g/100 g) 2.2 1.0 
Cholesterol (mg/100 g) 3 13 
Energy (kJ/100 g) 1272 1354 
Average Energy Intake Daily (kJ) ~380 - 
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1.2. ANIMAL CARE  
Age and weight matched male Wistar rats were used in the present study. At 4 weeks after birth, 
rats were weaned and allowed free access to standard rat chow and water. Rats were housed in 
cages (maximum 5 per cage) in a stable environment of 22 C, 40% humidity and a 12 hour 
artificial day/night cycle (light from 06:00 to 18:00) at the Central Research Facility, Stellenbosch 
University. The experimental procedure was revised and approved by the Committee for Ethical 
Animal Research for the Faculty of Health Sciences, University of Stellenbosch (Ethical 
Clearance: SU-ACUM14-00013). The revised South African National Standard for the care and 
use of laboratory animals for scientific purpose was followed (SABS, SANS 10386, 2008).  
 
1.3. ORAL GLUCOSE TOLERANCE TEST 
The Oral Glucose Tolerance Test (OGTT) was used to determine the efficacy of rats to clear blood 
glucose following oral ingestion of glucose. Animals were fasted overnight (with access to drinking 
water), before being anaesthetized by intraperitoneal injection with a very low dose of sodium 
pentobarbital (15 mg/kg) (Euthanaze, Bayer HealthCare, RSA). The body weights of the animals 
were determined and the initial, fasting blood glucose levels established from a tail prick using a 
standard glucometer (GlucoPlus Inc., Canada). In addition, 1 ml of fasting blood was collected 
directly from the carotid artery. Thereafter, a solution of 50% sucrose at a dose of 1 mg/g body 
weight, was administered by oral gavage and blood glucose levels monitored by a drop of blood 
from the tail prick and subsequent glucometer readings at various time points (3, 5, 10, 15, 20, 25, 
30, 45, 60, 90 and 120 mins). After the OGTT, animals were allowed to recover for one week from 
this metabolic insult before being sacrificed in other experiments.  
 
1.4. INTRAPERITONEAL FAT 
The intra-peritoneal fat of the control and HFD animals were dissected out and weighed at an 
opportune time after sacrifice and isolation of heart. 
 
1.5. INSULIN ASSAY 
The serum from the fasting blood was used to determine insulin levels of the animals. For the 
determination of serum insulin levels we made use of a commercially available Millipore Rat/Mouse 
Insulin Enzyme-linked immunosorbent assay (ELISA) (Merck (Pty) Ltd., RSA). This non-radioactive 
quantification assay contained an anti-rat insulin coated 96-well microplate and all relevant 
reagents were supplied by the assay kit. Before the assay, all reagents were pre-warmed to room 
temperature (25ºC). The required number of wells for all the blank, standard, quality control (QC) 
and serum samples were washed 3 times with 300 µl 10X diluted Wash buffer and aspirated. 10 µl 
Assay buffer (0.05 M phosphosaline, pH 7.4, containing 0.025 M EDTA, 0.08% sodium (Na)-azide 
and 1% BSA) was added to each blank and sample well and 10 µl Matrix solution (charcoal 
stripped pooled mouse serum) was added to the blank, standard and QC wells. Following this, the 
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standards (10 µl/ml, 5 µl/ml, 2 µl/ml, 1 µl/ml, 0.5 µl/ml, 0.2 µl/ml, 0 µl/ml) were prepared in 
duplicate. 10 µl of each standard was pipetted into the respective wells, 10 µl of the two QC 
samples were added to their appropriate wells, and 10 µl serum of both the control and HFD 
animals were added sequentially in duplicate to the remaining wells. 80 µl rat pre-titered 
biotinylated anti-insulin detection antibody was added to all the standards (including the blank and 
QC samples) and the serum samples followed by an incubation period of 2 hours at room 
temperature at moderate rotation speeds (400-500 rpms) (Incu-Shaker Mini, Benchmark Scientific 
Inc., USA). Afterwards, all the fluid was aspirated and the wells were washed thoroughly with 300 
µl 10X Wash Buffer. 100 µl pre-titered Streptavidin-Horse Radish Peroxidase (HRP)-conjugate in 
buffer was pipetted to each well and incubated for 30 mins at room temperature to visualize the 
target molecule, insulin. After washing the wells again 3 times with 300 µl 10X Wash Buffer, 100 µl 
3,3',5,5'-Tetramethylbenzidine (TMB) One-Step Substrate Reagent was added to each well and 
incubated for 15 mins at room temperature. Finally, 100 µl 0.3 M Stop Solution was pipetted into 
each well. This sulphuric acid solution changed the blue colour to a yellow colour. The intensity of 
the colour was immediately measured within 5 mins on the microplate reader at 450 nm and 590 
nm respectively. A 4-parameter logistic equation dose-response curve was set up by plotting the 
absorbance unit of 450 nm less that of 590 nm, on the Y-axis against the rat insulin standard 
concentrations on the X-axis. The increase in absorbance is directly proportional to the amount of 
insulin measured in the unknown serum samples; therefore the curve was set up with known 
standard insulin concentrations used as a reference for the determination of the samples of 
interest. The homeostasis model assessment for insulin resistance (HOMA-IR) index was 
calculated using the HOMA2 Calculator 2.2.3 software (Oxford University, UK), which calculates 
the product of fasting glucose concentration (mmol/L) multiplied by the fasting insulin concentration 
(μIU/mL) divided by 22.5 (HOMA-IR = [fasting glucose concentration X fasting insulin 
concentration]/22.5), as well as the product of 20 times insulin concentration divided by 3.5 units 
less than the fasting glucose concentration (HOMA-%B = [20 × fasting insulin 
concentration]/[fasting glucose concentration − 3.5]), which corrects for beta cell function (Levy et 
al., 1998).  
 
Similar to Western Blotting, the principle of ELISAs rely on immunodetection. Briefly, insulin 
detection using the Sandwich ELISA occurs through capture of the insulin molecules in a sample 
by binding to the monoclonal mouse anti-rat insulin antibody pre-treated microtiter plate wells, 
followed by binding of biotinylated polyclonal antibodies to the captured insulin. After washing off 
the free enzyme conjugates, the enzyme HRP is added and binds to the biotinylated antibodies. 
This is followed by addition of the substrate, TMB, inducing a colorigenic reaction - decreasing 
absorbency at 590 nm and increasing absorbency at 450 nm due to TMB’s ability to act as a 
hydrogen donor in response to HRP’s reduction of hydrogen peroxide to water. The increase in 
absorbency, or the increase in yellow colour development, is directly proportional to the amount of 
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bound insulin, and thus the insulin concentration of the samples and can be determined by 
comparing the absorbency with a standard curve of known insulin concentrations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Study layout of animal groups and objectives. Y, Young; C, control; HFD, high-fat, 
high-sucrose diet; P, Plates; 2DG, 2-deoxyglucose; PKB, protein kinase B; AMPK, AMP-activated 
kinase; GLUT4, glucose transporter 4.  
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AIM 2: DETERMINE THE POSSIBLE EFFICACY AND TOXICITY OF USING ASPALATHIN TO INDUCE 
GLUCOSE UPTAKE, IN CARDIOMYOCYTES FROM: 
c. young control rats to determine the effect of aspalathin on cell viability 
d. young, control and HFD rats to generate a glucose uptake response curve with 1-100M 
aspalathin and 1-100 nM insulin as positive control 
e. control and HFD rats to determine the effects of the inhibitor wortmannin (inhibits PI3K) on 
aspalathin-induced glucose uptake 
 
2.1. ISOLATION OF CARDIOMYOCYTES 
Rats were collected from the animal house a week prior to being used in experiments to reduce 
the stress of handling on the day of experimentation. Rats were anaesthetized with sodium 
pentobarbital (160 mg/kg) (Euthanaze, Bayer HealthCare, RSA). The rats were weighed and the 
non-fasting blood glucose (or random blood glucose test) value of the animals were determined 
from a tail prick using a standard glucometer (GlucoPlus Inc., Canada). After determining deep 
anaesthesia via an unresponsive foot pinch (pedal reflex), hearts were quickly excised (<1 minute 
after first incision) and arrested in ice cold Krebs-Henseleit (KH) buffer (Table 3.2). 
Cardiomyocytes in an unstimulated state were isolated essentially as initially described by Fischer 
et al. (1991). The hearts were mounted via the aorta onto a Langendorff perfusion system (<2 
mins after removal) (See Excision of the Heart in Appendix A for supplementary detail). The 
hearts were retrogradely perfused with a calcium-free HEPES-based medium containing 5.5 mM 
D-glucose and 2 mM pyruvic acid (Solution A, Table 3.2), at 37 oC in the presence of 100% O2 for 
5 mins to rinse out residual blood in the heart. The perfusion medium was then switched to a 
second recirculating medium containing 0.1% type 2 collagenase (Worthington Biochemical Corp., 
USA) and 15 mM 2,3-BDM (Sigma-Aldrich Life Science, USA) (Solution B, Table 3.2). After 20 
and 25 mins respectively, CaCl2 concentration was gradually increased, in order to prevent the 
calcium paradox (See Calcium Paradox in Appendix A for supplementary detail), to reach a 
total concentration of 200 M CaCl2. Perfusion was continued till the perfusate streamed 
continuously from the heart or for a total time of approximately 40 mins (Figure 3.2).  
 
Figure 3.2 Standard Langendorff Isolation Protocol 
Time (Min): 
Stabilization 
 0 5 20 25 40 
Enzymatic Digestion 
Streaming Ca2+ Raising 
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After digestion, hearts were removed from the system, the ventricles carefully isolated from the 
atrial and vascular remnants, minced with tweezers, and suspended in the same perfusion 
medium mentioned above, but containing 200 M CaCl2 and half the concentration of collagenase 
and 2,3-BDM (Solution C, Table 3.2). The suspension was placed in a flat-bottomed flask in a 
shaking incubator (Incu-Shaker Mini, Benchmark Scientific Inc., USA ) at 110 rpms and 37 C and 
further digested for 20 mins in the presence of 100% O2. The CaCl2 concentration was gradually 
raised to 1.25 mM over the last 5 min period. The isolated cells were filtered through a nylon mesh 
(200X200 m) and gently spun down at 100 rpms for 3 mins (Model CM Centrifuge, International 
Equipment Company, USA). The pellet obtained was resuspended in the first perfusion buffer, 
containing 1.25 mM CaCl2 and 2% fatty acid free BSA (Solution D, Table 3.2) and the viable cells 
allowed to settle through the BSA solution for 5 mins. The supernatant was carefully aspirated, 
and the loose pellet resuspended in the same buffer and allowed to recover from the trauma of 
isolation while slowly rotating (30 rpms) at 37 C for at least 1 hour. The cells were then washed 
three times in a substrate-free medium (Solution E, Table 3.2), each time aspirating the 
supernatant and spinning down at 300 rpms for 3 mins. Finally, the cells were resuspended in the 
desired volume of Solution E. 
 
Table 3.2 Buffer Compositions used in Isolation Protocol 
Solution Composition 
KH Buffer 
(pH = 7.4) 
119 mM NaCl, 25 mM NaHCO3, 4.75 mM KCl, 1.2 mM KH2PO4,  
0.6 mM MgSO4, 0.6 mM Na2SO4, 1.25 mM CaCl2 and 10 mM glucose 
HEPES Buffer 
(pH = 7.4) 
128 mM NaCl, 6 mM KCl, 1 mM Na2HPO4, 0.2 mM NaH2PO4,  
1.4 mM MgSO4, 10 mM HEPES 
Solution A 
 
128 mM NaCl, 6 mM KCl, 1 mM Na2HPO4, 0.2 mM NaH2PO4,  
1.4 mM MgSO4, 10 mM HEPES, 5.5 mM D-glucose, 2 mM pyruvic acid 
Solution B 128 mM NaCl, 6 mM KCl, 1 mM Na2HPO4, 0.2 mM NaH2PO4,  
1.4 mM MgSO4, 10 mM HEPES, 5.5 mM D-glucose, 2 mM pyruvic acid,  
0.7% BSA fatty acid free (faf) 22 500 U type 2 collagenase, 15 mM 2,3-BDM 
Solution C 
  
128 mM NaCl, 6 mM KCl, 1 mM Na2HPO4, 0.2 mM NaH2PO4,  
1.4 mM MgSO4, 10 mM HEPES, 5.5 mM D-glucose, 2 mM pyruvic acid,  
11 250 U type 2 collagenase, 7.5 mM 2,3-BDM, 1% BSA,  
1% BSA (faf), 200 uM CaCl2 
Solution D 128 mM NaCl, 6 mM KCl, 1 mM Na2HPO4, 0.2 mM NaH2PO4,  
1.4 mM MgSO4, 10 mM HEPES, 5.5 mM D-glucose, 2 mM pyruvic acid,  
2% BSA (faf), 1.25 mM CaCl2 
Solution E 128 mM NaCl, 6 mM KCl, 1 mM Na2HPO4, 0.2 mM NaH2PO4,  
1.4 mM MgSO4, 10 mM HEPES, 2% BSA (faf), 1.25 mM CaCl2 
Stellenbosch University  https://scholar.sun.ac.za
  
 
55 
    
2.2. CELL VIABILITY ASSAYS 
2.2.1. TRYPAN BLUE EXCLUSION ASSAY 
Cell viability was determined using a trypan blue exclusion assay. Live cells contain intact cell 
membranes which do not allow the trypan blue dye to cross inside the cytosol, whereas, the loss of 
membrane integrity in dead cells allow the dye to be taken up. This allows for visual assessment of 
the cell suspension – in viable cells we observe a clear cytoplasm; in non-viable cells the 
cytoplasm appears blue. For manual counting, 10 l of the cell suspension obtained at the end of 
the isolation protocol was vortexed with 10 l 0.4% trypan blue solution, loaded onto a 
haemocytometer and visualized using a standard light microscope (Olympus CKX41 Inverted 
Microscope). The amount of viable cells was obtained for each quadrant, totaled together and 
divided by 4 to obtain the average amount of viable cells. This number of cells were then multiplied 
by 105 to obtain the amount of viable cells present in 10 ml of the cell suspension. Each heart 
typically yielded approximately 5 million cardiomyocytes.  
 
2.2.2. PROPIDIUM IODIDE STAINING 
To investigate the effect of treatments on myocardial cell viability, isolated cardiomyocytes were 
pre-treated for both 1 or 3 hours with either DMSO, 10 M aspalathin or 10 nM insulin, and stained 
using propidium iodide (PI). Treatments were done in duplicate with one series receiving 5 μM of 
PI, and the other series remaining unstained (negative). This was followed by resuspending the 
cells in Lucham tubes and a 15 mins period of incubation at room temperature in the dark. The 
samples were then analysed at simultaneous 617 nm/535 nm wavelengths using fluorescence-
activated cell sorting (FACS) analysis. The PI-negative samples were used to establish the 
background fluorescence of the experimental samples and necessary to set up the photomultiplier 
tube voltages of the instrument using BD CellQuest Pro 5.2.1 software (BD FACSCalibur, Becton 
Dickinson Biosciences Inc., USA) (Figure 3.3). The captured files generated by the PC were 
analysed with the same software used for acquisition. First, viable cardiomyocytes were identified 
and separated from dead cells and debris using a defined region on an appropriate 
Forward/Sidescatter plot. Then the gated cells were analysed for their signal in fluorescence 
channel 2 using a FL-2 histogram. The percentages of PI positive and negative cells were 
determined for each sample and intervention by using a fixed border defined by a file from an 
unstained sample and applied to all files from stained samples (treated and untreated). PI staining 
occurs when there is a loss in cell membrane integrity, allowing the the PI-probe to enter the cell 
and then intercalate between double stranded DNA base pairs within the nucleus. PI has a 
fluorescence excitation maximum of 535 nm and an emission maximum of 617 nm. This staining 
serves as a marker of the non-viable or nectrotic cell population.  
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Figure 3.3 Fluorescence-activated cell sorter. PI is added to a concentrated cell suspension and 
then binds to double stranded DNA. The fluorescence of each cell is measured as it narrowly 
passes through a light beam. The angle, as well as the intensity of light can be measured, and 
used to determine cell size and shape. As the cells pass through the nozzle of the FACS machine, 
it receives an electric charge relative to its fluorescent count, which is an indication of the amount 
of bound dye. Using an electric field, the cells can be sorted according to charge, and the overall 
membrane integrity of the cell population determined. (Obtained from Craig, 2007)  
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2.3. GLUCOSE UPTAKE ASSAY 
Glucose uptake by adult ventricular myocytes was essentially determined according to the method 
published by Fisher et al. (1991). This method renders cells that are calcium tolerant but are in a 
quiescent and unstimulated state with GLUT4 situated in the internal compartments of the cell. 
This allows for measurement of stimulation of GLUT4 mediated glucose uptake. For the glucose 
uptake assay, the isolated cardiomyocytes were glucose starved in an oxygenated medium 
(Solution E, Table 3.2), while preincubating in a shaking water bath (Grant Instruments Ltd., UK) 
for 1-2 hours at 37C. Each experimental series was incubated with or without 400 M phloretin 
(for measurement of non-carrier or baseline mediated glucose uptake), 1-100 nM insulin, 1-100 µM 
aspalathin, 0.1% DMSO (used as solvent for synthetic aspalathin) and 100nM wortmannin as 
indicated. For the administration of aspalathin (Biomedical Research and Innovation Platform, 
MRC, South Africa) to isolated cardiomyocytes, the compound was first dissolved in dimethyl 
sulfoxide (DMSO) as stock solution for storage as aliquots at -80oC as this protects the compound 
against oxidation. The stock solution was then diluted in medium buffer (Solution E, Table 3.2) to 
render final concentrations of 1 μM, 10 μM or 100 μM. Insulin (Sigma-Aldrich Life Science, USA) 
stock solution was similarly made up as a 10μM solution in Solution E and stored as aliquots 
at -80 oC. This was then diluted to final concentrations of 1 nM, 10 nM and 100 nM in medium 
buffer (Solution E, Table 3.2). Phloretin (Sigma-Aldrich Life Science, USA) and wortmannin 
(Sigma-Aldrich Life Science, USA) were dissolved in DMSO as stock solutions of 64 mM and 2 mM 
respectively and stored as aliquots at −20 C or -80 C. Both were diluted with medium buffer 
(Solution E, Table 3.2) and used at final concentrations of 400 M Phloretin and 100 nM 
wortmannin. Each experiment was performed with two replicates per concentration per plate and 
the experiments repeated at least 3 times (n=3). At 35 mins, (Figure 3.4) after stimulation of the 
cells, glucose uptake was initiated by addition of 1.8 M (specific activity, 1.5 Ci/ml) 2-deoxy-D-
[3H]glucose (2DG). The experiment was allowed to proceed for 30 mins, after which the glucose 
uptake reaction was stopped by adding a final concentration of 400 M phloretin.  
 
Figure 3.4 Standard protocol for glucose uptake after acute treatments  
 
5 Time (Min): 
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The standard protocol was modified in subsequent experiments by allowing incubation of activators 
and inhibitors to proceed for either 60, 90, 120 or 150 mins before addition of 2DG for the last 
30 mins of the protocol (Figure 3.5). Cells were aspirated and resuspended in 1.5ml Eppendorf 
tubes and centrifuged at 14,500 rpm for 90 seconds at room temperature using an Eppendorff 
Minispin plus (Sigma-Aldrich Life Science, USA). The resultant supernatant was carefully 
aspirated and the cells washed with HEPES buffer (Table 3.2) to remove all traces of radiolabelled 
2DG in the supernatant. Aspiration and rewashing with HEPES buffer was repeated 2 more times, 
after which 500 μl 1N NaOH was added and samples heated in a water bath at 60 C to dissolve 
the pellets. 500 μl dH2O was then added to dilute the samples to a final concentration of 0.5N 
NaOH and samples were then vortexed thoroughly. An aliquot of 50 l per sample was used to 
assay its protein content in duplicate by the method of Lowry et al. (1951) (described below in 
section 2.4), while 100 μl per sample was aliquoted into radioscintillation vials containing 3 ml 
scintillation fluid (Emulsifier Scintillator Plus, Perkin-Elmer Inc., USA), and counted for 
radioactivity in duplicate using a LS6500 Liquid Scintillation Counter (Beckman-Coulter Inc., USA). 
One vial, used as a blank, only contained scintillation fluid, and another vial had 1.8 M (25 l) 
2DG to measure the total radioactive count to enable calculation of the specific activity.  
 
 
Figure 3.5 Extended protocol for glucose uptake after acute treatments  
 
The principle of 2DG uptake is explained as follows: Hexokinase phosphorylates glucose into G-6-
P as part of the first regulatory step committing glucose to further metabolism (refer to Chapter 2: 
Literature Review, Figure 2.5). However, hexokinase is also able to phosphorylate 2DG, a 
molecule with similiar structure to glucose (Figure 3.6), into 2-deoxyglucose-6-phosphate which is 
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unable to undergo further metabolism. The Km or half-maximal binding concentration of hexokinase 
for 2DG is effectively 10 times higher than that for glucose (Russell et al., 1992). Through this 
process, 2DG competitively inhibits glucose phosphorylation and reduces glycolysis which will 
eventually slow or inhibit glucose uptake. To be able to state that 2DG glucose uptake by cells is 
equivalent to glucose uptake, the concentration of 2DG should be in the low micromolar range. In 
addition, it has been shown by Fischer et al. (1991), that 2DG uptake, using this low concentration 
of 2DG, is linear up to 60 mins. 
 
 
         
 
 
 
 
 
Figure 3.6 Glucose molecule compared to a 2DG molecule. The 2-hydroxyl group of glucose is 
replaced with a hydrogen atom. 2DG: 2-deoxy-D-[3H]glucose  
 
2.4. LOWRY PROTEIN DETERMINATION 
To determine the protein concentration of each sample, 50 μl protein sample, 3 BSA 
concentrations (0.161, 0.322 and 0.644 mg/ml 0.5 N NaOH), used as standards and 0.5 N NaOH 
(used as blank) was pipetted into Lucham tubes in triplicates. 1ml reaction buffer, containing 2% 
Na2CO3, 1% CuSO45H20 and 2% Na
+K+-Tartrate, was added to each tube, vortexed and 
incubated at room temperature for 10 mins. Hereafter, 0.1 ml of a 1:3 dH20 diluted Folin Ciocalteus 
reagent was added to each tube, vortexed and incubated for 30 mins after which OD values were 
determined using a spectrophotometer (Spectronic 20 Genesys Spectrophotometer, Thermo 
Fisher Scientific Inc., RSA) at 750 nm. A standard curve was generated and the protein content of 
the samples determined. 
 
Under alkaline conditions, cupric ions (Cu2+) chelate with the peptide bonds of a protein resulting in 
a reduction of cupric ions (Cu2+) to cuprous ions (Cu+). Addition of reagents such as Folin Ciocalteu 
(phosphomolybdic-phosphotungstic acid) with the Cu+ creates chromogens that give a colour 
reaction resulting in an increased absorbance between 550 nm and 750 nm. Absorbance at the 
peak wavelength of 750 nm quantitate protein concentrations between 1-100 mg/ml, whereas 
550 nm is more suitable for quantifying higher protein concentrations (Sengupta & Chattopadhyay, 
1993). The amount of colour produced can be readily detected and is proportional to the amount of 
peptide bonds, and thus an indication of the amount of protein.   
     D-Glucose                        2-Deoxy-D-glucose 
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AIM 3: DETERMINE THE POSSIBLE EFFICACY AND TOXICITY OF EXTENDED ASPALATHIN TREATMENT 
ON DIFFERENTIATED CARDIOMYOCYTES DERIVED FROM H9C2 CELLS: 
3.1. CELL CULTURING 
Experiments were performed using an embryonic rat-heart derived H9C2 cardiomyoblast cell line 
(ECACC No. 8809294; Gifted by Prof F. Essop, Department of Physiological Sciences, 
Stellenbosch University, South Africa). During routine maintenance, cells were exponentially grown 
as monolayers in Dulbecco’s modified Eagle’s Medium (DMEM) with 5.5 mM glucose 
(supplemented with 10% foetal bovine serum (FBS) and 1% Penicillin-Streptomycin) at 37 °C in a 
humidified atmosphere of 95% air with 5% CO2 (Galaxy R CO2 Incubator). Cells were first allowed 
to proliferate in T75 culture dishes until they reached 70-80% confluency before being split into 
appropriate treatment plates or dishes. Sub-confluent cell populations were used for all 
experiments. Plating densities were previously determined (Dludla et al., 2014) for each cell 
subculture so that equivalent (sub-confluent) cell populations were always present at the time of 
treatment. 
 
3.1.1. SPLITTING OF CELLS 
Splitting was accomplished by washing the cell monolayer with 5ml sterile warm phosphate 
buffered saline (PBS) followed by incubation with 4 ml 0.25% Trypsin- Ethylenediaminetetraacetic 
acid (EDTA) solution at 37 °C for 4 mins, with occasional agitation to completely loosen the cells. 
Thereafter, double the volume of growth medium was added (8 ml per T75 flask) and the cells 
resuspended in a 15 ml Falcon tube. The tube was centrifuged at 1500 rpms for 3 mins using a 
Digicen 20 Centrifuge (Orto Alresa, Spain), the supernatant decanted and the cell pellet 
resuspended in an appropriate volume of medium. Cells were counted using the trypan blue assay 
(described in 3.1.2 below) and diluted with warm, growth medium to the appropriate 
concentration (seeding density of ~500,000 cells per T75 flask, 50,000 cells per well in 24-well 
plate, or 40,000 cells per well in 96-well plate) and volume, before aliquoted into flasks or plates. 
 
3.1.2. TRYPAN BLUE EXCLUSION ASSAY 
The viability of cells was determined prior to splitting and plating by using a trypan blue exclusion 
assay. The assay was performed either manually or automatically. Manual counting was performed 
as discussed in 2.2.1. above using a Nikon TMS-F Microscope (The Lab World Group, USA). 10 l 
of the cell suspension was mixed with 10 l 0.4% trypan blue solution. For automatic counting, 
10 ul of the homogenized solution was loaded onto a Countess Cell Counting Chamber Slide 
(Thermo Fisher Scientific Inc., South Africa) and counted using the Invitrogen Countess 
Automated Cell Counter (Thermo Fisher Scientic Inc., South Africa). Briefly, automatic counting 
occurs in the central location of the counting chamber. The entire volume of cells counted is 
0.4 L, the same as counting four (1mm x 1mm) squares in a standard haemocytomer. The 
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desired concentration of viable cells and the amount of cells needed for splitting into appropriate 
amount of wells or flasks were then calculated using the Invitrogen software. 
 
3.1.3. MYCOPLASM DETECTION ASSAY 
To test for contamination of H9C2 cell stocks, a mycoplasm detection kit was used (MycoAlert 
PLUS, Lonza Group Ltd., Switzerland). Mycoplasma are the smallest and simplest prokaryotes and 
are well recognized as a common contaminant in cell culture. The mycoplasma competes with 
cells for nutrients and as a result decreases cellular proliferation and influence cell functioning. 
These fluctuations can be detected using the MycoAlert Kit with a similiar mechanism to the 
Metabolic Assay described in 3.4 below. The experimental procedure was as follows: Just prior to 
plating of cells, 2 ml of cell suspension was centrifuged at 200xg for 5 mins to pellet the cells. Cells 
were resupsended in fresh media. 100 L of the cell suspension was placed in a luminometer and 
100 L MycoAlert PLUS Reagent added to each sample, followed by a 5 min waiting step at 
room temperature (optimum temperatures for kit enzymes). The absorbance was read using an 
ELx800 Absorbance Reader (BioTek Instruments Inc., USA). After reading, 100 L MycoAlert 
PLUS Substrate was added to each sample followed by a 10 min waiting step at room 
temperature. The absorbance was read once again and the ratio of second reading to first reading 
calculated. Briefly, viable mycoplasm are lysed and react in response to MycoAlert PLUS 
Substrate, which catalyzes the conversion of ADP to ATP. By measuring the level of ATP before 
and after the addition of the substrate, a ratio can be obtained which either implicates the presence 
or absence of mycoplasm. Should mycoplasm be present, the second reading will have a higher 
absorbance, indicating a reaction with the MycoAlert PLUS Substrate.  
 
3.2. DIFFERENTIATION OF H9C2 CELLS 
H9C2 cells were initially plated onto either 96-well, 24-well or 6 well plates with a seeding density 
of respectively 40,000, 50,000 or 100,000 cells/well and differentiated for 6-8 days, by reducing the 
serum content from 10% FBS to 1% horse serum and by adding 10nM retinoic acid (RA). The 
morphology of cells were monitored daily to determine when differentiation into adult 
cardiomyocytes occurred. Initially, H9C2 cells are immortal cells, but once differentiated, the cell 
nuclei start to migrate together, having a closer morphological resemblance to the isolated 
cardiomyocytes (Figure 3.7). 
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Figure 3.7 Retinoic acid induces differentiation of H9C2 cells. A) Phase-contrast image of 
typical cells treated with 10nM all-trans-RA for 7 days, compared to control cells in B). C) Nuclear 
staining of differentiated H9C2 cells, compared to controls in D). (Adapted from Ménard et al, 
1999)  
 
3.3. JC-1 STAINING 
The change in mitochondrial membrane potential (m) of the H9C2 cells was assessed using the 
fluorescent probe, 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazole-carbocyanide iodine (JC-
1). Once fully differentiated into adult cardiomyocytes in dark 96-well plates, the cells were 
incubated at 37 C in the presence of 95% O2 and 5% CO2 for 3h with DMEM with 5.5 mM 
glucose, containing or without 1 uM Aspalathin (Figure 3.8). 15 mins before the end of the 
experiment 1 nM Insulin was added to half the treated and untreated groups. At 3 hours, the cells 
were washed once with PBS and then stained with 2 mg/ml JC-1, made up in PBS buffer, and 
incubated for a further 15 mins at 37C. The plates were then scanned with a fluorescence 
microscope (Nikon Eclipse Ti, The Lab World Group, USA), using a Texas red-FITC (fluorescein 
isothiocyanate) filter cube. Qualitative analysis of cell morphology, and comparison of red:green 
fluorescence was performed. 
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Figure 3.8 JC-1 Staining Protocol 
In healthy cells, an intact mitochondrial membrane potential allows for mitochondrial uptake of the 
positively charged JC-1. As JC-1 accumulates, it forms J-aggregates, that fluoresce bright red (ex 
596 nm) under a microscope (Cossarizza et al., 1993). In contrast, in apoptotic and necrotic cells, 
the membrane potential collapses, thereby preventing JC-1 from entering the mitochondria. The 
result is an accumulation of JC-1 in the cytosol, which fluoresce green (ex 520 nm).  
 
3.4. METABOLIC ACTIVITY 
Metabolic activity was determined with an adenosine triphosphate (ATP) assay using a ViaLight 
Plus kit (Lonza Group Ltd., Switzerland). Since all cells are metabolically dependent on ATP to 
remain viable and perform specialized functions, detecting fluctuations or decreases in cytoplasmic 
ATP levels can be used to assess cell injury. The technique incorporates the enzyme luciferase, 
which catalyzes the formation of light from ATP and luciferin according to the following equation:  
 
 
 
 
 
The intensity of light emitted by this reaction is proportional to the ATP concentration and can be 
measured with a luminometer or β-counter.  
 
Once fully differentiated into adult cardiomyocytes in white 96-well plates, the cells were incubated 
at 37 C in the presence of 95% O2 and 5% CO2 for 3 h with DMEM and 5.5 mM glucose, with or 
without 1uM Aspalathin (Figure 3.9). 15 mins before the end of the experiment 1 nM insulin was 
added to half the treated and untreated groups. At 3 hours, the cells were removed and left at room 
temperature to acclimatise. The assay was conducted at room temperature (22 C), which is the 
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Treatment     Staining 
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Aspalathin                                            Lyse 
Time (Min):  0                                                                                  165    180       190 
Treatment       Assay 
                           ATP + 
Insulin          Luciferase 
optimal temperature for luciferase enzymes. Half the contents of each well was aspirated and 
replaced with Cell Lysis Reagent of the ViaLight Plus kit (Lonza Group Ltd., Switzerland) and left 
for 10 mins. Following this, ATP monitoring reagent plus (AMR plus), containing the luciferase, was 
added to generate a luminescent signal for 2 mins. The plate was then read using a luminometer 
(ELx800 Absorbance Reader, BioTek Instruments Inc.,USA). The direct luminometer output was 
used to calculate cellular response and cytotoxicity of the different treatments. 
 
 
 
 
 
 
 
 
Figure 3.9 ATP Assay Protocol 
 
3.5. GLUCOSE UPTAKE ASSAY 
Cells were plated into a 24-well plate with a seeding density of 50,000 cells per well and 
differentiated for 6 days. Once fully differentiated, the cells were assayed in the presence of 5.5 
mM glucose and treated with or without 1M Aspalathin for 3 or 6 hours, while incubating at 37 C 
in the presence of 95% O2 and 5% CO2 (Figure 3.10). 15 mins prior to the 3 hour or 6 hour time 
point respective, 1 nM Insulin was added to half the treated and untreated groups and glucose 
uptake was initiated by addition of 2-deoxy-D-[3H]glucose (1.5 Ci/ml; final concentration 1.8 M) 
(Perkin-Elmer Inc., USA). The experiment was allowed to proceed for 15 mins, after which the 
glucose uptake reaction was stopped by removing the supernatant and washing twice with ice cold 
PBS (For a more detailed description of the technique, see section 2.3. in the Methods 
section). 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  
 
65 
    
Figure 3.10 Glucose uptake protocol in H9C2 cells. Time points in black for 3 h protocol and red 
for 6 h protocol. 
 
500 μl 1N NaOH was added to each well and samples heated in a shaking incubator at 60 C 
(Incu-Shaker Mini, Benchmark Scientific Inc., USA) to dissolve the cells. 500 μl distilled H2O 
(dH2O) was then added to dilute the samples to a final concentration of 0.5 N NaOH and vortexed 
thoroughly. An aliquot of 50 l of this solution was used to assay protein content by the Bradford 
method (refer to section 3.6 below), while 100 l per sample was counted for radioactivity using a 
Tri-Carb 2810 TR Liquid Scintillation Analyzer (Perkin-Elmer Inc., USA) in duplicate. One vial, 
used as a blank, only received scintillation fluid, and another vial had 1.8 M (25 l) 2-deoxy-D-
[3H]glucose (2DG) to measure the total radioactive count. Average disintegrations per minute 
(DPM) was recorded for each sample and the blank subtracted. The specific activity, given as the 
activity of a radioisotope per unit mass, was determined by using the DPM of the total radioactive 
count divided by the exact amount of 2DG (1100 pmol in 25 ul of 1.8 M 2DG). This value could 
then be used to calculate the average DPM values for each sample, and together with the protein 
determination, determine the average pmol 2DG uptake per mg cell protein. 
 
3.6. BRADFORD PROTEIN DETERMINATION 
The Bradford protein determination method was used to determine the protein content of each well 
in the treatment plates (Bradford, 1976). A bovine serum albumin (BSA) stock solution with a 
concentration of 2mg/ml in dH2O. Just prior to protein determination, the stock was serially diluted 
into duplicate microtitre plate wells to generate concentrations between 0.125 and 2.0 mg/ml in a 
volume of 150 μl, creating a standard curve. 150 μl supernatant of the samples generated in the 
above experiments, were also aliquoted in duplicate microtitre plate wells. All standards and 
samples then received 150 μl of Quick Start Bradford reagent (Bio-Rad Laboratories Inc., USA), 
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and were incubated for 30 mins at room temperature. The absorbance values were measured 
using a microtitre plate spectrophotometer (ELx800 Absorbance Reader, BioTek Instruments Inc., 
USA) at 595 nm and the protein content of the samples determined from the standard curve 
plotted. 
 
AIM 4: UNDERSTAND THE MECHANISM OF ACTION OF ASPALATHIN, BY USING: 
e. Young, control and HFD rats with the same experimental treatments as in Aim 2 (d and e) 
above to determine expression and activation of the biochemical intermediates (total- and 
phospho-subunits of PKB and AMPK antibody) using standard Western blotting techniques 
f. young, control and HFD rats to determine Glut4 translocation induced by aspalathin 
 
4.1. GENERAL PREPARATION OF EXTRACTS FOR WESTERN BLOTTING 
To prepare lysates for immunoblotting, cardiomyocytes were isolated using the same procedure 
described in section 2.1. The cells were then glucose starved in an oxygenated medium (Solution 
E, Table 3.2), and left to preincubate in a shaking water bath (Grant Instruments Ltd., UK) for 5 ms 
at 37 C. Each experimental series was incubated with or without 10 nM insulin, 10 µM aspalathin, 
0.1% DMSO (used as solvent for synthetic aspalathin) and 100 nM wortmannin (Sigma-Aldrich Life 
Science, USA) for a period of 15 to 90 mins, depending on the aim. Figure 3.11 contains an 
overview of the standard experimental protocol followed to prepare lysates for acute treatment. 
Each experiment was performed with two replicates per treatment per plate and the experiments 
repeated at least 3 times (n=3) in order to yield enough lysates to investigate all the mechanisms 
of interest. At the end of the incubation period, the cells were quickly centrifuged and washed with 
ice-cold HEPES buffer without albumin.  
 
Figure 3.11 Standard experimental protocol prior to preparation of lysates from 
cardiomyocytes 
The cells were homogenized and lysed in Lysis buffer (Table 3.3), using a Bullet Blender (Next 
Advance Inc., USA) at 4 C for 5 ms, with a scoop of 0.15 mm diameter zirconium oxide beads 
equivalent to the volume of cells. The lysates were then microfuged at 1000 rpms for 10 mins at 4 
C (Sigma 1-14K Refrigerated Microfuge, Lasec SA (Pty) Ltd., RSA) and 5 µL supernatant was 
20 
Activators 
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used in Bradford protein determination (described below in section 3.2.). Hereafter, the protein 
concentration for each sample was calculated, and supernatant pipetted into Eppendorf tubes. 
Lysis buffer was added in order to dilute all samples to equal protein concentrations (50 g/12 l 
final solution). Finally, a mix of 850 l 1:2 Laemmli sample buffer (Table 3.3) with 150 l 
mercaptoethanol was made and added to the samples in a volume equal to half of the lysis buffer 
and sample buffer. The samples were boiled for 5 mins and stored at -80 C for future analysis by 
Western blotting. 
 
Table 3.3 Buffer and Gel Compositions used in Western Blotting Protocol 
Solution Composition 
Lysis Buffer 
20 mM Tris-HCl, 1 mM EGTA, 1 mM EDTA, 150 mM NaCl, 1 mM β-
glycerophosphate, 2.5 mM tetra-Na+-pirophosphate, 1 mM Na3VO4, 1% 
Triton X-100, 10 g/ml Leupeptin, 10 g/ml Aprotinin, 50 g/ml PMSF 
Fractionated Lysis 
Buffer 
20 mM Tris-HCl, 1 mM EGTA, 1 mM EDTA, 150 mM NaCl, 1 mM 
Na3VO4, 50 g/ml PMSF, 1% Triton X-100 (Membrane Fractions only) 
Laemmli Sample 
Buffer 
62.5 mM Tris-HCl (pH 6.8), 4% SDS, 10% glycerol, 0.03% bromophenol 
blue, 5% β-mercaptoethanol 
Bradford Reagent 
100 mg Coomassie Brilliant Blue G-250, 50 ml 95% Ethanol, 100 ml 
85% (w/v) Phosphoric Acid, 850 ml dH2O 
10% Polyacrylamide 
Resolving Gel 
4.9 ml dH2O, 2.5 ml 1.5 M Tris-HCl (pH 8.8), 100 uL 10% SDS, 2.5 ml 
40% acrylamide, 50 uL 10% APS, 20 uL 99% TEMED 
4% Polyacrylamide 
Stacking Gel 
3.05 ml dH2O, 1.25 ml 0.5M Tris-HCl (pH 6.84), 50 uL 10% SDS, 0.5 ml 
40% Acrylamide, 50 uL 10% APS, 10 uL 99% TEMED 
10% Fast-Cast Kit 
Resolving Gel 
3 ml TGX Stain-Free FastCast Resolver A, 3 ml TGX Stain-Free 
FastCast Resolver B, 30 uL 10% APS, 3 uL TEMED 
10% Fast-Cast Kit 
Stacking Gel 
1ml TGX Stain-Free FastCast Stacker A, 1ml TGX Stain-Free 
FastCast Stacker B, 10 uL 10% APS, 2 uL TEMED 
Running Buffer 25 mM Tris-HCl,192mM Glycine, 0.1% SDS (made up with dH2O)  
Trans-Blot Turbo 
Buffer 
600 mL dH2O, 200 mL 99.8% Ethanol, 200 mL Trans-Blot Turbo 
Buffer  
TBS-Tween Buffer 
(pH 7.6) 
20 mM Tris-HCl, 137 mM NaCl, 0.1% Tween-20 (diluted with dH2O) 
 
4.2. BRADFORD PROTEIN DETERMINATION 
The Bradford protein determination method was used to determine the protein content of tissue 
lysates (Bradford, 1976). A BSA stock solution (Bio-Rad Laboratories Inc., USA) with a 
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concentration of 5 mg/ml in dH2O was used. Just prior to protein determination, the stock solution 
was diluted 1:5 times with dH2O and then serially diluted into duplicate test tubes to generate 
concentrations between 1 and 30 μg in a volume of 100 μl. 5 μl supernatant of the samples 
generated in the above experiments, was diluted 1:10 with dH2O to dilute all detergents that may 
interfere with the assay. The diluted samples were then further diluted 1:20 in test tubes to reach a 
volume of 100 ul. All standards and samples received 900 μl of double filtered Bradford reagent 
(diluted 1:5 with H2O) (Table 3.3), vortexed and incubated for 30 mins at room temperature. The 
absorbance values were measured using a spectrophotometer (Spectronic 20 Genesys 
Spectrophotometer, Thermo Fisher Scientific Inc., RSA) at 595 nm and the protein content of the 
samples determined from the standard curve plotted.  
 
4.3. GLUT4 TRANSLOCATION IN ISOLATED CARDIOMYOCYTES 
Distribution of GLUT4 was observed by fractionating the cells into cytosolic and membrane 
compartments by differential centrifugation followed by Western blots of the separated proteins 
probed with a specific GLUT4 antibody. Cardiomyocytes were isolated using the same procedure 
described in section 2.1. Two hearts were combined per experiment to render enough cells to 
accommodate the membrane fractionation involved in this protocol (Webster et al. 2010). The cells 
were glucose starved in an oxygenated medium (Solution E, Table 3.2), while incubating at 37 C 
(Incu-Shaker Mini, Benchmark Scientific Inc., USA) and shaking at 30 rpm in the presence of 100% 
O2. Each experimental series was incubated with or without 10 nM insulin and 10 µM aspalathin. At 
the end of the incubation period, the cells were quickly centrifuged and washed with ice-cold 
HEPES buffer without albumin. Figure 3.12 contains an overview of the simplified experimental 
protocol followed. Each experiment was repeated 3 times for each of the Young, Control and HFD 
groups.  
 
Figure 3.12 Simplified protocol to prepare lysates of cytosol and membrane fractions 
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The cells were homogenized and lysed in 200 L Fractionated Lysis buffer without Triton X-100 
(Table 3.3), using a Bullet Blender (Next Advance Inc., USA) at 4 C for 5 mins, with a scoop of 
0.15 mm diameter zirconium oxide beads equivalent to the cell pellet size. The homogenates were 
then kept on ice for a further 15 mins after which they were microfuged at 1,000g for 10 mins at 
4 C (Sigma 1-14K Refrigerated Microfuge, Lasec SA (Pty) Ltd., RSA). The supernatant, 
containing the cytosol and membrane fractions (Figure 3.13), was carefully aspirated, without 
touching the beads and nuclear proteins (the pellet), and placed in 0.5 ml eppindorf tubes. The 
tubes were subsequently ultracentrifuged in a Beckman Ti50 rotor using adaptors for 0.5 ml 
eppindorf tubes, at 40,000 rpms (100,000g) for 60 mins at 4 C in a L7 Ultracentrifuge (Beckman-
Coulter Inc., USA). The supernatant was collected and considered to contain the cytosolic fraction. 
100 uL Fractionated Lysis buffer with 1% Triton X-100 (Table 3.3) was added to the pellet, 
containing the membrane fractions, and homogenized using a Bullet Blender (Next Advance Inc., 
USA) at 4 C for 5 mins, with a scoop of 0.15 mm diameter zirconium oxide beads equivalent to 
the size of the pellet . The homogenate was then quickly spun down to sediment the beads at 
14,500 rpms with an Eppendorff Minispinplus (Sigma-Aldrich Life Sciences Inc., USA) and the 
supernatant collected considered as the membrane fraction. 5 µL of the supernatant was used to 
determine the protein concentration using the method of Bradford (described above in section 
3.6.). Hereafter, the concentration for each sample was calculated, and a volume of supernatant 
containing equal amounts of protein, pipetted into Eppendorf tubes. Fractionated Lysis buffer 
(without 1% Triton X-100 for cytosol fractions and with 1% Triton X-100 for membrane fractions) 
was added in order to dilute all samples to equal protein concentrations (50 g/12 l final solution). 
Finally, a mix of 850 l 1:2 Laemmli sample buffer (Table 3.3) with 150 l mercaptoethanol was 
made and added to the samples in amounts equal to half of the lysis buffer and sample buffer. The 
samples were boiled for 5 mins and stored at -80 C for future analysis by Western blotting. 
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Figure 3.13 Cell fractionation by differential centrifugation. A cell suspension can be 
centrifuged at increasing speeds for increasing durations to selectively pellet specific cell 
structures. First, a centrifugal force of 600g (600 times the force of gravity) for 10 mins is 
necessary to sediment nuclei. The supernatant can then be further fractionated by cenrifugation at 
15,000g for 5 mins to obtain the mitochondrial fraction.. A subsequent centrifugation of the 
supernatant in an ultracentrifuge (100,000g × 60 mins) results in deposition of the plasma 
membrane. At 100,000g (50,000 rpm in an ultracentrifuge), the centrifuge rotor chamber is vacuum 
sealed and refrigerated to reduce friction-induced heating between the hyperspinning rotor and air 
molecules. The supernatant contains the cytosol and small ribosomal proteins en enzymes 
(Obtained from Lodish, 2000) 
 
  
Stellenbosch University  https://scholar.sun.ac.za
  
 
71 
    
4.4. WESTERN BLOT ANALYSIS 
4.4.1. LOADING AND SEPARATION OF PROTEINS 
Gels were either prepared by (i) polymerizing the 10% polyacrylamide resolving gel (Table 3.3) for 
30 mins, followed by addition and polymerization of 4% polyacrylamide stacking gel for 15 mins, (ii) 
by adding 10% Fast-Cast Kit resolver gel (Table 3.3), followed by immediately adding the 10% 
Fast-Cast Kit stacking gel and polymerizing for 40 mins (TGX Stain-Free FastCast Acrylamide 
Kit), or (iii) Mini-PROTEAN TGX Stain-Free Precast gradient (4-15%) Gels were used (Bio-Rad 
Laboratories Inc., USA). After polymerization, the gels were placed in a Mini-PROTEAN Tetra 
System (Bio-Rad Laboratories Inc., USA) and filled with Running Buffer (Table 3.3). After boiling 
the lysates, 50 ug of each sample was loaded onto the 4% stacking polyacrylamide gels. The first 
lane position on each gel was loaded with 5ul PageRuler Prestained Protein Ladder (Fermentas 
Life Sciences, RSA) for proteins of interest smaller than 100 kDa, whereas either 7.5 ul HiMark 
Pre-Stained Protein Standard (Thermo Fisher Scientific Inc., RSA) for proteins of interest larger 
than 100 kDa, to aid with determination of molecular weights of specific bands. The second lane 
was loaded with untreated controls, and subsequent lanes contained treated groups. Proteins were 
then separated using the principle of sodiumdodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE). Gels were run for 10 mins at 100 V and 200 mA, followed by 50 mins at 140 V and 
140 mA, in Running Buffer (Table 3.3).  
 
4.4.2. PROTEIN TRANSFER AND VISUALIZATION 
Following SDS-PAGE, proteins of interest <100 kDa were electrotransfered to polyvinylidene 
fluoride (PVDF) membranes, using a semi-dry Trans-Blot Turbo Transfer System (Bio-Rad 
Laboratories Inc., USA) for 30 mins at 25 V and 1.0 A. The membranes were then visualized with 
the ChemiDoc MP System (Bio-Rad Laboratories Inc., USA), and images stored for later use in 
normalization of samples. After washing of the membranes with TBS-Tween Buffer (Table 3.3), the 
membranes were blocked in TBS-Tween Buffer with 5% (w/v) fat-free dry milk, while gently 
agitating for 2 hours at room temprature. The membranes were then 3 times washed with TBS-
Tween Buffer for 5 mins, followed by incubation overnight at 4C with 1:1000 dilution of different 
antibodies in TBS-Tween Buffer, including the Total- or Phospho(Ser473)-PKB, Total- or 
Phospho(Thr172)AMPK, and Total-GLUT4. The membranes were then washed 3 times with TBS-
Tween Buffer for 5 mins, followed by agitation for 1 hour with 1:4,000 dilution in TBS-Tween Buffer 
of either anti-mouse or anti rabbit immunoglobulin G (IgG) horseradish peroxidase (HRP) linked 
whole antibody (Amersham Biosciences, UK, and Dako Cytomation, Denmark) at room 
temperature. Following secondary antibody incubation, membranes were washed again with TBS-
Tween Buffer and then visualized using either Clarity Western ECL Substrate for 5 mins or 
Luminata Forte Western HRP substrate for 2 mins and exposed with the Bio-Rad Chemidoc MP 
Imager for a specific time depending on the antibody used (Table 2.3). The optical density 
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readings of each band was expressed relative to the two untreated controls present in the second 
lane. All visualizations and quantification of protein bands on membranes were analyzed using 
Image Lab 5.0 (Bio-Rad Laboratories).  
 
Table 3.4 Optimized protocol for each primary and secondary antibody  
Proteins MW 
(kDa) 
Gel% Protein 
Loaded  
(ug) 
1st Antibody 
Preparation 
2nd Antibody 
Preparation 
Time 
Exposed 
Dilution 
Factor 
% 
Milk 
Dilution 
Factor 
% 
Milk 
PKB 60 10 50 1:1000 0% 1:4000 0% 10s – 10mins 
AMPKα 62 10 50 1:1000 0% 1:4000 5% 10s – 20mins 
GLUT4 45 10 50 1:1000 5% 1:4000 5% 10s – 30mins 
 
4.5. STATISTICAL ANALYSIS 
Unless stated otherwise, all results are presented as the means ± standard error of the mean 
(SEM). For comparative studies, statistical analysis was done with a Student’s t-test (unpaired) or 
one-way analysis of variance (ANOVA) followed by Bonferroni multiple comparisons test (for 
p<0.05) using GraphPad Prism 5 (Graphpad Software Inc., USA). P<0.05 was considered as 
significant. 
  
  
Stellenbosch University  https://scholar.sun.ac.za
  
 
73 
    
Body Mass distribution
between Rat  Models
Y
ou
ng
 
C
on
tr
ol
H
FD
0
200
400
600
800
***
***
***
B
o
d
y
  M
a
s
s
  (g
)
CHAPTER 4 
RESULTS: MODEL OF DIET-INDUCED OBESITY AND INSULIN 
RESISTANCE 
 
1. CHARACTERISTICS OF YOUNG, CONTROL AND HIGH-FAT, HIGH-CALORIC DIET RATS 
1.1 BODY WEIGHT OF YOUNG, CONTROL AND HFD RATS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Body weight of rat models – young (7 – 14 weeks; n=38), control (n=22) and HFD (24 
– 32 weeks; n=20); HFD: high-fat, high-sucrose diet; ***p<0.001 (Young vs Control and HFD, 
Control vs HFD) 
 
Table 4.1 summarizes the characteristics of the 3 animal models. At 7–14 weeks of age, the body 
weight of young rats averaged 246.8±6 g (n=38). At 24-32 weeks of age, the body weight of control 
rats averaged 417.3±9 g (n=22) and that of HFD rats averaged 508.5±11 g (n=20). The high-fat, 
high-sucrose diet had an average higher body weight  of 91.2 g or 21.9% (p< 0.001) (Figure 4.1). 
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1.2 VISCERAL ADIPOSE TISSUE OF CONTROL AND HFD RATS 
 
Figure 4.2 Visceral fat of diet rat models; HFD: high-fat, high-sucrose diet; ***p<0.001 (Control 
vs HFD) 
 
After 24 - 32 weeks of feeding, the visceral fat of control rats averaged 21.75±1.5g (n=22) and that 
of the HFD rats averaged 42.30±2.3g (n=20). The HFD rats had an average  94.5% higher visceral 
fat than the control rats (p< 0.001) (Figure 4.2). 
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1.3 FASTING BLOOD GLUCOSE OF CONTROL AND HFD RATS 
 
Figure 4.3 OGTT of rats on a 16 week control or high fat, high-sucrose diet; OGTT: Oral 
glucose tolerance test, HFD: high-fat, high-sucrose diet; *p<0.05 (Control vs HFD at 20, 25, 30, 45 
and 120 mins after glucose administration post fasting), **p<0.01 (Control vs HFD at 3 and 10 mins 
after glucose administration post fasting), ***p<0.001 (Control vs HFD at 0, 5 and 15 mins after 
glucose administration post fasting) 
 
To test for whole-body insulin resistance following a 16 week HFD, an OGTT was performed 
(Figure 4.3). Following overnight fasting, rats fed a high-fat, high-sucrose diet had elevated basal 
blood glucose levels compared to the controls (5.7±0.2 (n=5) vs 4.7±0.1 (n=9) mmol/L; p<0.001). 
After an oral glucose injection, the blood glucose levels of HFD rats continuted to remain 
significantly elevated for up to 45 minutes (7.2±0.3 (n=5) vs 5.4±0.4 (n=8) mmol/L; p<0.05). 90 
minutes after the test, the HFD and control group had the closest resembling blood glucose levels 
(5.6±0.3 (n=5) vs 5.2±0.4 (n=8) mmol/L; p=0.4571). However, at the end of the test (at 120 
minutes), the HFD rats once again had an elevated blood glucose level compared to the control 
rats (5.4±0.2 (n=5) vs 4.7±0.2 (n=9) mmol/L; p<0.05). 
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1.4 NON-FASTING BLOOD GLUCOSE OF YOUNG, CONTROL AND HFD RATS 
Figure 4.4 Non-fasting blood glucose prior to sacrificing of rats; HFD: high-fat, high-sucrose 
diet; *p<0.05 (Control vs HFD)  
 
Non-fasting blood glucose levels were obtained just prior to sacrificing rats. Young rats had an 
average blood glucose level of 7.3±0.3 mmol/L (n=9), control rats 7.1±0.2 mmol/L (n=20) and HFD 
rats 7.8±0.2 mmol/L (n=19). Non-fasting blood glucose levels were 9.9% higher in HFD rats 
compared to control rats (p<0.05) (Figure 4.4).  
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1.5 SERUM INSULIN LEVELS OF CONTROL AND HFD RATS 
Serum Insulin Levels of
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Figure 4.5 Fasting serum insulin levels of control and HFD rats; HFD: high-fat, high-sucrose 
diet; *p<0.05 (Control vs HFD) 
  
Fasting insulin levels were obtained from blood collected directly from the carotid artery. HFD rats 
had a signifcantly higher fasting serum insulin levels compared to controls rats (14.58±2.04 
IU/mL; n=5 vs 6.68±2.21 IU/mL; n=6; p<0.05), constituting an increase in serum insulin levels of 
118% (Figure 4.5).  
 
Table 4.1 Characteristics of Animal Models 
Parameters Young n Control n HFD n 
Body weight (g) 246.8±6 38 417.3±9 22 508.5±11 (***) 20 
Intraperitoneal 
Fat (g) 
- - 21.75±1.5 22 42.30±2.3 (***) 20 
Fasting blood 
glucose 
(mmol/L) 
- - 4.7±0.1 9 5.7±0.2 (***) 5 
Non-fasting 
blood glucose 
(mmol/L) 
7.3±0.3 9 7.1±0.2 20 7.8±0.2 (*) 19 
Fasting serum 
insulin (IU/mL)  
- - 6.68±2.21 6 14.58±2.04 (*) 5 
HOMA-IR index - - 0.86±0.28 6 1.93±0.28 (***) 5 
HFD: High-fat, high-sucrose diet; HOMA-IR: Homeostasis Model Assessment of Insulin 
Resistance; *p<0.05, **p<0.01, ***p<0.001 (Control vs HFD).  
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CHAPTER 5 
RESULTS: ASPALATHIN AND ISOLATED VENTRICULAR 
CARDIOMYOCYTES FROM YOUNG, CONTROL AND HFD 
RATS 
 
1. CELL VIABILITY ASSAYS 
1.1 CELL VIABILITY OF ISOLATED ADULT VENTRICULAR CARDIOMYOCYTES FROM YOUNG RATS 
AFTER ISOLATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Cell viability of isolated cardiomyocytes from young rats (using different 
collagenase type 2 batches) 
 
Proper enzyme selection is critical for successful isolation of cardiomyocytes (Johnson et al., 
2014). Therefore, each new batch of collegenase was tested to prevent batch variation affecting 
digestion and cell viability (Johnson et al., 2014). Trypan blue exclusion assays of isolated 
cardiomyocytes were performed using 3 different collagenase type 2 batches to assess the cell 
viability of the isolation protocol (Figure 5.1). There were no significant differences in cell viability 
between either 215U/mg (66.8±4.8% viable; n=1), 240U/mg (70.3±2.1% viable; n=1) or 255U/mg 
(65.7±1.7% viable; n=1) activity.  
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1.2 CELL VIABILITY OF ISOLATED CARDIOMYOCYTES FROM YOUNG RATS AFTER 
 TREATMENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Effect of treatments on cell viability of isolated cardiomyocytes. DMSO: Dimethyl 
sulfoxide, Asp: Aspalathin, Ins: Insulin; n = 1 individual young rat . 
 
To assess the cell viability of isolated cardiomyocytes from young rats (n=1) after 1 or 3 hours of 
treatment with DMSO, aspalathin or insulin, a PI-staining assay was performed as previously 
described (Figure 5.2). There was no significant diffences between treatment groups for either 1 or 
3 hours of treatment. After 1 hour of treatment, basal cell viability was 64.8±1.4%, DMSO treated 
groups 64.9±0.2%, 10M aspalathin treated groups 64.9±1.9%, 10 nM insulin treated group 
67.6±1.4% and 10 M aspalathin with 10 nM insulin 65.1±2.3%. After 3 hours of treatment, basal 
cell viability was 65.3±3.0%, DMSO treated groups 67.8±2.0%, 10 M aspalathin treated groups 
68.1±1.4%, 10 nM insulin treated group 67.1±3.7% and 10 M aspalathin with 10 nM insulin 
65.9±0.3% (Table 5.1).  
 
Table 5.1 Cell viability after 1 or 3 hours of treatment 
Treatment 
Time 
Cell Viability (%) 
Basal DMSO 10 M Asp 10 nM Ins 
10 M Asp 
+  
10 nM Ins 
n 
1 h 64.8±1.4 64.9±0.2 64.9±1.9 67.6±1.4 65.1±2.3 1 
3 h 65.3±3.0 67.8±2.0 68.1±1.4 67.1±3.7 65.9±0.3 1 
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Figure 5.3 Dot plot representing total events acquired and final gated population of 
untreated isolated cardiomyocytes. A forward-scatter against side-scatter plot was used to 
distinguish the cells (gated/encircled) from the debris. There was no significant difference in cell 
viability between 1 or 3 hours of incubation. 
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Figure 5.4 Dot plot representing total events acquired and final gated population of treated 
isolated cardiomyocytes. A forward-scatter against side-scatter plot was used to distinguish the 
cells (gated/encircled) from the debris. There was no significant difference in cell viability between 
1 or 3 hours of treatment.  
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2. GLUCOSE UPTAKE ASSAYS OF ISOLATED CARDIOMYOCYTES 
2.1 ACUTE ASPALATHIN DOSE RESPONSE OF CARDIOMYOCYTES FROM YOUNG RATS 
       Acute (45m)
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Figure 5.5 2DG after 45 mins of aspalathin dose response in cardiomyocytes (from young 
control rats). 2DG: 2-deoxy-D-[H3]-glucose, DMSO: Dimethyl sulfoxide, Asp: Aspalathin; n = 2 - 9 
individual preparations; *<p0.05 (DMSO vs. 10 M Asp), **p<0.01 (Basal vs. 10 M Asp), 
***p<0.001 (Basal vs. DMSO, 1 M Asp and 100 M Asp) 
 
We initially tried to establish an asapalthin dose response in isolated cardiomyocytes from young 
rats (Figure 5.5). Acute aspalathin treatment showed a significant decrease in glucose uptake for 
all three aspalathin dosages of 1 uM aspalathin (76.0±4.6% n=2; p<0.001), 10 uM aspalathin 
(88.9±5.6%; n=3; p<0.01) and 100 uM aspalathin (73.5±4.7%; n=3; p<0.001) compared to basal 
(100.0±1.0%; n=9). 0.1% DMSO, the effective concentration used for 100 uM synthetic aspalathin, 
also presented with a significant decrease in glucose uptake (75.4±3.5%; n=9; p<0.001) compared 
to basal. However, a dose of 10 uM aspalathin in 0.01% DMSO had an increase in glucose uptake 
of 14.5% compared to a 10% stronger concentration of DMSO. 
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2.2 ACUTE ASPALATHIN AND INSULIN DOSE RESPONSE IN CARDIOMYOCYTES FROM YOUNG 
RATS 
Acute (45m) Aspalathin and
Insulin-Mediated 2DG Uptake
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Figure 5.6 2DG after 45 mins aspalathin and insulin dose response in cardiomyocytes (from 
young control rats). 2DG: 2-deoxy-D-[H3]-glucose, Ins: Insulin, Asp: Aspalathin; n = 3 individual 
preparations; *p<0.05 (10 nM Ins vs. 10 M Asp + 10 nM Ins; 10 nM Ins vs 100 uM Asp + 10 nM 
Ins), **p<0.01 (Basal vs.1 nM Ins), ***p<0.001 (Basal vs. 10 nM Ins)  
 
We investigated whether asapalathin can acutely induce glucose uptake through enhancing 
insulin’s action in isolated cardiomyocytes from young rats (Figure 5.6). Acute insulin was able to 
significantly induce glucose uptake of both 1 nM insulin (107.4±2.6%; p<0.01) and 10 nM insulin 
(158.3±9.4%; p<0.001) compared to basal (100.0±1.0%). Co-treating 1 nM insulin with increasing 
aspalathin concentrations showed a strong trend towards dose-dependent increases in glucose 
uptake for 1 uM aspalathin (116.9±7.5%) and 10 uM aspalathin (130.4±18.7%), while the effect 
was dissipated when co-treating with 100 uM aspalathin (99.6±14.9%). Likewise, co-treating 10 nM 
insulin with aspalathin also showed a strong increase in glucose uptake for concentrations of 10 
uM aspalathin (220.5±28.4%), while the effect was dissipated when co-treating with 100 uM 
aspalathin (121.3±0.2%). Co-treating 10 nM insulin with 10 uM aspalathin had a significant 
increase in glucose uptake (220.5±28.4%; p<0.05) compared to 10 nM insulin (158.3±9.4%). This 
equated to an effective increase in glucose uptake of 62.2%.  
  
Stellenbosch University  https://scholar.sun.ac.za
  
 
84 
    
2.3 ACUTE INSULIN DOSE RESPONSE OF CARDIOMYOCYTES FROM YOUNG, CONTROL AND HIGH-
FAT, HIGH-SUCROSE DIET RATS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 2DG uptake after 45 mins insulin dose response in cardiomyocytes from rat 
models (young control, diet control and high-fat diet rats). 2DG: 2-deoxy-D-[H3]-glucose, HFD: 
high-fat, high-sucrose diet, Asp: Aspalathin, Ins: Insulin; n = 3-7 individual preparations; **p<0.01 
(Control Basal vs. 10 nM Ins), ***p<0.001 (Young Basal vs. 10 nM Ins and 100 nM Ins; Control 
Basal vs. 100 nM Ins). 
 
A 45 minute insulin dose response (as described in Materials and Methods, Figure 3.4) was 
performed on cardiomyocytes isolated from young, control and HFD rats (Figure 5.7). The young 
group had the strongest glucose uptake response to increasing concentrations of insulin, with 
10 nM insulin having a significant increase of 45.4±8.4% (n=7; p<0.001) and 100nM insulin 
97.1±14.3% (n=3; p<0.001) compared to basal (100.0±1.8; n=7). The control group also presented 
with an increase in glucose uptake response to increasing concentrations of insulin, with 10 nM 
inducing a significant increase in glucose uptake of 46.2±5.1% (n=5; p<0.01) and 100 nM insulin 
56.0±6.2% (n=5; p<0.001) compared to basal 101.4±2.0% (n=5). The HFD group had no 
significant glucose uptake response to increasing concentrations of insulin. 
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2.4 ACUTE ASPALATHIN AND INSULIN RESPONSE IN CARDIOMYOCYTES FROM YOUNG, CONTROL 
AND HIGH-FAT, HIGH-SUCROSE DIET RATS 
2.4.1 NORMALIZED TO BASAL 
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Figure 5.8 %2DG uptake after 45 mins aspalathin and insulin treatment in cardiomyocytes 
from rat models (young control, diet control and high-fat diet rats). 2DG: 2-deoxy-D-[H3]-glucose, 
HFD: high-fat, high-sucrose diet, Asp: Aspalathin, Ins: Insulin; n = 3 - 5 individual preparations; 
*p<0.05 (Young 10 nM Ins vs. 10 uM Asp + 10 nM Ins), **p<0.01 (HFD Basal vs. 10 nM Ins and 
10 uM Asp + 10 nM Ins), ***p<0.001 (Control Basal vs. 10 nM Ins and 10 uM Asp + 10 nM Ins). 
 
We performed a preliminary study on cardiomyocytes isolated from diet rats to investigate whether 
asapalthin can acutely induce glucose uptake in the presence or absence of insulin (Figure 5.8). 
The addition of aspalathin to insulin was able to significantly increase glucose uptake in the young 
group (331.1±50.2%; n=5; p<0.05) compared to insulin alone (213.7±21.5%; n=5) (Figure 5.6), 
resulting in a 117% glucose uptake induction. Insulin significantly induced glucose uptake in both 
age-matched control groups (229.8±19.9%; n=3; p<0.001) and HFD groups (197.1±18.65%; n=3; 
p<0.01) compared to their respective basal levels (100.0±1.3; n=3 and 100.0±10.7; n=3). Co-
treatment of insulin samples with aspalathin did not induce a further significant uptake in glucose 
for either of the aged or diet rats compared to insulin samples (226.9±26.5%; n=3; p<0.001 
compared to control basal) (177.1±17.9%; n=3; p<0.01).  
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2.4.2 ABSOLUTE AMOUNTS OF GLUCOSE UPTAKE 
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Figure 5.9 Absolute 2DG uptake after 45 mins aspalathin and insulin treatment in 
cardiomyocytes from rat models (young control, diet control and high-fat diet rats). 2DG: 2-
deoxy-D-[H3]-glucose, HFD: high-fat, high-sucrose diet, Asp: Aspalathin, Ins: Insulin; n = 3 - 5 
individual preparations; *p<0.05 (HFD Basal vs. 10 uM Asp + 10 nM Ins), **p<0.01 (Young Basal 
vs. 10 nM Ins; HFD Basal vs. 10 nM Ins), ***p<0.001 (Young Basal vs. 10 uM Asp + 10 nM Ins; 
Control Basal vs. 10 nM Ins and 10 uM Asp + 10 nM Ins). 
 
The results from the previous experiment (Figure 5.8) was recalculated to the absolute 
concentrations of 2DG uptake, normalized to the amount of protein of each sample (Figure 5.9). At 
45 mins treatment, 10 nM insulin independently, as well as in combination with 10 uM aspalathin 
significantly increased glucose uptake in cardiomycoytes isolated from all 3 rat models compared 
to basal (in pmol 2DG/mg protein): young rats (72.17±10.26; n=10; p<0.01 and 96.84±11.51; n=5; 
p<0.001 vs 39.75±4.81; n=11), control rats (66.08±5.80; n=6; p<0.001 and 69.96±6.10; n=6; 
p<0.001 vs 38.29±2.92; n=6) and HFD rats (91.19±11.53; n=6; p<0.01 and 73.27±8.15; n=4; 
p<0.05 vs 53.37±4.81; n=6). There was no significant difference in glucose uptake between the 3 
different animal models in response to any treatment.   
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2.5 EXTENDED ASPALATHIN AND INSULIN RESPONSE IN CARDIOMYOCYTES FROM YOUNG, 
CONTROL AND HIGH-FAT, HIGH-SUCROSE DIET RATS 
2.5.1 NORMALIZED TO BASAL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 %2DG uptake after 1-3h of treatment in cardiomyocytes from rat models (young 
control, diet control and high-fat diet rats); 2DG: 2-deoxy-D-[H3]-glucose, HFD: high-fat, high-
sucrose diet, Asp: Aspalathin, Ins: Insulin; n = 3 - 5 individual preparations; *p<0.05 (Young Basal 
vs. 10 uM Asp at 1h30m; Control 10 nM Ins vs. 10 uM Asp + 10 nM Ins at 1h30m; HFD Basal vs 
10 uM Asp + 10 nM Ins at 1h30m), **p<0.01 (Young Basal vs. 10 nM Ins and 10 uM Asp + 10 nM 
Ins at 1h30m; HFD Basal vs. 10 nM Ins at 1h30m), ***p<0.001 (Control Basal vs. 10 nM Ins and 10 
uM Asp + 10 nM Ins at 1h30m) 
 
Extending the activation time up to 3 hours, we repeated the aspalathin and insulin stimulation in 
cardiomyocytes isolated from young, control and HFD rats (Figure 5.10, Figure 5.11). Figures 5.8 
and 5.9 illustrate that 45 minutes of aspalathin treatment was not sufficient to induce glucose 
uptake in isolated cardiomyocytes. However, at 1 and a half hours of treatment, 10 M aspalathin, 
independent of insulin, significantly increased glucose uptake in cardiomycoytes isolated from 
young rats (138.3±15.9%; n=4; p<0.05) compared to basal (100.0±2.7%; n=4), resulting in a 38% 
increase in glucose uptake. No further increase in glucose uptake by sole action of aspalathin was 
observed for either of the rat models, even when the experiment was allowed to run for 3 hours. 
Aspalathin also induced glucose uptake in conjunction with insulin in the aged control group 
(300.2±25.7%; n=5; p<0.05) compared to insulin (226.1±21.8%; n=5). There was no signifcant 
difference in glucose uptake when co-treating insulin with aspalathin in young rats (343.4±107.2%; 
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n=3; p=0.3388) compared to insulin (244.0±46.9%; n=4), as well as in HFD rats (218.2±42.50%; 
n=4; p=0.4719) compared to insulin (181.8±24.75%; n=4). Consistently, younger rats had a more 
robust response to insulin, followed by the aged-matched control group, and lastly the high-fat, 
high-sucrose diet group. 
 
2.5.2 ABSOLUTE AMOUNTS OF GLUCOSE UPTAKE 
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Figure 5.11 Absolute 2DG uptake after 1-3h of treatment in cardiomyocytes from rat models 
(young control, diet control and high-fat diet rats); 2DG: 2-deoxy-D-[H3]-glucose, HFD: high-fat, 
high-sucrose diet, Asp: Aspalathin, Ins: Insulin; n = 3 - 6 individual preparations; *p<0.05 (Young 
Basal vs 10 uM Asp at 1h30m; Control Basal vs 10 uM Asp + 10 nM Ins; HFD Basal vs 10 uM Asp 
+ 10 nM Ins), **p<0.01 (Young Basal vs 10 uM Asp at 2h and 3h; HFD Basal vs 10 nM Ins), 
***p<0.001 (Young Basal vs Control Basal and HFD Basal, 10 nM Ins and 10 uM Asp + 10 nM Ins; 
Control Basal vs 10 nM Ins and 10 uM Asp + 10 nM Ins) 
 
The results from the previous experiment (Figure 5.10) were recalculated to the absolute 
concentrations of 2DG uptake, normalized to the amount of protein of each sample (Figure 5.11). 
The young rats had a significantly higher basal glucose uptake at 1 and a half hours compared to 
the control and HFD rats (22.0±2.5 pmol dGluc/mg protein; n=4 vs. 10.0±0.8 pmol dGluc/mg 
protein; n=6 and 10.3±2.0 pmol dGluc/mg protein; n=4; p<0.001). At 1 and a half hours of 
treatment, 10 M aspalathin, 10 nM insulin and a combination of both all significantly increased 
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glucose uptake in cardiomycoytes isolated from young rats (37.2±3.6 pmol dGluc/mg protein; n=3; 
p<0.05, 46.6±3.6 pmol dGluc/mg protein; n=3; p<0.001, and 52.2±6.8 pmol dGluc/mg protein; n=3; 
p<0.001 vs basal: 22.0±2.5 pmol dGluc/mg protein; n=4). Furthermore, 10 uM aspalathin treatment 
in young rats significantly increased glucose uptake for both 2 hours and 3 hours (44.1±0.01 pmol 
dGluc/mg protein; n=2; p<0.01 and 44.1±3.7 pmol dGluc/mg protein; n=2; p<0.01) compared to 
basal. In aged control rat cardiomyocytes, treatment with 10 nM insulin and a combination of 10 
uM aspalathin and 10 nM insulin for 1 and half hours both significantly increased glucose uptake 
compared to basal (23.5±2.9 pmol dGluc/mg protein; n=6; p<0.001 and 28.7±3.0 pmol dGluc/mg 
protein; n=5; p<0.001 vs 10.0±0.8 pmol dGluc/mg protein; n=6). In HFD rat cardiomyocytes, 
treatment with 10 nM insulin and a combination of 10 uM aspalathin and 10 nM insulin for 1 and a 
half hours both significantly increased glucose uptake compared to basal (26.4± 5.3 pmol 
dGluc/mg protein; n=3; p<0.01 and 24.2±5.3 pmol dGluc/mg protein; n=4; p<0.05 vs 10.3±2.0 pmol 
dGluc/mg protein; n=4). No further increase in glucose uptake by aspalathin was observed for 
either older controls or HFD rats when the experiment was extended to 3 hours. Consistently, 
younger rats had the most robust glucose uptake response with or without treatments, whereas 
aged-rats had similar responses to each other, but weak in comparison with the young rats.   
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CHAPTER 6 
RESULTS: ASPALATHIN AND DIFFERENTIATED H9C2 CELLS 
 
1. CELL VIABILITY ASSAYS 
1.1 METABOLIC ACTIVITY OF DIFFERENTIATED H9C2 CELLS AFTER TREATMENT 
                    ATP Assay after
                    3 hours of  Treatment
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Figure 6.1 Metabolic Activity (ATP Assay) after 3h of treatment. Asp: Aspalathin, Ins: Insulin; n 
= 3 individual culture preparations; *p<0.05 (Basal vs. 10 uM Asp and 10 uM Asp + 1 nM Ins) 
 
The metabolic activity of differentiated H9C2 cells were determined after being pretreated for 3 
hours with 10 uM aspalathin, or 1 nM insulin for the last 15 mins or a combination of both (Figure 
6.1). Treating differentiated H9C2 cells with 10 M aspalathin for 3 hours, as well as 3 hour 10 M 
aspalathin treatment with 15 mins 1 nM insulin co-treatment significanly increased metabolic 
activity (107.8±2.6%, p<0.05 and 107.0±2.0%, p<0.05), respectively by 7.8% and 7.0% compared 
to basal (100.1±2.5%). 1 nM insulin treatment for 15 mins did not significanly increase metabolic 
activity (100.4±3.7%) compared to basal.  
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1.2 MEMBRANE INTEGRITY OF DIFFERENTIATED H9C2 CELLS AFTER TREATMENT 
 
                    JC-1 Stain after 3 hours
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Figure 6.2 JC-1 Staining assay after 3h of treatment. Asp: Aspalathin, Ins: Insulin; n = 3 
individual culture preparations; *p<0.05 (Basal vs. 10 uM Asp), **p<0.01 (Basal vs 10 uM Asp + 10 
nM Insulin), ***p<0.001 (Basal vs 10 nM Ins) 
 
In order to determine the cell viability of differentiated H9C2 cells, cells were treated for 3 hours 
with or without 10 uM aspalathin, 10 nM insulin or a combination of both, after which the 
membrane depolarization was determined using JC-1 staining. Unfortunately, fluorescence was 
only qauntified at 596 nm (Figure 6.2), an indication of the effective viable portion of cells, whereas 
it is orthodox to quantify the green fluorescence at 520 nm as well, indicative of the non-viable 
portion of cells. The ratio of viable to non-viable would then be calculated as an overall indication of 
viability for the treatment groups. Figure 6.3 shows the JC-1 staining fluorescence of the 
respective treatment groups, and it is immediately evident that the viable portion of cells 
(yellow/red fluorescence) is significantly greater than the non-viable portion of cells (green 
fluorescence) for each of the treatment groups. We therefore concluded that the treatments were 
not toxic to the differentiated H9C2 cells.  
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Figure 6.3 JC-1 Staining assay of Differentiated H9C2 cells after 3h of treatment. Image 
magnification at 40x. Panels (A) represent control cells without treatment, (B) 10 uM aspalathin 
treatment for 3 hours, (C) 1 0nM insulin treatment for the last 15 mins of 3h incubation, and (D) 
10 uM aspalathin for 3 hours, together with 10 nM insulin for the last 15 mins of 3h incubation. The 
fluorescent yellow/red cells indicate the viable cells, while the green stains, indicated by the arrow 
in (B), is a measure of non-viable cells. 
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2. GLUCOSE UPTAKE ASSAY IN DIFFERENTIATED H9C2 CELLS 
2.1 DELAYED ASPALATHIN AND INSULIN RESPONSE IN DIFFERENTIATED H9C2 CELLS 
                   2DG Uptake compared to Basal
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Figure 6.4 2DG uptake in differentiated H9C2 cells after 3h and 6h of treatment. 2DG: 2-
deoxyglucose-D-[H3]-glucose, Asp: Aspalathin, Ins: Insulin; n = 4 individual culture preparations; 
*p<0.05 (Basal vs. 1 nM Ins and 1 nM Ins + 10 uM Asp at 3h, and Basal vs. 1 nM Ins + 10 uM Asp 
at 6h), **p<0.01 (Basal vs. 10 uM Asp at 3h and 6h)  
 
Differentiated H9C2 cells were assayed for glucose uptake in the presence of a 5.5 mM glucose 
solution (Figure 6.4). After 3 and 6 hours respectively of aspalathin treatment, with or without 
insulin for the last 15 mins of the protocol, glucose uptake was initiated by addition of 2DG for 15 
mins. 10 M aspalathin was able to significantly increase glucose uptake after both 3 and 6 hours 
of treatment (122.1±6.6%, p<0.01 and 122.0±3.3%, p<0.01) compared to basal (99.9±3.9% and 
100.0±7.3% respectively), equating to an average of increase in glucose uptake of 22%. 1 nM 
insulin was also able to significantly increase glucose uptake when added 15 mins prior to the 3 
hours timepoint (120.5±7.5%, p<0.05) compared to basal, however the same effect could not be 
confirmed when 1 nM insulin was added 15 mins before the 6 hour time point (109.9±6.2%, 
p=0.3120). 2 hours 45 mins of treatment with 10 uM aspalathin, followed by the addition of 1 nM 
insulin also prompted a significant increase in glucose uptake (125.8±11.7%, p<0.05), equating to 
a 25.8% increase. Likewise, after 5 hours 45 mins of treatment with 10 uM aspalathin, followed by 
the addition of 1 nM insulin, glucose uptake was significantly increased (122.9±4.9%, p<0.05) 
compared to basal, which was similar to 10 uM aspalathin independently. 
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CHAPTER 7 
RESULTS: THE MECHANISM OF ACTION OF ASPALATHIN 
 
1. INSULIN-DEPENDENT GLUCOSE UPTAKE INHIBITION 
1.1 ACUTE ASPALATHIN WITH WORTMANNIN IN ISOLATED CARDIOMYOCYTES FROM YOUNG 
RATS 
Figure 7.1 2DG uptake after inhibition of PI3K with wortmannin and stimulation with 
aspalathin and insulin in cardiomyocytes (from young rats). 2DG: 2-deoxy-D-[H3]-glucose, 
Wort: Wortmannin, Asp: Aspalathin, Ins: Insulin; n = 3 individual preparations; *p<0.05 (Basal vs. 
100 nM Wort; 10 nM Ins vs 10 uM Asp + 10 nM Ins), **p<0.01 (10 uM Asp + 10 nM Ins vs 100 nM 
Wort + 10 uM Asp + 10 nM Ins), ***p<0.001 (10 nM Ins vs 100 nM Wort + 10 nM Ins) 
 
To investigate the mechanism whereby aspalathin may induce glucose uptake, wortmannin was 
added to isolated cardiomyocytes from young rats as a selective inhibitor of PI3K, thus inhibiting 
the insulin-dependent pathway of glucose uptake (Figure 7.1). 100 nM wortmannin was able to 
significantly decrease basal glucose uptake (82.15±5.1% vs 100.0±4.1%, n=3; p<0.05). Co-treating 
10 nM insulin with 100 nM wortmannin significantly decreased glucose uptake (78.1±7.0%; n=3; 
p<0.001) compared to 10 nM insulin alone (158.3±9.4%; n=3). Furthermore, co-stimulating 10 nM 
insulin with 10uM aspalathin again (Refer Figure 5.6; Figure 5.8; Figure 5.9) significantly 
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increased glucose uptake in isolated young rat heart cells (220.5±28.4%; n=3; p<0.05) compared 
to 10 nM insulin, while addition of 100 nM wortmannin completely inhibited all of the glucose 
uptake potential of the combination of aspalathin and insulin (59.0±6.2%; n=2; p<0.01).  
 
1.2 EXTENDED ASPALATHIN WITH WORTMANNIN IN ISOLATED CARDIOMYOCYTES FROM 
CONTROL AND HFD RATS 
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Figure 7.2 2DG uptake after inhibition of PI3K with wortmannin and stimulation with 
aspalathin and insulin in cardiomyocytes (from control and HFD rats). HFD: High-fat, high-
sucrose diet, 2DG: 2-deoxy-D-[H3]-glucose, Wort: Wortmannin, Asp: Aspalathin, Ins: Insulin; n = 2 
individual preparations; *p<0.05 (Control Basal vs. 100 nM Wort, 10 nM Ins and 10 uM Asp + 
10 nM Ins; Control 10 nM Ins vs 100nM Wort + 10 nM Ins; Control 10 uM Asp + 10 nM Ins vs 100 
nM Wort + 10 uM Asp + 10 nM Ins; HFD Basal vs. 10 nM Ins and 10 uM Asp + 10 nM Ins; HFD 
10nM Ins vs 100nM Wort + 10nM Ins; HFD 10uM Asp + 10nM Ins vs 100nM Wort + 10 uM Asp + 
10 nM Ins). 
 
To investigate the mechanism whereby aspalathin may induce glucose uptake in aged rats, 
wortmannin was added to isolated cardiomyocytes from control and HFD rats as a selective 
inhibitor of PI3K, thus inhibiting the insulin-dependent pathway of glucose uptake (Figure 7.2). 
100nM wortmannin was also able to significantly decrease basal glucose uptake in control rats 
(58.7±1.4% vs 100.0±9.1%; n=2; p<0.05). Co-treating 10 nM insulin with 100 nM wortmannin 
significantly decreased glucose uptake in both controls (106.0±10.6 vs 272.4±17.4; n=2; p<0.05) 
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and HFD rats (86.8±19.4 vs 216.8±58.6; n=2; p<0.05). Furthermore, inhibiting PI3K signaling with 
100 nM wortmannin, completely inhibited the additive effects of 10 nM insulin and 10 uM 
aspalathin on glucose uptake for control rats (136.2±13.6 vs 255.6±18.0; n=2; p<0.05).  
 
2. PROTEIN EXPRESSION AFTER ACUTE ASPALATHIN TREATMENT IN YOUNG RATS 
2.1 MYOCARDIAL PKB CONTENT AND ACTIVATION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3 PKB expression and activation in isolated cardiomyocytes from young rats after 
15 minutes in vitro stimulation. SF: Stain-free Technology for Normalization, Asp: Aspalathin, 
Ins: Insulin, Wort: Wortmannin. A) Phospho-PKB (Ser473) content. n = 4 individual preparations; 
*p<0.05 (10 nM Ins vs 10 nM Ins + 100 nM Wort; 10 uM Asp + 10 nM Ins vs 10 uM Asp + 10 nM 
Ins + 100 nM Wort), **p<0.01 (Basal vs. 10 uM Asp + 10 nM Ins), ***p<0.001 (Basal vs. 10 nM Ins 
and 100 nM Wort). B) Total-PKB content.; n = 6 individual preparations; *p<0.05 (Basal vs. 10 nM 
Ins; 10 uM Asp + 10 nM Ins vs. 10 uM Asp + 10 nM Ins + 100 nM Wort), ***p<0.001 (Basal vs. 100 
nM Wort). C) Phospho- to Total-PKB. n = 3 individual preparations; *p<0.05 (Basal vs. 10 nM Ins 
and 10 uM Asp + 10 nM Ins).  
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Lysates were prepared from cardiomyoyctes isolated from young rats acutely (15 mins) treated 
with 0.1% DMSO, 10 uM aspalathin, 10 nM insulin and 100 nM wortmannin, and assayed for the 
relative total PKB expressed and PKB activation as measured by Ser473 phosphorylation, as a 
measure of the insulin-dependent mechanism of signaling (Figure 7.3). Normalization was done 
for each sample by using the Stain-Free technology (Bio-Rad Laboratories Inc., USA) embedded 
in the composition of gels, allowing for visualization of the total protein for each lane. 
Phosphorylated (activated) PKB was increased in samples treated with insulin (2.25±0.3 fold 
increase; n=4; p<0.001), while insulin in combination with aspalathin had a similar increase 
(2.64±0.6 fold increase; n=3; p<0.01) compared to basal (1.00±0.02; n=4). Wortmannin completely 
inhibited the activation of basal PKB levels (0.49±0.19 fold decrease; n=4; p<0.001). Addition of 
wortmannin before insulin resulted in a 2-fold decrease (1.04±0.10 compared to 2.25±0.34; n=4; 
p<0.05), whereas addition of wortmannin before aspalathin and insulin also completely inhibited 
PKB activation resulting in a 5-fold decrease (0.51±0.21 compared to 2.64±0.6; n=3; p<0.05). 
Furthermore, total (expressed) PKB was only upregulated in insulin stimulated samples 
(1.19±0.12; n=4; p<0.05) compared to basal (1.00±0.02; n=4) and not in samples co-stimulated 
with aspalathin and insulin. Wortmannin decreased the expression of PKB (0.74±0.08; n=4; 
p<0.001) compared to basal, while pretreating insulin plus aspalathin with wortmannin also 
significantly decreased PKB expression compared to insulin plus aspalathin (0.78± 0.08 compared 
to 1.06±0.09; n=4; p<0.05). The phospho to total ratio of PKB, a determinant of how much of the 
total PKB is activated, showed significant increases on stimulation with insulin (2.12±0.54 fold 
increase; n=4; p<0.05) and a similar increase for insulin in combination with aspalathin (2.70±1.08; 
n=3; p<0.05) compared to basal (1.00±0.03; n=4). DMSO did not influence the total, 
phosphorylated or total-to-phosphorylated ratio of PKB compared to basal.  
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2.2 MYOCARDIAL AMPK CONTENT AND ACTIVITY 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4 AMPK expression and activation in isolated cardiomyocytes from young rats 
after 15 minutes in vitro stimulation. SF: Stain-free Technology for Normalization, Asp: 
Aspalathin, Ins: Insulin, Wort: Wortmannin. A) Phospho-AMPK content. n = 6 individual 
preparations; **p<0.01 (Basal vs. 10 uM Asp + 10 nM Ins). B) Total-AMPK content; n = 5 individual 
preparations; *p<0.05 (Basal vs. 10 uM Asp and 10 uM Asp + 10nM Ins), ***p<0.001 (Basal vs. 10 
nM Ins). C) Phospho- to Total-AMPK Ratio. n = 5 individual preparations 
 
Lysates were prepared from cardiomyoyctes isolated from young rats acutely (15 mins) treated 
with 0.1% DMSO, 10 uM aspalathin, 10 nM insulin and 100 nM wortmannin, and assayed for the 
relative total AMPK expressed and AMPK activated, as a measure of the insulin-independent 
mechanism of aspalathin (Figure 7.4). Normalization was done for each sample by using the 
Stain-Free technology (Bio-Rad Laboratories Inc., USA) embedded in the composition of gels, 
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allowing for visualization of the total protein for each lane. Phosphorylated (activated) AMPK was 
significantly increased in samples treated with 10 nM insulin plus 10 uM aspalathin (1.32±0.15 fold 
increase; n=3; p<0.01) compared to basal (1.00±0.01; n=3), whereas neither insulin nor aspalathin 
had a significant effect on their own (0.98±0.09; n=3; p=0.7321 and 1.16±0.14; n=3; p=0.1040). 
Furthermore, the total (expressed) AMPK was upregulated in response to aspalathin (1.17±0.10 
fold increase; n=4; p<0.05) and insulin (1.37±0.17 fold increase; n=3; p<0.001) while insulin and 
aspalathin co-treatment had a similiar response to insulin alone (1.34±0.21 fold increase; n=4; 
p<0.05) compared to basal. There were no significant differences in the phospho to total ratio of 
AMPK, a determinant of how much of the total AMPK is activated, between any of the treatment 
groups. Furthermore, as expected, wortmannin did not induce any significant differences in AMPK 
expression or activation, since wortmannin only selectively inhibits PI3K, a signaling pathway that 
is not essential for AMPK expression and activation.  
 
3. PROTEIN EXPRESSION AFTER EXTENDED ASPALATHIN TREATMENT IN YOUNG, 
CONTROL AND HFD RATS 
3.1 MYOCARDIAL PKB CONTENT AND ACTIVITY 
 
 
 
 
Figure 7.5 Treating cardiomyocytes with 10 nM insulin for 1 h 30 mins, leads to 
overexpression and activation of PKB compared to baseline. SF: Stain-free technology for 
normalization, + Positive Control, Y: Young, C: Control, F: High-fat, high-sucrose diet, B: Basal, A: 
10uM Aspalathin, I: 10nM Insulin, AI: 10uM Aspalathin + 10nM Insulin. 
 
The treatment time of samples was extended by an additional 1 h and 15 mins and lysates 
prepared for immunoblot analaysis. Figure 7.5 shows that PKB expression and activation 
differered significantly between samples treated with or without insulin for 1 and a half hours. As a 
result, samples had to be run separately to investigate the mechanism of aspalathin. The 
membranes were overexposed and analysed separately in Figure 7.6 and Figure 7.7.  
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Figure 7.6 PKB expression and activation in isolated cardiomyocytes from young, control 
and HFD rats after 1h 30 mins in vitro stimulation with aspalathin. SF: Stain-free Technology 
for Normalization, Y: Young, C: Control, F: High-fat, high-sucrose diet, B: Basal, A: 10 uM 
Aspalathin. A) Phospho-PKB content. B) Total-PKB content. C) Phospho- to Total-PKB. 
  
In the present experiment, untreated cardiomyocytes from a young control rat was used as positive 
control. Isolated cardiomyocytes from young, control and HFD rats treated with aspalathin for 1h 
30 mins showed no significant differences between basal and aspalathin treated groups for either 
or between either of the 3 animal models (Figure 7.6) 
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Figure 7.7 PKB expression and activation in isolated cardiomyocytes from young, control 
and HFD rats after 1h 30 mins in vitro stimulation with aspalathin plus insulin. SF: Stain-free 
Technology for Normalization, Y: Young, C: Control, F: High-fat, high-sucrose diet, I: 10 nM Insulin, 
AI: 10 uM Aspalathin + 10 nM Insulin. A) Phospho-PKB content; *p<0.05 (10 nM Ins vs. 10 uM Asp 
+ 10 nM Ins for Young Rats). B) Total-PKB content. C) Phospho- to Total-PKB.  
 
In the present experiment, untreated cardiomyocytes from a young control rat was used as positive 
control. Isolated cardiomyocytes from young, control and HFD rats were treated with insulin and/or 
aspalathin for 1 h 30 mins. In the young group, co-treating 10 nM insulin with 10 uM aspalathin led 
to significant increase in PKB activation (1.30±0.03 fold increase; n=3; p<0.05) compared to the 10 
nM insulin treatment. No significant differences between insulin and aspalathin co-treatment was 
found for the age-matched control and HFD group (Figure 7.7).  
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3.2 MYOCARDIAL AMPK CONTENT AND ACTIVATION 
 
 
 
 
 
Figure 7.8 Representative blot of AMPK expression and activation in young, control and 
HFD rats. SF: Stain-free technology for normalization, + Positive Control, Y: Young, C: Control, 
HFD/F: High-fat, high-sucrose diet, B: Basal, A: 10 uM Aspalathin, I: 10 nM Insulin, AI: 10 uM 
Aspalathin + 10 nM Insulin. 
 
AMPK expression and activation was observably higher in aged-rats compared to young rats. This 
might in part be due to a variation in whole lysate composition (SF in Figure 7.8), i.e. the specific 
protein profile present in cardiomyocytes from young and aged rats after a concentration of 50 ug 
‘protein’ /ul was loaded onto the gels for separation with SDS-PAGE.  
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Figure 7.9 AMPK expression and activation in isolated cardiomyocytes from young, control 
and HFD rats after 1h 30 mins in vitro stimulation. SF: Stain-free Technology for Normalization, 
Y: Young, C: Control, F: High-fat, high-sucrose diet, B: Basal, A: 10 uM Aspalathin, I: 10 nM 
Insulin, AI: 10 uM Aspalathin + 10 nM Insulin. A) Phospho-AMPK content; *p<0.05 (Young Basal 
vs Control Basal). B) Total-PKB content; *p<0.05 (Young Basal vs Control Basal) C) Phospho- to 
Total-PKB; *p<0.05 (Young Basal vs 10 uM Aspalathin) 
 
Isolated cardiomyocytes from young, control and HFD rats were treated with 10 uM aspalathin, 10 
nM insulin or both for 1 h 30 mins (Figure 7.9). The phospho-to-total AMPK ratio, or the measure 
of the amount of total expressed AMPK activated, was significantly increased after treatment with 
aspalathin in young controls (1.29±0.03; p<0.01) compared to basal (0.84±0.06), resulting in a 
54% increase. This might be indicative of the mechanism by which glucose uptake was induced in 
Figure 5.8. There were no significant differences between the treatment groups for the age-
matched control and HFD group. However, comparison of the basal AMPK activation and 
expression levels, showed a significant increase in the older controls (0.52±0.03 vs 0.85±0.07 for 
AMPK activation, p<0.01; 0.42±0.03 vs 0.85±0.05 for AMPK expression, p<0.01).  
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3.3 MYOCARDIAL GLUT4 CONTENT AND ACTIVITY 
 
 
 
 
 
 
 
Figure 7.10 GLUT4 expression in cytosolic and membrane fractions obtained from young, 
rat cardiomyocytes (using Mini-PROTEAN TGX Stain-Free Precast Gels). +, positive control; 
1st letter abbreviations (Y: Young, C: Control, F: High-fat, high-sucrose diet); 2nd letter 
abbreviations (C: Cytosolic, M: Membrane); 3rd letter abbreviations (B: Basal, A: 10 uM Aspalathin: 
10 nM Insulin, AI: 10 uM Aspalathin + 10 nM Insulin). A) Stain-Free technology gel after protein 
separation of 1st set of samples. B) PVDF membrane after transfer of gel proteins in A. C) GLUT4 
expression of 1st set of samples, following addition of ECL Clarity.  
 
Cardiomyocytes isolated from young control rats were treated with 10 uM aspalathin, 10 nM insulin 
or a combination of both, after which they were fractionated into membrane and cytosolic fractions 
for determination of GLUT4 translocation (Figure 7.10). The GLUT4 primary antibody and the anti-
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mouse IgG HRP-linked secondary antibody and were diluted in TBS-Tween Buffer. Initial 
determination with total GLUT4 antibodies, using Clarity ECL as a chemiluminescence agent, 
resulted in non-specific binding to the 25 kDa region of the cytosolic fractions. This is well below 
the expected locus of GLUT4, which is between 45 kDa, the established molecular weight of 
GLUT4, and 50 kDa, according to the manufacturer’s data sheets (Cell Signaling Technology, 
USA). Initially, It was speculated that the primary antibody used in question, might have lost it’s 
binding specificity.GLUT4 expression could not be determined from this experiment. 
3.4  
 
           
 0    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
Figure 7.11 GLUT4 expression in cytosolic and membrane fractions obtained from young, 
age-matched control and HFD rat cardiomyocytes (using Mini-PROTEAN Precast Gels). 1st 
letter abbreviations (Y: Young, C: Control, F: High-fat, high-sucrose diet); 2nd letter abbreviates (C: 
Cytosolic, M: Membrane); 3rd letter abbreviations (B: Basal, A: 10 uM Aspalathin: 10 nM Insulin, AI: 
10 uM Aspalathin + 10 nM Insulin). A) Precast gel after protein separation of 1st set of samples. B) 
PVDF membrane after transfer of gel proteins in A. C) GLUT4 expression of 1st set of samples, 
following addition of Luminata Forte Western HRP substrate. D) Precast gel after protein 
separation of 2nd set of samples. E) PVDF membrane after transfer of gel proteins in D. F) GLUT4 
expression of 2nd set of samples, following addition of Luminata Forte Western HRP substrate. 
 
Cardiomyocytes isolated from young control, age-matched control and HFD rats were treated with 
10 uM aspalathin, 10 nM insulin or a combination of both, after which they were fractionated into 
membrane and cytosolic fractions for determination of GLUT4 translocation (Figure 7.11). After 
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being unable to find total GLUT4 expression with the previous protocol (Figure 7.9), a new total 
GLUT4 antibody was diluted in TBS-Tween Buffer. The chemiluminescent agent was also changed 
to Luminata Forte Western HRP substrate. Normally, the HRP of the secondary antibody catalyze 
the oxidation of luminol into photons (or chemiluminescence) which can be detected by charged 
coupled devices. Luminata Forte prevents spontaneous oxidation of luminol, which results in a 
stronger and more stable signal detectable. The addition of Luminata Forte resulted in various non-
specific signals, and the same non-specific binding at 25 kDa was observed as in (Figure 7.9). 
Overexposed bands in line with GLUT4’s size (45 - 50 kDa) were observed for all the cytosol 
fractions of young, control and HFD groups. However, determining the specific optical density 
between the treatment groups was not possible due to the overexposure.  
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Figure 7.12 GLUT4 expression in membrane fractions obtained from young, age-matched 
control and HFD rat cardiomyocytes. +, positive control; 1st letter abbreviations (Y: Young, C: 
Control, F: High-fat, high-sucrose diet); 2nd letter abbreviations (M: Membrane); 3rd letter 
abbreviations (B: Basal, A: 10 uM Aspalathin: 10 nM Insulin, AI: 10 uM Aspalathin + 10 nM Insulin). 
A) Stain-free technology gel after protein separation of 1st set of samples. B) Stain-free technology 
membrane after transfer of gel proteins in A. C) GLUT4 expression of 1st set of samples, following 
addition of Luminata Forte Western HRP substrate. D) Stain-free technology gel after protein 
separation of 2nd set of samples. E) Stain-free technology membrane after transfer of gel proteins 
in D. F) GLUT4 expression of 2nd set of samples, following addition of Luminata Forte Western 
HRP substrate.  
 
Cardiomyocytes isolated from young control, age-matched control and HFD rats were treated with 
10uM aspalathin, 10nM insulin or a combination of both, after which they were fractionated into 
membrane fractions for determination of GLUT4 translocation (Figure 7.12). The same protocol 
was followed as in Figure 7.9, except the primary and secondary antibody were diluted in TBS-
Tween Buffer with 2.5% Milk in order to reduce non-specific binding of proteins that led to the 
overexposure of bands observed in the previous experiment. Non-specific binding was significantly 
less after addition of Luminata Forte in this experiment, but still presented with the same non-
specific binding at 25 kDa as observed in (Figure 7.9). GLUT4 expression could not be determined 
from this experiment.  
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Figure 7.13 GLUT4 expression in cytosolic fractions obtained from young, age-matched 
control and HFD rat cardiomyocytes (using a TGX Stain-Free FastCast Acrylamide Kit). +, 
positive control, 1st letter abbreviations (Y: Young, C: Control, F: High-fat, high-sucrose diet); 2nd 
letter abbreviations (C: Cytosolic); 3rd letter abbreviations (B: Basal, A: 10 uM Aspalathin: 10 nM 
Insulin, AI: 10 uM Aspalathin + 10 nM Insulin). A) TGX Stain-Free FastCast gel after protein 
separation of 1st set of samples. B) PVDF membrane after transfer of gel proteins in A. C) GLUT4 
expression of 1st set of samples, following addition of Luminata Forte. D) Stain-free technology gel 
after protein separation of 2nd set of samples. E) PVDF membrane after transfer of gel proteins in 
D. F) GLUT4 expression of 2nd set of samples, following addition of Luminata Forte.  
 
Cardiomyocytes isolated from young control, age-matched control and HFD rats were treated with 
10 uM aspalathin, 10 nM insulin or a combination of both, after which they were fractionated into 
cytosolic fractions for determination of GLUT4 translocation (Figure 7.13). The blocking protocol 
was changed (3 washes with 5% BSA in TBS-Tween) and the total GLUT4 antibody was diluted in 
Calbiochem Signalboost and the result was less non-specific binding resulting in a clearer 
image. The same non-specific binding at 25 kDa was observed as in Figure 7.9, and the bands 
present at the 45-50 kDa region were very diffused, making it questionable whether it can be 
assumed to represent GLUT4. GLUT4 expression could not be determined from this experiment.  
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CHAPTER 8 
DISCUSSION 
 
1. INTRODUCTION 
Obesity is associated with increased risk for insulin resistance and defective glucose homeostasis 
(Boden et al., 2011). Furthermore, in the majority of type 2 diabetic patients, insulin resistance is 
the earliest detectable abnormality (DeFronzo & Tripathy, 2009). Even severe insulin resistance 
can however still be managed by normal β-cell function. In this case, sufficient insulin is still 
produced to balance out faulty insulin action. Thus, in order for the condition to progress to type 2 
diabetes, both insulin action AND insulin secretion need to be defective. By the time type 2 
diabetes is diagnosed, both of these conditions are well established and determining the primary 
defect or initial cause is impossible (DeFronzo, 2004). Nevertheless, it is known that no matter 
which defect (insulin resistance or impaired insulin secretion) first disturbed glucose homeostasis, 
with time both conditions will present in type 2 diabetic patients. Since various current medication 
available to treat T2D have problems with remaining effective after prolonged treatment (Misbin, 
2005) or become toxic to liver and heart as the treatment progresses (Boussageon et al., 2011), a 
search for safer alternatives has been instigated in recent years. One of these promising 
nutraceuticals, aspalathin, has recently attracted many investigators for its potential in regulating 
glucose metabolism (Kawano et al., 2009; Muller et al., 2012; Mazibuko et al., 2013; Son et al., 
2013). Aspalathin has been shown to induce glucose uptake directly in rat L6 skeletal muscle cells 
(Kawano et al., 2009, Son et al., 2013). Treating with ARF was also able to increase glucose 
uptake in mouse C2C12 skeletal muscle cells (Muller et al., 2012). Furthermore, treating palmitate-
induced insulin-resistant C2C12 skeletal muscle cells with green rooibos extract (GRE) and 
fermented rooibos extract (FRE) induced elevated glucose uptake levels (Mazibuko et al., 2013). 
Also, aspalathin suppressed elevated fasting blood glucose and improved impaired glucose 
tolerance in ob/ob mice (Son et al., 2013) and db/db mice (Kawano et al., 2009). In view of these 
previous observations and to deepen our understanding of myocardial glucose metabolism in 
ageing, obesity and insulin-resistance, we investigated the potential of aspalathin to induce 
glucose uptake in isolated cardiomyocytes from young (8 weeks old), age-matched control (22 
weeks old) and HFD (22 weeks old: 6 weeks + 16 weeks of a high fat, high sucrose diet) rats.  
 
In the present study, we aimed to elucidate the effects and mechanism of aspalathin treatment on 
glucose homeostasis, focusing on glucose uptake by isolated adult ventricular cardiomyocytes 
from normal and obese, insulin resistant rats, as well as H9C2 cardiomyoblasts.  
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2. CHARACTERISTICS OF A HIGH-FAT, HIGH-CALORIC DIET 
The prevalence of obesity and insulin-resistance increases the risk for cardiovascular diseases 
(Cardiovascular Disease, WHO, 2015). In order to investigate these conditions, we made use of a 
diet-induced obese and insulin resistant Wistar rat model. Obesity is the consequence of 
overconsumption coupled to a reduced energy expenditure (Hill et al., 2012). This mechanism was 
exploited in our present study by using a high-fat, high-sucrose diet (rat chow, supplemented with 
holsum fat, sucrose and condensed milk) for 16-30 weeks to induce obesity by hyperphagia and 
insulin-resistance in caged rats. They were compared to age-matched controls (normal rat chow). 
In the present study, the high-fat, high-sucrose diet rats had a significantly higher body weight 
(Figure 4.1) and visceral fat (excess fat) content (Figure 4.2) compared to the age-matched 
controls, similar to what was previously published (Huisamen et al., 2013). As indicated by the 
biometric parameters, they also became insulin resistant (Table 4.1). This included raised fasting 
insulin levels and a higher HOMA-IR index. In genetically and environmentally susceptible 
individuals, chronic overnutrition with an excessive energy intake and low energy expenditure 
causes the subcutaneous fat to saturate, consequently leading to enlarged adipocytes and visceral 
fat formation (Blüher, 2013). Furthermore, diet-induced visceral fat accumulation is an important 
factor in the development of insulin resistance and a risk factor for the metabolic syndrome 
(Grundy, 2012).  
 
One of the first clinical consequences of insulin resistance is a dysregulation in glucose 
homeostasis, the maintenance of blood glucose concentration within very narrow physiological 
limits (Norris & Rich, 2012). This abnormality can be determined by measuring the fasting blood 
glucose concentration. Fasting blood glucose is closely regulated by endogenous glucose 
production (hepatic glycogenolysis, gluconeogenesis) and glucose utilization by insulin-senstive 
tissues. In the present study, an OGTT of the diet rats, showed the HFD group to have a 
significantly higher fasting blood glucose levels compared to the controls, and following 
administration of glucose, the HFD group’s blood glucose remained significantly elevated for at 
least 45 minutes compared to the controls (Figure 4.3). It was also significantly higher at the 
clinically relevant 2-hour time point. In addition, concurringly, the non-fasting blood glucose levels 
(or random blood glucose test levels) taken just prior to sacrificing of rats, also showed a significant 
increase (Figure 4.4). The cardiovascular effects of a 16 week high-sucrose diet without high-fat 
has been well characterised by Huisamen et al. (2011). These rats presented with whole-body 
insulin resistance, as well as myocardial insulin resistance. In the present study, increasing 
concentrations (1-100nM) of insulin elicited a weak response in glucose uptake in cardiomyocytes 
isolated from HFD rats (Figure 5.7), corroborating previous studies using a similar model 
(Huisamen et al., 2011; Huisamen et al., 2013). In contrast, age-matched control diet rats had a 
dose-dependent increase in glucose uptake, and cardiomyocytes isolated from young control rats 
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had the most robust increases in glucose uptake response to increasing concentrations of insulin. 
We speculate that the mechanism for insulin resistance formation following a high-fat, high-caloric 
diet is due to an increase in adipose tissue which causes elevated circulating free fatty acids (FFA) 
levels, altering adipose tissue derived factors, such as increasing leptin (responsible for inhibiting 
appetite) and TNFα (known to induce peripheral insulin resistance) and decreasing adiponectin 
(sensitize insulin action) (Yadav et al., 2013), followed by the eventual viceral fat accumulation 
(Ding, 2015, Grundy, 2012). In this regard, an increase in plasma FFA may have contributed to the 
elevated glucose levels as follows: (i) induction of insulin resistance by altering glucose transport, 
phosphorylation or both (inhibition of insulin-mediated glucose uptake pathways) in cardiac muscle 
and possibly skeletal muscle and adipose tissue, (ii) increasing endogenous glucose production by 
increasing hepatic glucose output (Boden, 2011), (iii) and increased FFA-induced insulin secretion 
exacerbated by FFA-induced insulin resistance (Boden, 1999).  
 
3. ACUTE (45 MINUTES) TREATMENT WITH ASPALATHIN 
3.1 CELL VIABILITY OF CARDIOMYOCYTES FOLLOWING THE ISOLATION PROTOCOL 
Our first experiment was the determination of cell viability following the isolation in cardiomyocytes 
from young rats. According to the International Organization for Standardization (ISO 10993, 
2009), cell viability percentages above 80% are considered non-cytotoxic, 60-80% weak cytotoxic, 
40-60% moderate cyotoxic and below 40% strong cytotoxic. In the present study, cell viability after 
the isolation protocol of cardiomyocytes from young rats was always maintained between 60-75% 
(Figure 5.1 and Figure 5.2), effectively being categorized as a ‘weak’ cytotoxic cell environment. 
Fortunately, the cardiomyocytes were robust enough to still allow further investigation. Likewise, 
aspalathin as a strong anti-oxidant (Van der Merwe, 2010), and possible metabolic regulator, also 
overcame this obstacle, which led to the obtainment of significant results.   
 
3.2 EFFECTS OF ACUTE ASPALATHIN TREATMENT ON GLUCOSE UPTAKE IN CARDIOMYOCYTES 
ISOLATED FROM YOUNG RATS 
We first tested the hypothesis that aspalathin treatment has the ability to stimulate glucose uptake 
by using cardiomyocytes. In order to achieve this, we tried to establish an aspalathin dose 
response (1-100M) in cardiomyocytes of young control rats (Figure 5.5). 10 M aspalathin was 
able to significantly increase glucose uptake above DMSO while 100M seemed to attenuate this 
effect. The vehicle, DMSO, also attenuated basal glucose uptake by the cardiomyocytes. To test 
for the possible cytotoxic effects of aspalathin and DMSO, we performed a cell viability assay using 
propidium iodide (Described under Section 2.2.2 in the Materials and Methods Chapter). There 
was no significant difference in cell viability between the treatment groups (Figure 5.2), therefore 
the observed suppression in glucose uptake was not due to DMSO toxicity, but possibly through 
some other responsive mechanism. In a study done by Berenquer et al. (2011) on 3T3-L1 
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adipocytes and L6 myotubes, they found that low concentrations of DMSO was able to induce 
GLUT1 and GLUT4 recruitment to the cell surface, but simultaneously also inhibit the activity of the 
glucose transporters. The half-life for reversing the effects was t1/2 ~ 12 mins in 3T3-L1 
adipocytes, and could possibly be longer in cardiomyocytes. No similar studies had been done to 
test for the possible glucose transport inhibiting effects of DMSO in cardiomyocytes. We thus 
speculate that aspalathin, solubilized in DMSO, would need an extended time to elicit a response 
on glucose uptake in cardiomyocytes. We also propose that, since 0.1% DMSO was not toxic to 
the cells, the reduction in glucose uptake observed could be due to DMSO inhibiting GLUT4 
activity, and this effect is exacerbated by an increasing DMSO concentration. This would explain 
why 10M aspalathin, containing a lower concentration of 0.01% DMSO, showed a significant 
increase in glucose uptake, compared to the 0.1% DMSO in 100M aspalathin. Also, the marked 
increase in glucose uptake in 10M aspalathin compared to 1M aspalathin would have to be 
solely due to the glucose uptake potential of aspalathin in cardiomyocytes.  
 
3.3 EFFECTS OF ACUTE ASPALATHIN CO-TREATED WITH INSULIN ON GLUCOSE UPTAKE IN 
 CARDIOMYOCYTES ISOLATED FROM YOUNG AND AGED OBESE-INSULIN RESISTANT RATS 
We explored the possibility that aspalathin might have an indirect effect on glucose uptake in 
cardiomyocytes through a synergistic effect with insulin’s action in young control rats (Figure 5.6; 
Figure 5.8 and Figure 5.9). When 10nM insulin was co-treated with 10M aspalathin for 45 mins, 
glucose uptake significantly increased compared to 10nM insulin. The fact that aspalathin could not 
acutely induce glucose uptake independent of insulin, infer that insulin plays an important role in 
eliciting aspalathin’s response through increasing co-activation or co-expression of the insulin-
dependent signaling pathway proteins. This mechanism has been noted by Mazibuko et al. (2013), 
who showed palmitate-induced insulin resistant C2C12 muscle cells had a low glucose uptake 
response to treatment with insulin, but once co-treated with GRE (high aspalathin content) there 
was a markable increase in glucose uptake. However, in the present study cardiomyocytes 
isolated from obese, insulin-resistant and age-matched control rats, showed no significant 
differences in glucose uptake when treated with aspalathin, or aspalathin in conjuction with insulin 
(Figure 5.8 and Figure 5.9). The decline in insulin sensitivity, observed when determining the 
effect of increasing insulin concentrations on glucose uptake between cardiomyocytes isolated 
from from young rats, aged control rats and obese-insulin resistant rats (Figure 5.7), implicates the 
importance of insulin sensitivity in facillitating aspalathin’s response. The fact that aspalathin in 
conjunction with insulin was able to induce glucose uptake in cardiomyocytes from young control 
rats, indicate that the mechanisms of ageing, which independently reduce the sensitivity of the 
insulin signaling pathways, is an important factor diminishing aspalathin’s glucose uptake potential. 
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4. EXTENDED (1H - 6H) TREATMENT WITH ASPALATHIN 
4.1 EFFECTS OF CHRONIC ASPALATHIN CO-TREATED WITH INSULIN IN DIFFERENTIATED H9C2 
CELLS 
In order to confirm that aspalathin can in fact induce glucose uptake independent of insulin, 
cultured rat-heart derived embryonic H9C2 cell line, were used as an analog for the isolated 
cardiomyocytes from rats, to test the efficacy of aspalathin as treatment. First, the immortal H9C2 
cells were differentiated using the protocol established by Ménard et al. (1999). Chronic treatment 
of the H9C2 cells with 10nM retinoic acid (RA) enhances Ca2+-channel expression, which is a 
defining feature of the cardiac phenotype. Simultaneously, by virtue of cardiac differentiation, 
myogenic transdifferentiation is also inhibited, preventing the cells from differentiating into skeletal 
myocytes. Full differentiaton was established 6 days after initiation of a reduced serum 
concentration of 1% HS and addition of 10nM RA, after which the experiment was performed on 
homogeneous cell populations. The cells were cultured in the presence of 5.5 mM glucose as 
opposed to being completely glucose starved. It was argued this would give a more natural insight 
into the effect of aspalathin, which would clinically be used to lower blood glucose in hyperglycemic 
patients. ATP levels were determined as a measure of the metabolic activity and therefore the 
overall health of the cell population (Described under Section 3.4 in the Materials and Methods 
Chapter). Our first observation was that aspalathin treatment, as well as co-treating cells with 1nM 
insulin for the last 15 mins, significantly increased metabolic activity of differentiated H9C2 cells 
after 3 hours of incubation (Figure 6.1). The same effect was not seen when insulin was treated 
independently for the last 15 minutes. In addition, staining the cells with JC-1 to show 
mitochondrial integrity, also demonstrated that aspalathin improved the percentage of live cells at 
this time point (Figure 6.2 and Figure 6.3). This observation was underscored by measuring 2DG 
accumulation after 3 and 6 hours respectively. Aspalathin significantly enhanced 2DG uptake in the 
absence or presence of insulin (Figure 6.4). Balderas-Villalobos et al. (2013) showed that 
oxidative stress in cardiomyocytes resulted in impaired sarco(endo)plasmic reticulum Ca2+ ATPase 
activity. This correlates with cardiac contractile dysfunction which impairs overall cell health, 
however, these effects could be reversed by treatment with strong anti-oxidants (Balderas-
Villalobos et al., 2013). In this regard, aspalathin, a known strong anti-oxidant (Joubert, 2006) may 
have been able to improve cell health by reversing the basal oxidative stress of the cell population 
induced by the cell culture environment, such as fluctuations in temperature, oxygen, carbon 
dioxide and nitrogen. H9C2 cells, similar to fetal and early postnatal cardiomyocytes, primarily 
contain GLUT1 as opposed to GLUT4 (Montessuit & Lerch, 2013), and will therefore rely more 
heavily on inducing GLUT1 to the cell membrane. In this regard, the inherent characteristics of 
H9C2 cells are significantly different from isolated cardiomyocytes, and determining the 
mechanism of aspalathin’s glucose transport potential in cell culture, would not be a true indicator 
of what occurs in cardiomyocytes. However, it has been shown by Yu et al. (1999) in H9C2 
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myotubes that insulin and K+ depolarization can increase glucose uptake through recruitment of 
GLUT4 from the intracellular vesicles to the cell membrane. It is possible that aspalathin also made 
use of these signaling mechanisms to induce glucose uptake in differentiated H9C2 
cardiomyocytes although this was not determined in the current study.   
 
4.2 EFFECTS OF EXTENDED ASPALATHIN/INSULIN CO-TREATMENT ON GLUCOSE UPTAKE IN 
YOUNG, CONTROL AND HFD RATS 
 After demonstrating that aspalathin was able to induce 2DG uptake in H9C2 cells with longer 
incubation times, we extended our experiments on adult ventricular cardiomyocytes to 3 hours 
(Figure 5.10 and Figure 5.11). Surprisingly, incubating aspalathin for 1 and a half hours (a mere 
45 mins longer than in the acute model) (Figure 5.8 and Figure 5.9) resulted in a significant 
increase in glucose uptake in cardiomyocytes from young controls, which persisted for 3 hours of 
treatment. Surprisingly, the effect in conjunction with insulin in young control cardiodiomyocytes 
was only pronounced in the acute model, but not after 1 and a half hours of treatment. This is 
contrary to the older controls with aspalathin inducing a significant increase in insulin-mediated 
glucose uptake after 1 and a half hours of treatment. The high fat diet group showed no significant 
increases when treated with aspalathin with or without insulin, but insulin treatment for 1 and a half 
hours did stimulate glucose uptake significantly. Aspalathin’s surpressed effect in aged, obese, 
insulin resistant rats strengthens the argument that aspalathin’s actions are in part dependent on 
the insulin-signaling pathway of glucose uptake. In a study done by Purintrapiban & 
Ratanachaiyavong (2003), L8 myotubes were co-treated with insulin and metformin (a known 
hypoglycemic agent and anti-diabetic treatment) for 5 hours in culture, after which they determined 
glucose uptake and found that 2mM metformin was able to induce glucose uptake independent of 
insulin, but co-treatment resulted in a further activation of glucose uptake. Similarly, we also 
propose aspalathin is able to induce glucose uptake independent of insulin, but downregulation of 
the insulin signaling pathway in older animals, and even more so in obese animals, result in a 
desensitization of the entire insulin-signaling pathway and subsequently surpress glucose uptake 
induced by aspalathin.  
 
5. ASPALATHIN’S MECHANISM OF ACTION 
We investigated the mechanism by which aspalathin induced this slight increase in myocardial 
glucose uptake by western blot analysis. In particular, the markers of interest was: PKB, an insulin-
dependent, pro-‘life’, growth marker; and AMPK – the body’s key metabolic regulator, which is an 
insulin-independent marker of glucose uptake quite central to all metabolic cell signaling. 
Furthermore, we made use of wortmannin pretreatment, a selective inhibitor of PI3K, to inhibit the 
insulin-dependent mechanism of glucose uptake and thus elucidate the degree of dependance 
aspalathin has on the same signaling pathway.  
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5.1 PI3K-DEPENDENCE 
Insulin is dependent on PI3K to elicit it’s cellular responses after binding of the insulin receptor. 
Inhibiting PI3K through selective pretreatment with wortmannin, can result in total inhibition of 
insulin’s beneficial effects. This was the case when wortmannin was administered before insulin 
and aspalathin samples, which resulted in a complete loss of glucose uptake potential in 
cardiomyocytes isolated from young rats (Figure 7.1), as well as aged, obese, insulin-resistant rats 
and age-matched controls (Figure 7.2). This also indicates the importance of PI3K’s activity, and 
arguably the entire PI3K pathway’s downstream effectors, in eliciting glucose uptake after 
aspalathin treatment. Pretreatment with wortmannin also resulted in inhibition of PKB activation 
and expression to levels below baseline (Figure 7.3). 
  
5.1.1 PKB-MEDIATED EFFECTS 
The role of PKB in eliciting the responses of aspalathin is still controversial. In rats supplemented 
for 7 weeks with GRE and FRE, Pantsi et al. (2011) found low to no effect by rooibos flavonoids 
(including aspalathin) on total PKB levels in the hearts. To the contrary, Mazibuko et al. (2013) 
found that rooibos did in fact increase phospho-PKB levels in C2C12 mouse skeletal myotubes. In 
another study done by Son et al. (2013), rooibos also did not activate PKB in normal L6 myocytes, 
whereas Mazibuko et al. (2013) was able to show the mechanism in insulin resistant C2C12 
myocytes. Mazibuko et al. observed that phospho-PKB levels of the palmitate treated cells 
resembled that of normal PKB levels when stimulated by insulin, suggesting that rooibos can 
resensitise downstream insulin signaling. In agreement with Mazibuko et al. (2013), in our present 
study, PKB activation was significantly increased in young rats treated for 15 minutes with both 
insulin and aspalathin (Figure 7.3). This effect was also observed when comparing the ratio of 
activated PKB to the total amount of PKB expressed, and could explain the potential glucose 
uptake observed after 45 mins of aspalathin co-treatment with insulin (Figure 5.6, Figure 5.8 and 
Figure 5.9). After 1 and a half hours of treatment, PKB activation was also significantly increased 
in cardiomyocytes from young rats when insulin was co-treated with aspalathin. However, there 
were no significant differences found in the older diet rats, possibly indicating that the PKB 
pathway becomes less sensitive as ageing progress. In a study done by Frøsig et al. (2013), aged 
mice fed a high-fat diet had reduced signaling of PKB, coinciding with insulin resistance and 
impaired glucose homeostasis. Even though in our present study we could not find a marked 
decrease in PKB expression or activation between young and older rats, the observed decrease in 
glucose uptake potential in aged rats when treated with insulin, a known PKB activator, and 
aspalathin, a possible PKB activator, could be a direct consequence of a reduced PKB sensitivity. 
  
Stellenbosch University  https://scholar.sun.ac.za
  
 
116 
    
 
 
5.2 PI3K-INDEPENDENCE 
One of the earliest detectable signs of insulin resistance, is an impairment of insulin-stimulated 
glucose transport (Wilcox, 2005). The impairment also correlates with a reduction in GLUT4 protein 
expression, as well as impaired GLUT4 translocation (Wilcox, 2005). However, GLUT4 
translocation can still be induced through an insulin-independent pathway of glucose uptake, such 
as AMPK, which phosphorylates AS160, a gate-keeper protein also independently stimulated by 
insulin, which induce glucose uptake by promoting the translocation of GLUT4 to the plasma 
membrane.  
 
5.2.1 AMPK-MEDIATED EFFECTS 
Mazibuko et al. (2013) found that insulin resistant mouse C2C12 skeletal muscle cells treated with 
rooibos, resulted in the activation of the insulin-independent AMPK pathway which culminated in 
increased levels of GLUT4. Similiarly, Son et al. (2013) found that aspalathin activated AMPK 
signaling and promoted endogenous GLUT4 translocation to the plasma membrane in L6 
myocytes and in skeletal muscle of ob/ob mice. In C2C12 mouse skeletal muscle cells, Muller et al. 
(2012) also showed aspalathin is able to improve glucose uptake, while this same effect could not 
be mimicked in Chang liver cells, which does not contain GLUT4. This strongly implicates GLUT4 
and AMPK as essential role players in eliciting aspalathin’s response. In our present study, 
aspalathin significantly increased the expression of AMPK independent of insulin in young rats 
after 15 minutes of stimulation (Figure 7.3). This, however, did not correlate with an increase in 
glucose uptake (Figure 5.6; Figure 5.8 and Figure 5.9). It could be that an increase in AMPK 
expression is the first step towards recruiting the necessary downstream signaling proteins, such 
as AS160, to induce glucose uptake and a longer incubation time would give a more pronounced 
response in glucose uptake. Furthermore, after 15 minutes of incubation in cardiomyocytes 
isolated from young rats, aspalathin increased AMPK activation in the presence of insulin (Figure 
7.4), which strongly implicates AMPK’s role in eliciting aspalathin’s acute effects on glucose uptake 
when co-treated with insulin (Figure 5.6; Figure 5.8 and Figure 5.9). After one and a half hours of 
stimulation, aspalathin signficantly increased the phospho-to-total ratio of AMPK in young rats, 
correlating with the glucose uptake induced at the hour and a half time point (Figure 5.10 and 
Figure 5.11). Taken together, we propose that initially aspalathin induces an increase in AMPK 
expression, followed by a time-dependent AMPK activation the longer aspalathin is incubated in 
isolated young rat cardiomyocytes. This process potentiates glucose uptake, which can have a 
hypoglycemic effect. 
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5.2.2 AMPK AND AGEING 
The effect of AMPK on ageing is still controversial. Ageing is often associated with poor stress 
tolerance and decreased insulin sensitivity, which has been linked to a decline in AMPK activity 
(Mulligan et al., 2005). Poor stress tolerance could indicate a decline in basal AMPK levels, while 
an acute onset of stress could be met with a diminished AMPK activity (Mulligan et al., 2005). 
Conversely, Jin et al. (2004), found that ageing increased AMPK activation in rat kidneys, while 
Frøsig et al. (2013) found increased AMPK activation in mice livers. In our present study, we also 
found that both expression and basal activation of AMPK was increased in aged controls 
compared to young rats (Figure 7.9). The fact that aspalathin was not able to induce glucose 
uptake independent of insulin in aged rats (Figure 5.10 and Figure 5.11), suggest that 
upregulation of AMPK expression alone is not sufficient to induce aspalathin-stimulated glucose 
uptake, but relative activation of AMPK need to exceed AMPK expression in order to elicit the 
same response observed in younger rats. In this regard, ageing attenuates AMPK’s sensitivity 
through an unexplored mechanism. This further implicates the role of AMPK as a prominent 
metabolic regulator as ageing progresses.  
 
5.3 GLUT4-MEDIATED EFFECTS 
The first step of glucose metabolism is the transport of glucose across the plasma membrane. 
Within the heart, glucose enters through either facillitated diffusion or active diffusion accompanied 
by the glucose transporters, GLUT1 and GLUT4. Blood glucose is always higher within the blood, 
than intracellularly, causing a glucose gradient which drives the influx of glucose. The gradient is 
maintained by abundant hexokinase enzymes, which phosphorylate glucose as it enters the 
cardiomyocytes, leaving the transport into cells as the rate-limiting step (Montessuit & Lerch, 
2013). GLUT4 is primarily located in intracellular membrane compartments and translocated to the 
cell membrane in response to known stimuli, including increased workload, adrenaline and insulin 
(Wheeler et al., 1994). Both GLUT1 and GLUT4 have similiar structures and enzymatic turnover, 
but GLUT4 has a higher affinity for glucose. The higher expression and higher affinity for glucose, 
makes GLUT4 the primary determinant of glucose uptake within cardiomyocytes with an average 
4-7mM concentration or number of GLUT4 transporters present at the cell surface (Montessuit & 
Lerch, 2013). In our present study we proposed to determine GLUT4 translocation by fractionating 
aspalathin and insulin treated isolated cardiomyocytes into plasma membrane and cytosolic 
fractions, followed by immunoblotting for the total GLUT4 content. We were, however, 
unsuccessful in detecting GLUT4 in either of our positive control, young rat, aged obese and 
insulin resistant, or age-matched control group samples (Figure 7.10, Figure 7.11, Figure 7.12 
and Figure 7.13). Regardless, Purintrapiban & Ratanachaiyavong (2003), discussed above, 
showed that insulin stimulated glucose uptake resulted in increased membrane translocation of 
GLUT4 from the intracellular compartment. Wang et al. (1999) demonstrated that constitutively 
activated PKB (through transfection of a viral Gag protein) resulted in upregulated GLUT4 
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translocation in L6 myoblasts. Furthermore, Yamaguchi et al. (2005) showed in 3T3-L1 adipocytes, 
activation of AMPK, by the known AMPK activators, 5-aminoimidazole-4-carboxamide-1-beta-D-
ribofuranoside (AICAR) and 2,4-dinitrophenol (DNP), also resulted in acceleration of GLUT4 
translocation. Combining both our findings that aspalathin induced AMPK and PKB activation, we 
propose that aspalathin’s mechanism of glucose uptake, in the absence or presence of insulin, 
would similarly result in GLUT4 translocation to the plasma membrane (Figure 8.1).  
 
 
Figure 8.1 Aspalathin’s proposed mechanism of action to induce glucose uptake in 
cardiomyocytes 
 
5.4 ANTIOXIDANT-MEDIATED EFFECTS 
The balance between reactive oxygen species, antioxidants and their related co-factors are critical 
when managing health, ageing and age-related disorders (Rahman, 2007). Oxidative stress is 
constantly in balance between the body’s endogenous antioxidant systems, regulated by co-
factors, and exogenous antioxidants ingested as part of a diet. If the protection provided by the 
body’s inherent antioxidants and certain co-factors are surpassed by an abundance of free 
radicals, oxidative damage start to accumulate, and as aging progress can result in various 
complications, including CVD and diabetes (Rahman, 2007). Elevated blood glucose levels have 
been shown to increase oxidative stress (Midaoui & Champlain, 2005). In a study done by 
Yasunari et al. (1999), the antioxidants, probucol and α-tocopherol, increased glucose uptake in 
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coronary vascular smooth muscle cells (VSMC) in a high glucose medium (22.2mM) by reducing 
protein kinase C (activated PKC generates reactive oxygen species) and glycoxidation (results in 
oxidative stress following the oxidation of proteins in the presence of glucose), effectively 
supressing intracellular oxidative stress. In contrast, in another study done by Kim et al. (2013), 50-
100M capsaicin was able to induce glucose uptake in C2C12 muscle cells via ROS generation 
and activation of the ROS/AMPK/p38/MAPK pathway (refer to Section 1.4.6 in the Literature 
Review Chapter). Co-treatment with the non-specific antioxidant, N-acetyl-cysteine (NAC), 
resulted in attenuation of the increases in both capsaicin-induced AMPK phosphorylation and 
capsaicin-induced glucose uptake. It has been shown that aspalathin can exhibit both pro- and 
antioxidant properties depending on the concentration administered (Mennen et al., 2005; Dludla et 
al., 2014). In the present study we did not measure the anti-oxidant activity of aspalathin, but 
aspalathin could induce glucose uptake through either of these two independent mechanisms: (i) 
by acting as a pro-oxidant, inducing glucose uptake via ROS generation, which is a known 
activator of AMPK, or (ii) by acting as an antioxidant, attenuating the oxidative stress induced by 
hyperglycemia.  
 
6. SUMMARY OF FINDINGS 
The individual findings are as follows:  
 a high-fat, high-sucrose diet of at least 16 weeks is an effective model to induce insulin-
resistant, obese rats 
(i) a high-fat, high-sucrose diet of at least 16 weeks raise body weight and induce 
obesity (Figure 4.1); 
(ii) a high-fat, high-sucrose diet of at least 16 weeks raise visceral fat accumulation 
(Figure 4.2); 
(iii) a high-fat, high-sucrose diet of at least 16 weeks induce fasting hyperglycemia 
(Figure 4.3); 
(iv) a high-fat, high-sucrose diet of at least 16 weeks induce non -fasting hyperglycemia 
(Figure 4.4); 
(v) a high-fat, high-sucrose diet of at least 16 weeks raise fasting blood insulin levels 
(Figure 4.5); 
(vi) a high-fat, high-sucrose diet of at least 16 weeks raise the HOMA-IR index (Table 
4.1);  
(vii) insulin treatment for 45 mins dose-dependently increase glucose uptake more 
significantly in cardiomyocytes isolated from young rats, followed by older control 
rats, and had a weak response HFD rats (Figure 5.7); 
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 aspalathin and insulin co-treatment for 45 mins induce glucose uptake in cardiomycoytes 
isolated from young rats  
(viii) the isolation protocol persistently yielded a cell viability between 65 – 70% in 
cardiomyocytes isolated from young rats (Figure 5.1);  
(ix) aspalathin treatment for 1 to 3 h did not affect cell viability in cardiomyocytes 
isolated from young rats (Figure 5.2); 
(x) aspalathin treatment for 45 mins did not induce glucose uptake in cardiomyocytes 
isolated from young rats (Figure 5.5); 
(xi) aspalathin co-treatment with insulin for 45 mins increase glucose uptake compared 
to insulin in cardiomyocytes isolated from young rats (Figure 5.6; Figure 5.8), while 
this effect is not observed in aged rats (Figure 5.8; Figure 5.9); 
 
 aspalathin treatment for 3 and 6 hours induce glucose uptake in differentiated H9C2 cells 
(xii) aspalathin treatment for 3 h, as well as co-treating with 1nM insulin for the last 15 
mins increased metabolic activity in differentiated H9C2 cardiomyocytes (Figure 
6.1); 
(xiii) aspalathin treatment for 3 h increased cell integrity in differentiated H9C2 
cardiomyocytes (Figure 6.2, Figure 6.3); 
(xiv) aspalathin treatment for 3 and 6 h increased glucose uptake in differentiated H9C2 
cardiomyocytes (Figure 6.4); 
 
 aspalathin treatment for 1 hour 30 minutes to 3 hours induce glucose uptake in cardiomyocytes 
isolated from young rats, whilst stimulating insulin-mediated glucose uptake in aged controls 
after 1 hour 30 minutes 
(xv) aspalathin treatment for 1 h 30 mins, 2 h and 3 h increased glucose uptake in 
cardiomyocytes isolated from young control rats (Figure 5.10, Figure 5.11); 
(xvi) aspalathin treatment for 1 h 30 mins increased, in a concentration-dependent 
manner, the insulin-stimulated glucose uptake in cardiomyocytes isolated from aged 
control rats (Figure 5.10);  
(xvii) aspalathin treatment (0 – 3 h) did not affect insulin-stimulated glucose uptake by 
cardiomyocytes isolated from obese, insulin resistant animals (Figure 5.10, Figure 
5.11) ; 
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 aspalathin treatment for 15 minutes induce AMPK expression, while co-treatment with insulin 
increase AMPK activation, PKB activation and PKB activation/expression ratio in 
cardiomyocytes isolated from young rats.  
(xviii) aspalathin and insulin pretreatment with wortmannin for 45 mins results in complete 
inhibition of glucose uptake in cardiomyocytes isolated from young rats (Figure 7.1), 
aged control and HFD rats (Figure 7.2); 
(xix) aspalathin and insulin pretreatment with wortmannin for 15 mins results in a 
complete loss of PKB activation and expression in cardiomyocytes isolated from 
young rats (Figure 7.3); 
(xx) aspalathin and insulin co-treatment for 15 mins resulted in increased PKB activation 
and PKB activation/expression ratio in cardiomyocytes isolated from young rats 
(Figure 7.3); 
(xxi) aspalathin treatment for 15 mins resulted in increased AMPK expression in 
cardiomyocytes isolated from young rats, while co-treatment with insulin increased 
AMPK activation (Figure 7.4); 
 
 aspalathin treatment for 1 hour 30 mins increase the AMPK activation/expression ratio, while 
co-treatment with insulin increase PKB activation in cardiomyocytes isolated from young rats. 
AMPK expression and activation increases with age in wistar rats. 
(xxii) aspalathin treatment for 1 h 30 mins did not result in increased PKB activation or 
expression in cardiomyocytes isolated from either young, aged obese and insulin 
resistant, or age-matched control rats (Figure 7.6); 
(xxiii) aspalathin and insulin co-treatment for 1 h 30 mins resulted in increased PKB 
activation in cardiomyocytes isolated from young control rats (Figure 7.7); 
(xxiv) aspalathin treatment for 1 h 30 mins resulted in increased AMPK 
activation/expression ratio in cardiomyocytes isolated from young rats (Figure 7.9); 
(xxv) aged control rats have significantly higher AMPK expression and activation 
compared to young rats (Figure 7.9); 
  
Controversially, in the present study, aspalathin had no significant effect on glucose uptake, or 
mechanistically, in isolated cardiomyocytes from obese, insulin-resistant rats.  
 
7. STUDY LIMITATIONS 
The rats used in the study were housed in a controlled environment without exposure to toxins, 
environmental hazards, and related factors that would further exacerbate obesity and insulin 
resistance in humans (Murea et al., 2012). Furthermore, caging of the animals force them to 
become sedentary, accelerating obesity, glucose intolerance and effectively increase their 
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susceptibility for premature death (Martin et al., 2010) which might not serve as accurate controls 
for the disease conditions in humans. Furthermore, the diet program (weeks of feeding) was not 
kept constant throughout the study, necessitating the use of diet rats differing up to 14 weeks in 
age. Experiments were always performed in same-aged animals after which the results were 
normalized to the baseline treatment group. These factors can potentially skew interspecie 
extrapolation with regards to obesity, metabolism and T2D.  
 
In the present study we only investigated the effect of aspalathin in the ventricular cardiac tissue. 
Given that the heart comprises various different cell types in which aspalathin could induce an 
effect, further investigation using isolated perfused hearts would be needed to explore aspalathin’s 
role on functional parameters of the whole heart. Furthermore, we were unable to find GLUT4 
translocation in membrane and cytosol fractions of ventricular cardiomyocytes isolated from rat 
hearts. We have tried various different methods to visualize the total GLUT4 antibody in our tissue 
lysates, but was unsuccessful at the culmination of this thesis.  
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CHAPTER 9 
CONCLUSION AND FUTURE RESEARCH 
 
1. CONCLUSION 
Aspalathin has been shown to have certain effects on skeletal muscle glucose transport in lean 
and diabetic animals, but it’s myocardial effects, as well as it’s role in obesity and insulin resistance 
are not well established. We considered aspalathin’s potential as a hypoglycemic agent in 
treatment of hyperglycemia in obesity and insulin resistance. 
  
The present thesis demonstrated the glucose uptake effects of relatively short-term in vivo 
treatment with aspalathin on cardiomyocytes isolated from the hearts of healthy, young and aged 
rats, as well as aged obese and insulin resistant rats. To determine the safety and efficacy of using 
aspalathin, we also demonstrated the glucose uptake ability of aspalathin in cultured differentiated 
H9C2 cardiomyocytes.  
 
The main findings of this thesis are the following:  
 the high-fat, high-sugar diet is an effective model to induce insulin resistance in rats 
 aspalathin enhances metabolic activity and retain membrane integrity in cultured H9C2 
cells 
 aspalathin induces myocardial glucose uptake directly and potentiated the effects of insulin 
in cardiomyocytes isolated from young rats 
 in older animals, aspalathin had a more indirect effect on glucose uptake through mediating 
insulin’s action 
 the possible mechanism of aspalathin is through: 
o  activation of PKB 
o  increasing the expression and activation to expression ratio of AMPK 
 aspalathin had no significant effect when used as treatment in heart cells from obese, 
insulin-resistant rats.  
 
Finally, this thesis demonstrated that aspalathin, as a pleiotropic compound, has a very specific 
dosage duration and elicits its effects in a dose dependent manner.  
 
2. PERSPECTIVES FOR THE FUTURE 
Rooibos’ success in reducing cardiovascular risk factors when consumed daily is evident 
(Marnewick et al., 2012). Dietary intake has especially been met with favorable outcomes, and 
could reinforce existing treatments (Coman et al., 2012). The next step is consumption of the main 
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compounds within rooibos, such as aspalathin as part of a dietary regime in order to clinically 
investigate the effects of aspalathin. For future studies, aspalathin, as a phytomedicine, needs to 
be used as part of a feeding regimen, therefore in vivo, to investigate its effects on insulin 
resistance (induced by a high-fat diet), obesity, heart function and protection, metabolism, long-
term oxidative status and anti-inflammatory properties. It is not possible to culture adult 
cardiomyocytes indefinitely as they are terminally differentiated cells, and therefore it is 
questionable whether the pathology induced by metabolic changes in cell culture is 
retained. Therefore, we need to study the effects of aspalathin on the hearts of control and obese, 
insulin-resistant animals as commercial cell lines only partially represent true heart cells. 
Furthermore, aspalathin (acute- and long-term) still needs to be investigated as treatment for 
ischeamia/reperfusion injury and its role in mitochondrial autophagy (mitophagy) and dysfunction 
determined. 
 
Aspalathin's mechanism has only been partially elucidated in vitro with specific regards to two 
proteins (AMPK and PKB). Future studies need to elaborate on the signaling molecules involved in 
other pathways, including the map kinases, ERK42/44, the glycogen synthase regulator, GSK-3β 
and auto-immune regulators, such as STAT-3. Of special importance, the role of aspalathin on 
GLUT4 expression and translocation to the cell membrane still needs to be elucidated. 
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CHAPTER 10 
APPENDIX A 
 
1. SECONDARY FACTORS CONTRIBUTING TO OBESITY 
1.1 INACTIVITY 
Physical inactivity, especially during adolescence, is an genetically independent indicator of total 
and abdominal obesity in young adulthood (Pietiläinen. 2008). In short, a physically inactive 
lifestyle triggers weight gain by altering our energy balance. Conversely, leading an active lifestyle 
triggers weight loss by discarding more energy than is consumed.  
 
1.2 UNHEALTHY DIET 
A diet is fine-tuned for personal needs based on health goals, taste, satiety, cost and experience. 
However, certain food is classified as unhealthy based on the long-term health implications. These 
include a high caloric diet (not dispensed by activity), inadequate consumption of fruits and 
vegetables high in anti-oxidants, high consumption of salted products and processed sugars, as 
well as high consumption of saturated- and trans-fatty acids (Obesity, WHO, 2015).  
 
1.3 PREGNANCY 
The childbearing years can be an essential period for most women, but possibly also result in 
substantial increase in weight during pregnancy. In a study done by the Center for Disease Control 
and Prevention (CDC) in 2009, an estimated 43% of pregnant women gain more weight than is 
recommended. High gestational gain also increases the risk of becoming overweight post-
pregnancy, possibly due to altered lifestyle habits in the postpartum period (Gunderson, 2009).  
Obese or overweight women undergoing their first pregnancy tend to also retain and gain more 
weight postpartum compared to women of average weight (Gunderson & Abrams, 1999). Maternal 
overweight and obesity increases the risk for gestational diabetes mellitus, hypertensive disorders, 
and newborn macrosomia (Catalano, 2007). 
 
1.4 LACK OF SLEEP 
Sleep is an essential regulator of neuroendocrine function and glucose metabolism and 8 hours is 
recommended (Beccuti & Pannain, 2011). However, a lack of sleep (below 7 hours) alters 
metabolism by reducing glucose tolerance and disrupts endocrine function through the appetite 
regulating hormones leptin (decreasing satiety) and ghrelin (stimulating hunger). Multiple 
laboratory and epidemiological studies link short sleep duration and poor sleep quality (overall 
sleep loss) to obesity risk (Beccuti & Pannain, 2011). 
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1.5 MEDICATION 
Various psychiatric medications, including certain anti-depressants, antipsychotics, anti-seizure 
medication and moodstabilizers, have shown to increase weight gain and ultimately lead to obesity 
in certain patients (Griggs, 1991; Schwartz et al., 2004). It is still speculated as to the extent of 
weight gain caused by short term versus long term treatments with these medications.  
Corticosteroids, effective in treatment of acute inflammatory conditions such as ashtma, 
inflammatory bowel disease and rheumatoid arthritis, is also well documented to cause weight gain 
(Manson et al., 2009). 
 
Sulfonylureas, used in the treatment of type 1 and type 2 diabetes to lower blood glucose, have 
been shown to increase appetite and weight gain (Nathan et al., 2009). Similarly, Insulin was also 
shown to increase weight gain, but the exact mechanism remains unknown (Russell-Jones & 
Khan, 2007). It is speculated that, by reducing blood glucose without reducing caloric intake, 
insulin may trigger the excess calories to be stored as added weight.  
 
β-blockers, used in the treatment of hypertension to reduce elevated cardiac output, increases the 
patients propensity for weight gain (Sharma et al., 2001). This is primarily due to changes in the 
metabolic profile of patients taking these drugs.  
 
Hormonal contraceptives have long been speculated to increase weight gain (Gallo et al., 2011). 
However, it is still unclear to date whether weight fluctuations noticed in women on birth control are 
due to increases in fat explicitly or due to temporary fluid retention and muscle composition 
changes.  
 
1.6 MEDICAL PROBLEMS 
Obesity can also be induced by medical conditions, including Prader-Willi syndrome and Cushing’s 
syndrome (Heart Disease, Mayo Clinic, 2015). Certain conditions, such as arthritis, can indirectly 
cause obesity by decreasing a person’s physicality as a consequence of pain or discomfort. To 
date, it is still unclear whether a decrease in thyroid function, a condition often synonymous with 
having a “slow metabolism”, influences the development of obesity (Longhi & Radetti, 2013). 
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2. HEART DISORDERS 
The World Health Organization defines cardiovascular diseases as “a group of disorders of the 
heart and blood vessels,” including:  
 coronary heart disease (compromised blood supply to the heart muscle) 
 cerebrovascular disease (compromised blood supply to the brain) 
 peripheral arterial disease (compromised blood supply to arms and legs) 
 rheumatic heart disease (weakening of the heart due to rheumatic fever) 
 congenital heart disease (heart defects since birth) 
 deep vein thrombosis (bloot clots in periphery of body) 
 pulmonary embolism (dislodged blood clots travelling to the heart and lungs) 
 
Heart attacks refer to a blockage that prevents blood from flowing to the heart and brain. This 
event is most commonly caused by deposits of adipose tissue that clog the inner linings of blood 
vessels supplying the heart and brain. 
 
2.1 CAUSES 
Behavioural risk factors, such as an unbalanced diet, inactive lifestyle, smoking and alcohol abuse 
give way to heart disease and strokes. Clinically, these risks manifest as hyperglycemia, 
hypertension, hyperlipidemia and obesity. These preliminary symptoms can be detected at primary 
care facillities and aid in assessing the risk for cardiovascular diseases. Also, the forces driving 
social, economic and cultural change, such as globalization, urbanization, population ageing, 
poverty, stress and hereditary factors can be added determinants of cardiovascular disease. 
 
2.2 EPIDEMIOLOGY 
Cardiovascular diseases (CVD) are the leading cause of death in the world (Cardiovascular 
Disease, WHO, 2015). An estimated 17.5 million people died from CVD in 2012 alone, 
representing 31% of all global deaths. Of these 7.4 million were due to coronary heart disease and 
6.7 million were due to strokes. Low- and middle-income countries account for 75% of CVD 
deaths. People in these countries are often not exposed to early detection and subsequent 
treatments, leading to younger deaths. Furthermore, the poorest people are affected most. This 
seems to create a vicious circle in which increasing health expenses contribute to poverty, placing 
a heavy burden on the economy of these countries.  
 
2.3 TREATMENTS FOR CARDIOVASCULAR DISEASES 
The fact is, CVD can be prevented by addressing behavioural risk factors such as smoking, 
physical inactivity, alcohol abuse, consuming unbalanced diets and being obese. These risk 
factors, left unaddressed, cause hypertension, diabetes and hyperlipidemia, culminating in 
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cardiovascular diseases. When early detection of these risk factors fails, the disease needs to be 
controlled through counselling and medication.  
 
2.3.1 LIFESTYLE CHANGES 
Reducing salt and alcohol intake, avoiding smoking, increasing consumption of fruits and 
vegetables and regular physical exercise have been shown to reduce CVD complications. Health 
policies essentially serve to enforce these habits by creating an environment tolerant of healthy 
behaviours. Unfortunately, complications arise when risk factors are not addressed, necessitating 
drug treatment to prevent further progression of CVD’s.  
 
2.3.2 INTERVENTIONS 
Currently there are two approaches to alleviate the CVD burden: population-wide interventions and 
individual interventions. Population-wide interventions include amongst others, tobacco control 
policies, taxation to reduce the intake of foods high in fat, sugar and salt, building manual 
infrastructure such as walking and cycling paths, strategies to prevent alcohol abuse and enforcing 
good meal plans for youth programs. Individual level interventions are primarily targeted to people 
with a high total cardiovascular risk or having extreme single risk factor levels such as 
hypertension and hypercholesterolaemia. 
 
2.3.3 MEDICATION 
Secondary prevention in patients who already have cardiovascular diseases, include medicinal 
treatment with aspirin (anti-prostaglandin action – reduces inflammation, fever and pain; and anti-
platelet action – blood thinner), beta-blockers (blocks the action of adrenaline, reducing heart rate 
and effectively lowering blood pressure), angiotensin-converting enzyme inhibitors (inhibits 
constriction of blood vessels, reducing blood pressure) and statins (block formation of cholesterol 
in the liver, reducing LDL-cholesterol in the blood) (Mayo Clinic Staff, 2014). Furthermore, if the 
disease evolves, surgical interventions are needed. These operations include coronary artery 
bypass, balloon angioplasty, valve repair and replacement, heart transplantation and artificial heart 
operations. Medical devices can also be inserted to treat CVDs. These specialized equipments 
include pacemakers, prosthetic valves and patches to cover heart damage.  
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3. INVESTIGATING HEART FUNCTION 
Various disease states negatively targets heart function and as a consequence, the whole 
organism becomes susceptible to the disease. In order to investigate the effect of treatments and 
disease states on heart function, models are used to test the efficacy of intervention protocols 
(Lumkwana, 2014). These models can be broadly categorized into:  
 in vivo models (using the whole organism/animal) 
 ex vivo models (isolating the organs of an animal), and 
 in vitro models (culturing isolated organ cells).  
 
These models will be discussed with specific reference to the heart. 
 
3.1 IN VIVO MODEL (WHOLE BODY ORGANISM) 
In vivo models utilize the entire animal, in either a conscious or subconscious (induced by 
anaesthesia) state. This approach shares a close resemblance to human clinical studies, and can 
therefore serve as a strong indicator of possible effective therapies (Ytrehus, 2006). Animals most 
commonly used include rats, mice, rabbits and dogs. However, the cause and effect observed in 
animals are often difficult to establish, given uncontrollable factors, unrelated to the heart. These 
include the techniques and instruments used to isolate hearts during surgery, and the 
unpredictability of inducing anaesthesia on the central nervous system of the animals. Drawbacks 
for these models include time-consuming maintenance when treating the animals (Ytrehus, 2006). 
  
3.2 EX VIVO MODEL (ISOLATED HEARTS) 
Isolated heart models have been employed with varying success to explore the principles of 
cardio-protection, cell signaling and investigating metabolic changes in the myocardium (Ytrehus, 
2006). Two prominent models exist, including the Langendorff perfusion model and the Morgan 
working heart model. Isolated heart models enable researchers to study contractile function, as 
well as biochemical and metabolic changes (Mirica, 2009). However, these models remain very 
expensive and time-consuming, and in addition needs to be operated by a perfusion specialist. 
  
3.2.1 RAT AND MICE HEART MODELS 
A popular animal model used to mimic the human pathophysiology in obese patients, is the diet-
induced obesity model, whereby an elevated caloric intake via fat in the diet results in increased fat 
and insulin resistance (Sumiyoshi et al., 2006). Studies using isolated working heart models from 
obese and insulin resistant ob/ob and db/db mice noted elevated fatty acid oxidation compared to 
normal control mice (Mazumber, 2004; Belke et al., 2000). The elevated fatty acid oxidation was 
paralleled by a suppression of glucose oxidation and glycolysis and a suppression in cardiac 
efficiency. Mitochondrial respiration, when using palmitate as fuel source, was also kept constant, 
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even in obese mice, but pyruvate oxidation and pyruvate dehydrogenase activity was reduced. 
This indicated that obesity did not impair fatty acid oxidation, but rather negatively affected 
carbohydrate metabolism in a manner consistent to diabetes (Boudina et al., 2005). Also, in 
isolated rat hearts with diet-induced obesity and insulin resistance, as the fatty acids’ contribution 
to total energy production increased, the rats were prone to become more glucose intolerant and 
insulin resistant. Other mechanisms, however, such as LPL (lipoprotein lipase) activity can also 
increase β-oxidation, as was observed in an obese mouse model prior to substrate changes 
(Burkhoff et al., 1991). 
 
3.3 IN VITRO MODEL (HEART CELLS) 
Cellular models enable investigators to study the heart at cell function level. These models can 
also be employed in analyzing biochemical pathways, observe changes in morphology and 
investigate the effects of genetic manipulation. In general, there are three different types of heart 
cell models, including cardiac cell lines, neonatal cardiomyocytes and adult cardiomyocytes. The 
major advantage of using cell models is that there is no need for animals, saving cost on handling 
and feeding of animals, and saving time by not having to complete the feeding regimes or gain 
ethical clearance. 
  
3.3.1 CARDIAC CELL LINES 
Cardiac cell lines are isolated from embryonic hearts and are available commercially as 
immortalised cell lines. The most popular cell lines include HL-1 (Claycomb et al., 1998) and H9C2 
(Hescheler et al., 1991). The primary advantage of cell lines is their ability to remain viable in 
culture for extended periods of time, not necessitating constant re-isolations. However, this is also 
their drawback, since constant division of cells is not a function of terminally differentiated 
cardiomyocytes of in vivo adult hearts (Watkins et al., 2010). Furthermore, both HL-1 and H9C2 
differ from adult cardiomyocytes in morphology and metabolism. HL-1 cells are round-shaped and 
H9C2 spindle-shaped, and both rely on glucose as their primary energy substrate, whereas adult 
cardiomyocytes are rod-shaped and utilize both glucose and fatty acids for energy metabolism 
(Eimre, 2008).  
 
3.3.2 NEONATAL CARDIOMYOCYTES 
Neonatal cardiomyocytes are obtained from newborn rats or mice, usally 1-5 days in age 
(Chlopčíková et al., 2001). The isolation process is considered to be simpler than isolating adult 
heart cells since the young rat heart are calcium tolerant and maintains viability, whereas adult 
hearts are calcium sensitive, making it difficult to completely arrest the heart and reduce infarct 
size (Louch et al., 2011). However, neonatal cardiomyocytes do not represent fully differentiated 
rod-shaped adult cardiomyocytes, utilize only glucose as energy substrate and contains a 
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pseudopodia shape (“false feet” visible as extended branches protruding from the cell membrane) 
(Lumkwana, 2014).  
 
3.3.3 ADULT CARDIOMYOCYTES 
Adult cardiomyocytes are most similar to in vivo hearts when comparing development, morphology 
and metabolism (White et al., 2004). Compared to the other two cell models, adult cardiomyocytes 
give the best representation of the human adult when investigating diseases more prevalent in the 
adult population, such as myocardial infarction and diabetes type 2.  
 
Adult ventricular cardiomyocytes was first isolated by Powell & Twist in 1976, and the protocol has 
been modified several times since (Lumkwana, 2014). However, no single isolation procedure 
produces high quality, viable cells without modifications. This drawback makes isolating and 
culturing of adult cardiomyocytes the least common model used and is therefore only performed by 
perfusion specialists (Döring, 1990). Various factors can influence the viability of cells acquired 
during isolating, including: 
 
 ANAESTHESIA 
Administration of an anaestethic, by either injection of barbiturates (pentobarbital) or inhalation of 
ether, halothane or isoflurane, can influence heart performance (Biebuyck et al., 1987). In a study 
done by Segal et al., (1990), the effects of anaesthesia on rat heart function in response to 
calcium-influx-mediated activity was compared to that of non-anaesthetized animals using the 
Langendorff system. Both hearts experienced an increase in inotropic activity (the force of muscle 
contraction) in response to gradual increases in calcium concentration of the perfused medium. 
However, anaesthesia inhibited thyroid hormonal function, dissipating the added inotropic activity 
of thyroid hormones. Also, hearts subjected to anaesthesia was more prone to arrhythmias in 
response to gradual increases of calcium (Segal et al., 1990). Although administering anaesthesia 
has its disadvantages, intraperitoneal injection of barbiturates is most widely used given that no 
complicated equipment is necessary and the depressive effect on heart function is entirely 
eliminated after 10 minutes of ceasing anaesthesia (Döring & Dehnert, 1988). 
 
 ANIMAL HANDLING 
Regardless of the procedure to follow, conscious effort needs to be taken to reduce exposing the 
animal to a stressful environment prior to its sacrifice. This also includes minimizing its handling 
altogether. Before surgery can commence, the animal needs to present with a total lack of pain 
response, determined by initiating a pain stimulus, such as pinching its paws (the pedal withdrawal 
reflex) (Skrzypiec-Spring et al., 2007).  
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 EXCISION OF THE HEART 
The time between excision of the heart, the subsequent transferring into ice cold saline (Krebs-
Henseleit) solution with low calcium (to stop the heart from beating and prevent ischemic injury 
prior to perfusion), followed by mounting of the heart on the perfusion system is the most crucial 
aspect in acquiring healthy, viable cells. It is recommended that this entire step be performed in 
less than 30 seconds and kept constant between experiments, since prolonged exposure to this 
ischemic period establishes ischemic preconditioning of the heart (Sutherland & Hearse, 2000). 
 
 CANNULATION OF THE HEART 
Before the heart is cannulated onto the perfusion apparatus, the cannula and tubes of the system 
need to be inspected for leakages and air bubbles. It is advised to let the perfusate drip freely 
before mounting the heart (Doring & Dehnert, 1988). Upon mounting of the heart, stretching or 
ripping of the aorta need to be avoided and the cannula should not penetrate the aortic heart valve, 
giving inadequate perfusion of the coronary arteries (Figure. 10.1)(Xu & Colecraft, 2009). Once the 
aorta is secured in place using sutures, the appropriate flow rate or flow pressure of the perfusate 
is established. The heart will turn pink as residual blood from the capillaries are removed. Within 10 
minutes, normal contractile function and regular heart rhythm are reinstilled (Doring & Dehnert, 
1988).  
 
 
Figure 10.1 Cannulation of the rat heart. (A) After excision from the rat, the heart is kept in ice 
cold Krebs-Henseleit buffer and mounted onto a cannula. (B) The cannula is inserted into the aorta 
and fastened in position with adequate space to allow proper flow through the coronary arteries 
(Louch et al., 2011) 
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 PERFUSION SOLUTIONS 
Most perfusion studies make use of a bicarbonate-based physiological salt solution, developed by 
Krebs and Henseleit. The solution mimics the contents of blood plasma, has a pH of 7.4 at 37°C 
and is continuously gassed with 95% O2 and 5% CO2. The most common perfusion solution 
constitutes 118.5mM NaCl, 25.0mM NaHCO3, 4.7mM KCl, 1.2mM MgSO4, 11mM Glucose and 
2.5mM CaCl2 (Sutherland & Hearse, 2000). Popular modifications to the solution include lowering 
calcium and potassium concentrations (these bind to proteins present blood plasma, but no 
proteins are present in perfusates), lowering glucose concentration (5.5mM), adding insulin (2-10 
IU/L), pyruvate (2-10mM) or fatty acids (0.3-0.9mM) (Skrzypiec-Spring et al., 2007). The 
drawbacks of using buffer preparations include elevated coronary flow rates, the lack of 
hemoglobin makes oxygen transport problematic, as well as the absence of proteins, hormones 
and cellular components present in and when compared to blood (Skrzypiec-Spring et al., 2007).   
   
 TEMPERATURE OF PERFUSION 
Cardiac contractile function, especially heart rate, is strongly influenced by temperature. Therefore, 
perfusion need to be performed at body temperature of the specie (37C for Rats and Humans) 
used in the experiment (Sutherland & Hearse, 2000). In order to negate the effects of the room 
temperature air surrounding the heart and perfusates, a glass reservoir with recirculating water 
(thermostatically controlled), encapsulates the heart and perfusion solutions.  
 
 OXYGEN DURING PERFUSION 
In the Langendorff perfusion system, oxygen availability results from the product of coronary flow 
and the oxygen content of the medium (Kammermeier, 1994). A mixture of 95% oxygen and 5% 
carbon dioxide (maintain the correct pH of the Krebs-Henseleit buffer at 37C) is added to the 
perfusion solutions through gassing. However, crystalloid buffers have very low oxygen carrying 
capacity, resulting in elevated coronary perfusion rates. Some researchers supplement the 
perfusion solutions with red blood cells, known for their ability to carry oxygen, which results in 
normalization of coronary flow rates (Bergmann et al., 1979).  
 
 CALCIUM PARADOX 
When normal calcium-levels are reintroduced in cardiac muscles, after perfusion with calcium-free 
buffers, calcium overload of the cells can occur, whereby they remain in a sustained contracted 
state and die. This phenomenon is known as the calcium paradox (Piper, 2000). In order to prevent 
this and produce calcium-tolerant cardiomyocytes, calcium needs to be systematically reintroduced 
to the cells, starting at concentrations far below physiological calcium concentrations. During 
perfusion the first stepwise increase of calcium is started, as well as during further enzymatic 
digestion of the hearts after removing the hearts from the Langendorff perfusion system.  
Stellenbosch University  https://scholar.sun.ac.za
  
 
134 
    
 ENZYMATIC DIGESTION 
Using a Langendorff Apparatus, hearts are retrogradely perfused with a calcium free solution to 
rinse out all the blood from the coronary arteries (Mitcheson et al., 1998). The perfusion solution is 
then switched to contain enzymes, such as Colleganse Type II, to digest the extracellular matrix. 
Due to the high cost of enzymatic solutions, the perfused medium is recycled till the heart reaches 
“streaming” – the point where solution freely runs through the heart by gravitational pull, denoting 
that the bulk of the heart’s inner matrix is fully digested (Louch et al., 2011). 
 
 
 
Figure 10.2 Langendorff apparatus. The heart can be perfused by either constant pressure 
perfusion, under gravitational pull (LEFT) or constant flow perfusion, using a mechanised flow 
regulator (RIGHT) (Louch et al., 2011)  
 
The choice of enzymes used, is also a significant indicator of the overall health of cardiomyocytes. 
The most widely used enzyme for cardiomyocyte isolation is Collagenase Type II (Worthington), 
containing the highest clostripain activity of any enzyme (Louch et al., 2011). Other suitable 
enzymes include proteases and pancreatin, as well as collagenase B & D (Roche). Significant 
variation can be observed between batches, and it is therefore recommended that newly 
purchased batches be tested for their enzyme activity. A simple technique to calculate enzyme 
activity is to perform a cell count after isolation, by comparing the amount of rod-shaped and 
round-shaped cells (Mitcheson et al, 1998). 
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4. ALTERNATIVE PATHWAYS OF INSULIN-DEPENDENT GLUCOSE UPTAKE 
4.1. ERK PATHWAY 
ERK (extracellular-signal-regulated kinases) or mammalian MAPK (mitogen-activated protein 
kinases) are intracellular protein kinases which plays a diverse role in cell differentiation and cell 
division. The ERK pathway is activated in response to a multitude of extracellular effectors, 
including growth factors, cytokines, viral infections, transforming agents, GPCR (G-protein coupled 
receptor) ligands and carcinogens.  
  
The best understood MAPK is ERK1 (p44 MAPK) and ERK2 (p42 MAPK) which are distributed in 
all tissue types. ERK p42/p44 are MAPK subtypes that mediate the mitogenic and the pro-
inflammatory effects of insulin (Sasaoka et al., 1994). In resting cells, ERK1/2 immediately 
accumulates in the nucleus upon stimulation. The activation of the ERK cascade is mediated by 
upstream mitogen-activated protein kinase kinase 1/2 (MEK1/2). Once activated, ERK1/2 
phosphorylate a variety of substrates, such as the membrane proteins, CD120a, Syk and calnexin, 
the nuclear substrates, SRC-1, Pax-6, Elk-1, MEF2, c-Fos, c-Myc and STAT3, several MAPK-
activating protein kinases (MK’s), MAPK-interacting (MNK’s) and cytoskeletal proteins. Due to the 
magnitude of influence of the ERK pathway, is has been seen to play conflicting roles in cellular 
processing, including proliferation, differentiation, metabolism, morphology, survival and 
programmed cell death (Deng et al., 2012). The ERK cascade consists of Ras, Rafs, MEK1/2, 
ERK1/2 and the MAPKAPK’s (MAPK-activating protein kinases), Elk-1, Sap1a and c-Fos. 
 
4.2. P38 PATHWAY 
p38’s, also called CSBP (cytokinin specific binding proteins), are a class of MAPK’s sensitive to 
cytokines and stress signals. They play a role in cell differentiation, apoptosis and autophagy. The 
p38 family has 4 different isoforms, p38α, p38, p38γ and p38δ and similar to the other MAPK’s are 
expressed throughout all tissue types (Deng et al., 2012). The p38 consists of the upstream 
molecules MEKK3, MKK3/4/6, which activates p38 and in turn activates the MK’s, MK2/3/5. Elk-1, 
CHOP, ATF2 and MEF2A. The p38 MAPK cascade is stimulated by promigratory factors, such as 
platelet-derived growth factor (PDGF), Ang II, S1P and thrombin, environmental stresses, including 
ultraviolet radiation, heat shock and osmotic shock, and inflammatory cytokines (Deng et al., 
2012).  
 
4.3. JNK PATHWAY 
JNK (c-Jun N-terminal kinases) or SAPK (Stress-activated protein kinases) are kinases that form 
part of the MAPK family and is activated in response to cytokines and cellular stress. The JNK 
family comprises 3 different isoforms, JNK1, JNK2 and JNK3, also known as SAPKγ, SAPKα and 
SAPKβ resprectively. Generally, JNK1/2 are localised throughout every tissue type, whereas JNK3 
is primarily found in the brain (Bode & Dong, 2007). The MAPK’s, MKK4 and MKK7, activate JNK, 
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which then binds and phosphorylates the Ser-63 and Ser-73 subunits of c-Jun, leading to 
inflammation. JNK can also be inactivated by Ser/Thr and Tyr protein phosphatases (Ip & Davis, 
1998).  
 
JNK is more sensitive to upstream activators compared to the other MAPK’s and in turn lends to 
the complexity and role of JNK. The JNK pathway can be stimulated in response to UV-radiation, 
protein synthesis inhibitors (anisomycin), osmotic shock, heat shock, toxins, anticancer drugs, 
ceramide, peroxide, anti-inflammatory cytokines and ischemia/reperfusion injury during heart 
attacks (Deng et al., 2012). Upon activation, JNK translocates to the nucleus where subsequent 
phosphorylation of effector molecules occur. These include ATF2, NF-ATc1, HSF-1, c-Myc, p53, 
STAT3 and DPC4/SMAD4/MADH4. JNK can also regulate non-transcription factors, including Bcl-
2, Bcl-xL and paxillin. The cascade is involved in various cellular processes, including neuronal 
degeneration and development, as well as cell development, differentiation and death. It also 
regulates inflammation and cytokine production.  
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CHAPTER 11 
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